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Abstract 
The aetiology of inflammatory bowel disease (IBD) combines genetic predisposition 
and environmental factors. In both ulcerative colitis and Crohn disease, patients 
perceive that diet affects the course of their disease. 
 
This thesis addresses the frequently observed compromise of the epithelial integrity of 
the gut in IBD and subsequent effect of the luminal content, which makes up the main 
part of the environmental stimulus, thus introducing the role of diet in IBD. Initially I 
conducted a survey, demonstrating the current practice of dietary manipulation and 
exclusion in IBD and irritable bowel syndrome, determining that advice given is 
generally empiric and that sensitivity testing is infrequently used in practice. 
 
A subsequent observational study compared the occurrence of serum IgG antibodies to 
foods in IBD patients compared to controls. It showed that IBD is associated with 
increased serum IgG antibodies to a wide range of foods but that this does not correlate 
with patient reported food intolerance.  
 
A further study investigated the colonic mucosal response to food antigen exposure, 
patient reported food intolerances, food specific serum IgG antibodies and intestinal 
permeability. The mucosal response did not correlate with patients' perception of food 
intolerance nor alterations in intestinal permeability. 
 
This work reinforces the importance of food intolerance in IBD and attempts to 
correlate those intolerances to available tests. While gastroenterologists do give dietary 
advice to their patients with IBD, the available evidence does not allow unequivocal 
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advice. No objective relationship between patient-perceived food intolerance and 
hypersensitivity testing was demonstrated.  
 
Future studies should seek to clearly define the association between intolerance tests 
and patient symptoms, investigate the mechanisms by which such tests might predict 
intolerance, and investigate the most promising strategies in carefully designed and 
controlled studies of dietary intervention.
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Chapter I Dietary factors in the aetiology of 
IBD 
I.1 The pathogenesis of inflammatory bowel disease 
 
he exact pathogenesis of inflammatory bowel disease (IBD) has proven elusive. 
What is clear is that susceptibility to IBD comes from the interaction of genetic 
predisposition and environmental factors. Mapping of the human genome has allowed 
genome wide scanning for abnormalities associated with IBD. Isolation of the 
environmental influences that modify those genetic influences has not been so 
complete. The interaction of genetic predisposition and environmental pressure has the 
net effect of causing epithelial barrier dysfunction and dysregulation of the mucosal 
immune system. Thus there are three essential, interactive cofactors in the pathogenesis 
of IBD: host susceptibility, largely determined by genetic factors; environmental 
factors, including the enteric microflora and the diet; and dysregulated mucosal 
immunity, which combines the mucosal immune system and epithelial barrier function 
(Fiocchi 1998; Xavier and Podolsky 2007). 
 
This section serves as an overview of the information available regarding the 
aetiopathogenesis of IBD, prior to an in-depth discussion of the direct influences of diet 
as a specific environmental factor in the development of IBD. The intention is to place 
in context the relative importance of genetic, immune, environmental and dietary factors 
in the causation of Crohn disease and ulcerative colitis.  
T 
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I.1.1 Dysregulated mucosal immunity  
Immune dysregulation in the presence of active IBD is evidenced by changes in the 
inflammatory milieu within the mucosa of patients with IBD. Whether this represents a 
primary defect in the regulation of the immune system or a secondary consequence of 
immune activation is debated.  
I.1.1.1 Disturbances in adaptive immunity 
In IBD the balance of regulatory and effector cells is disturbed. The pattern of 
disruption differs somewhat between ulcerative colitis (UC) and Crohn disease (CD), 
the simplistic model being a greater activation of the Th1 effector T lymphocytes in CD 
and Th2 lymphocytes in UC, with decreased activity of the Th3 regulatory system in 
both diseases. The Th1/2 distinction was described initially in the mouse immune 
system (Mosmann, Cherwinski et al. 2005). Mosmann et al. characterised two distinct 
patterns of lymphokine activity in mouse helper T cells. One subset of lymphokines 
included interleukin-(IL)2, interferon-gamma, granulocyte monocyte-colony stimulating 
factor (GM-CSF), and IL3 and defined the type 1 T helper cell, the other clone 
produced distinct lymphokines, in particular IL4, and was designated Th2.  
 
This distinction appears to have some applicability in CD (Niessner and Volk 1995). 
Neissner et al. used quantitative RT-PCR to determine the cytokine mRNA 
concentrations in the mucosa of patients with IBD. In CD there was greater expression 
of the Th1 cytokines: interferon (IFN)-γ and interleukin (IL)-2. The pattern of cytokine 
dysregulation in UC is less clear. There is greater expression of IL-5 and IL-13 present, 
cytokines more commonly associated with a Th2 response; however, the archetypal Th2 
cytokine IL-4 is not upregulated, and greater levels of IFN-γ are seen (Brown and 
Mayer 2007). 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Dysregulation of another immune effector system, the IL23/IL17 axis was recently 
described (Fujino, Andoh et al. 2003). Fujino et al. evaluated IL-17 expression in tissue 
samples and sera of patients with active and inactive IBD. IL-17 was not detected in the 
tissue or sera of normal individuals, infectious colitis, or ischaemic colitis patients. It 
was increased in the tissue samples and sera of active IBD patients. IL-17 is an 
inflammatory cytokine expressed by activated CD4+ T cells, referred to as Th17 cells 
(Harrington, Hatton et al. 2005). IL17 triggers the NF-kB signalling cascade and MAP 
kinase pathway, leading to T cell proliferation and up-regulation of inflammatory 
molecules (Hata, Andoh et al. 2002).  
 
IL-23 is a cytokine which has been shown to play a strong role in the maintenance and 
expansion of Th17 cells (Bettelli, Carrier et al. 2006; Mangan, Harrington et al. 2006; 
Veldhoen, Hocking et al. 2006). The importance of IL23 in the production of intestinal 
inflammation was demonstrated by Yen et al. Using IL10 knockout mice as a model of 
T cell-mediated IBD, they showed that mice deficient for IL23 had marked suppression 
of colitis (Yen, Cheung et al. 2006). In addition treatment with anti IL-23p19 antibodies 
can cure established colitis in mice (Elson, Cong et al. 2007). Further evidence of the 
role of IL-23 in IBD comes from genome-wide association studies, which have linked 
CD to a number of IL-23 pathway genes, notably IL23R (interleukin 23 receptor). 
Similar associations in IL-23 pathway genes have been observed in UC (Abraham and 
Cho 2009). 
I.1.1.2 Disturbed innate immunity 
Recent investigation has centred on the role of the innate immune system in both CD 
and UC. The innate immune system depends on the immediate recognition of highly 
conserved signals, mostly derived from microbes (Janeway and Medzhitov 2002). The 
presence of both extracellular and intracellular microbial-associated molecular pattern is 
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detected by mammalian cells through pattern-recognition molecules, such as the 
cytosolic nucleotide-binding oligomerization domain containing (NOD)-like receptors 
and the membrane-bound Toll-like receptors (TLR) (Inohara, Chamaillard et al. 2005; 
Akira, Uematsu et al. 2006). The mucosal epithelium and the luminal microflora are in 
constant communication, resulting in fluxes in the expression of co-stimulatory 
molecules (Toy, Yio et al. 1997), components of the human major histocompatibility 
complex (MHC)  (Hershberg, Framson et al. 1997), toll-like receptors (TLRs)  
(Hershberg 2002), NOD proteins (Kobayashi, Chamaillard et al. 2005), inflammatory 
cytokines (Yang, Eckmann et al. 1997), as well as antimicrobial peptides (Canny and 
Colgan 2005).  
 
Disturbances of the innate immune mechanisms in IBD take the form of alterations in 
the pattern of TLR expression (Cario and Podolsky 2000), upregulation of NOD2 in 
intestinal epithelial cells (IECs) and disturbances in antigen recognition and processing 
by antigen-presenting cells (Berrebi, Maudinas et al. 2003). 
I.1.1.2.1 TLR expression 
Patients with IBD have disturbed innate immune mechanisms of the epithelial layer 
with alterations in the pattern of TLR expression in the mucosal epithelial cells (Cario 
and Podolsky 2000). Cario et al. characterised the expression pattern of TLR expression 
in biopsies from the small intestine and colon in patients with IBD as compared with 
controls. In the IECs of normal mucosa TLR3 and TLR5 were constitutively expressed, 
conversely TLR2 and TLR4 were only barely detectable. In active CD TLR3 was 
significantly down regulated in the IECs, but not in UC. In contrast, TLR4 was strongly 
upregulated in both UC and CD. TLR2 and TLR5 expression remained unchanged in 
IBD (Cario and Podolsky 2000). 
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The exact mechanism by which this alteration of expression might contribute to 
pathogenesis is not known. TLR signalling is crucial in maintaining intestinal 
homeostasis through regulation of the expression of cytokines, chemokines, and 
antimicrobial peptides. Mice deficient for MyD88, an essential mediator of TLR 
signalling, showed increased susceptibility to dextran sodium sulfate-induced colitis 
(Rakoff-Nahoum, Paglino et al. 2004). 
 
Nenci et al. (Nenci, Becker et al. 2007) provided further elucidation of the underlying 
mechanism. They showed that deficiency of NF-kappaB, a master regulator of pro-
inflammatory responses, led to a spontaneous, chronic inflammatory response in the 
mouse colon, initially dominated by innate immune cells but later also involving T 
lymphocytes. In mice deficient for the MyD88 adaptor protein the development of 
intestinal inflammation was prevented, demonstrating that Toll-like receptor activation 
by intestinal bacteria was essential for disease pathogenesis in their mouse model. NF-
kappaB deficiency also increases susceptibility to infectious colitis in the mouse 
(Erdman, Fox et al. 2001). 
 
In CD, but not UC, this is further supported by the finding that loss of function 
mutations of TLR2, TLR4, and their intracellular adaptor known as TIRAP [for Toll–
IL-1 receptor (TIR) domain-containing adapter protein] confer increased predisposition 
to CD (Pierik, Joossens et al. 2006; De Jager, Franchimont et al. 2007). 
I.1.1.2.2 Upregulation of NOD2 
The NOD2 gene on chromosome 16q12 was the first susceptibility gene for CD to be 
successfully identified. NOD2 encodes an intracellular receptor predominantly 
expressed in monocytes and Paneth cells. It has been implicated in the innate immune 
response to muramyldipeptide (MDP), a component of peptidoglycan in bacterial cell 
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walls (Zhang, Massey et al. 2008). NOD2 activation leads to the activation of NF-
kappaB and there is evidence of cross-talk between NOD2 and TLR pathways. 
 
There is upregulation of NOD2 expression in the IECs of patients with IBD (Berrebi, 
Maudinas et al. 2003). However, the CD associated gene defects are associated with a 
significant diminution in responsiveness to MDP (Kelsall 2005). Thus, the exact 
mechanism by which defects in TLR and NOD2 expression and function might affect 
the pathogenesis of IBD remains unclear, but it may be that reduced ability to clear 
bacteria by innate immune mechanisms leads to immune dysregulation and the initiation 
of a chronic immune response.  
 
Figure 1. Models of activation and regulation of NOD and TLR pathways by 
peptidoglycan (adapted from Kelsall 2005)  
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I.1.1.2.3 Disturbances in antigen recognition 
The dendritic cells (DCs) of the intestinal epithelium are the main antigen presenting 
cells in the gut (Hart, Al-Hassi et al. 2005). Their dendrites penetrate between epithelial 
cells, allowing constant sampling of luminal antigens without any effect on barrier 
function. Hart et al. investigated the properties of intestinal DCs in IBD compared with 
controls. They demonstrated that there was upregulation of TLR2 and TLR4 expression 
in DCs from patients with IBD compared with controls. Intestinal DCs in CD patients 
also expressed significantly higher levels of the maturation/activation marker CD40, 
and more DCs produced the pro-inflammatory cytokines IL-12 and IL-6 than controls, 
suggesting that intestinal DCs are activated in CD and produce pathologically relevant 
cytokines. They concluded that intestinal DCs were likely to be key initiators or 
perpetuators of the inflammatory response in IBD (Hart, Al-Hassi et al. 2005). 
I.1.2 Autophagy 
The autophagy process is a basic cellular process whereby cellular contents are 
encapsulated in a double membrane organelle, the autophagosome, and delivered to the 
lysosome for degradation. A role in the pathogenesis of IBD was not strongly suspected 
until genome wide association scans identified two genes, ATG16L1 and IRGM, known 
to be involved in autophagy, that were significantly associated with CD (Hampe, Franke 
et al. 2007; Parkes, Barrett et al. 2007; Rioux, Xavier et al. 2007; Wellcome Trust Case 
Control Consortium 2007; Barrett, Hansoul et al. 2008). 
 
Functional studies have since shown that chimeric mice with Atg16L1- deficient 
haematopoietic cells have increased levels of the inflammatory cytokines IL-1b and IL-
18 and are very susceptible to colitis induced by treatment with dextran sodium sulfate 
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(DSS). The DSS-induced colitis can be ameliorated by treatment with antibodies to IL-
1b and IL-18 that block the activity of these cytokines (Saitoh, Fujita et al. 2008). 
 
In turn these functional studies have drawn attention to the Paneth cell in the aetiology 
of CD. The role of Paneth cells in CD was previously suspected because NOD2 is 
highly expressed in these cells (Lala, Ogura et al. 2003) and the expression of 
antimicrobial peptides is reduced in NOD2 knockout mice (Kobayashi, Chamaillard et 
al. 2005) and patients with ileal CD (Wehkamp, Salzman et al. 2005). Mice that 
expressed reduced levels of ATG16L1 protein displayed defects in the Paneth cells of 
the small intestine (Cadwell, Liu et al. 2008). Homozygous deletion of another 
autophagy gene, Atg5, in the intestinal epithelium of mice also produced abnormal 
Paneth cells, indicating that these cells can be particularly sensitive to autophagy defects 
(Cadwell, Liu et al. 2008). Most exciting was the finding that CD patients homozygous 
for the ATG16L risk allele have abnormal Paneth cells in biopsies of uninvolved 
ileocolonic resection samples (Cadwell, Liu et al. 2008). 
 
Less is known about IRGM, the other autophagy gene associated with CD and further 
functional studies are needed (Parkes, Barrett et al. 2007; Barrett, Hansoul et al. 2008). 
Common genetic variations in these and other autophagy genes are likely to have a major 
impact on the response of the innate immune system to intestinal microbiota and 
susceptibility to IBD.  
I.1.3 Mucosal epithelial barrier function  
The barrier function of the intestinal epithelium is crucial to the function of the mucosal 
immune system. The epithelium is made up of a single layer of IECs that are connected 
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by tight junctions. They interact with lamina propria DCs, lamina propria lymphocytes 
(LPL), intraepithelial lymphocytes (IEL) and mediators of the immune and the enteric 
nervous system (Neutra, Mantis et al. 2001). 
 
The IECs are actively involved in immune regulation through expression of 
costimulatory molecules (Toy, Yio et al. 1997) and components of the human major 
histocompatibility complex (MHC) (Hershberg, Framson et al. 1997), toll-like receptors 
(TLRs) (Hershberg 2002), NOD proteins (Kobayashi, Chamaillard et al. 2005), 
inflammatory cytokines (Yang, Eckmann et al. 1997), as well as antimicrobial peptides 
(Canny and Colgan 2005). The role of antigen presentation and pattern recognition has 
been discussed above. This section focuses on epithelial barrier function, in particular 
intestinal permeability (IP), and defects in function that have been associated with IBD. 
I.1.3.1 Intestinal permeability 
Many methods are available for measuring IP. This section aims to deal with the 
published data regarding their use in IBD. Further comments as to the technical aspects 
of their use and their relative attributes are discussed in more detail in the methods 
section of Chapter V.  
 
Medline was searched using the search terms “inflammatory bowel disease”, “ulcerative 
colitis”, “Crohn disease” and “intestinal permeability”. In addition the references of 
identified articles were checked for other appropriate publications. Publications were 
considered if they compared the results of IP testing in patients with UC or CD to that 
of a control group. 
I.1.3.1.1 51Chromium EDTA intestinal permeability testing in CD 
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A total of eleven studies using 51Chromium ethylenediaminetetraacetic acid 
(51CrEDTA) testing in CD were identified. 9 were in adults and 2 in children. The total 
number of CD patients studied was 321 and the total number of controls 315 (see Table 
1) 
 
One study compared the IP of patients with CD depending on the site of disease 
(Bjarnason, O'Morain et al. 1983). This study showed that IP was highest in small 
bowel and ileocolonic disease, but was also increased in 5 of 11 patients with isolated 
colonic disease. Three studies demonstrated that permeability was greatest in those with 
active disease (Resnick, Royal et al. 1990; Adenis, Colombel et al. 1992; Berstad, 
Arslan et al. 2000). One further study used only radiolabelled 99mTc-
diethylenetriaminopentaacetic acid in 16 adult CD patients and 10 controls and also 
demonstrated increased permeability (Casellas, Aguade et al. 1986). Resnick et al. used 
the same technique alongside 51CrEDTA, with similar results from both substrates 
(Resnick, Royal et al. 1990). 
 
All but one study demonstrated increased IP to 51CrEDTA (Howden, Gillanders et al. 
1994). This study enrolled 10 patients with CD remission who also had a relative who 
was willing to participate and had no gastrointestinal disease or past surgery.  The 
median 24 hour urinary excretion of 51CR-EDTA was 1.7% in the CD patients 
compared with 1.35% in the unaffected relatives. This was compared to the study 
centre’s own historical control value of 2% and active small intestinal CD value of 
4.33%. Certainly the patient group studied in this report was very carefully selected for 
inactive disease. This is compared to the positive studies where generally patients with a 
range of disease activities were studied.
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 Patient 
group 
Number of patients Findings 
Bjarnason, 
O'Morain et 
al. 1983  
Adults 28 controls, 10 small 
bowel CD, 11 
ileocolonic CD, 11 CD 
colitis 
Increased permeability in small 
bowel and ileocolonic CD and 
5 of 11 CD colitis patients 
Peled, Watz 
et al. 1985 
Adults 27 controls, 6 CD 5 of 6 had increased 
permeability 
Turck, 
Ythier et al. 
1987  
Children 7 control adults, 11 
control children, 17 CD 
children 
Increased permeability 
compared to controls 
Ainsworth, 
Eriksen et 
al. 1989 
Adults 28 controls, 15 CD Increased permeability 
compared to controls 
Resnick, 
Royal et al. 
1990  
Adults 11 controls, 35 CD Increased permeability 
compared to controls 
Adenis, 
Colombel et 
al. 1992  
Adults 13 controls, 22 CD Increased permeability 
compared to controls 
Teahon, 
Smethurst et 
al. 1992  
Adults 25 controls, 28 CD Increased permeability 
compared to controls 
Issenman, 
Jenkins et 
al. 1993 
Children 26 paediatric controls, 
51 active paediatric CD, 
80 adult controls, 63 
adults with active CD 
Increased permeability 
compared to controls 
Howden, 
Gillanders et 
al. 1994 
Adults 10 CD with inactive 
disease (and 10 
unaffected relatives) 
No difference in permeability 
between patients and historical 
or related controls 
Berstad, 
Arslan et al. 
2000 
Adults 18 IBS, 17 CD Increased permeability 
compared to controls, 
permeability increased with 
increasing disease activity 
Suenaert, 
Bulteel et al. 
2005 
Adults 31 controls, 25 active 
CD 
Increased permeability 
compared to controls 
Table 1. Studies of intestinal permeability in Crohn disease using 51Chromium 
EDTA 
 
I.1.3.1.2 Polyethylene glycol intestinal permeability testing In CD 
The results from studies that used polyethylene glycol (PEG) as a substrate for 
measuring IP are much more varied. A total of nine studies were identified. Eight were 
in adults and one in children.  
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Three studies showed a decrease in IP to PEG in CD, two studies showed an increase in 
IP and four studies showed no difference between CD patients and controls. One study 
that demonstrated a decrease in IP in CD was only able to do so for small bowel CD but 
not colonic CD (Teahon, Smethurst et al. 1992). In one study PEG was also instilled 
directly into the colon (Olaison, Sjodahl et al. 1989). This showed the greatest 
absorption of PEG across the colonic mucosa in those subjects with colonic CD.  
 
 Patient 
group 
Number of 
patients 
Findings 
Magnusson, 
Sundqvist et 
al. 1983  
Adults 24 controls, 24 
CD 
Decreased permeability compared to 
controls 
Olaison, 
Sjodahl et al. 
1989  
Adults 14 controls, 59 
CD (15 colonic, 
44 ileal) 
Decreased permeability compared to 
controls  
Teahon, 
Smethurst et 
al. 1992  
Adults 25 controls, 28 
CD 
Decreased permeability in small 
bowel CD but not colonic CD 
compared to controls 
Jenkins, 
Goodacre et 
al. 1986  
Adults 40 controls, 15 
CD 
Increased permeability compared to 
controls 
Hollander, 
Vadheim et 
al. 1986  
Adults 17 controls, 11 
CD 
Increased permeability compared to 
controls 
Zellweger, 
Freiburghaus 
et al. 1990 
Adults 24 controls, 12 
CD 
No difference in permeability 
between patients and controls 
Ruttenberg, 
Young et al. 
1992 
Adults 31 controls, 45 
CD 
No difference in permeability 
between patients and controls 
Lindberg, 
Soderholm et 
al. 1995 
Children 30 controls, CD 
33 
No difference in permeability 
between patients and controls 
Munkholm, 
Langholz et 
al. 1994 
Adults 31 controls, 47 
CD 
No difference in permeability 
between patients and controls 
Table 2. Studies of intestinal permeability in Crohn disease using polyethylene 
glycol (ordered by result then year) 
 
26 
I.1.3.1.3 Lactulose:mannitol intestinal permeability testing In CD 
The most extensively investigated technique for the assessment of IP is the 
lactulose:mannitol (L:M) absorption test. A total of 23 studies comparing the L:M ratio 
in CD patients to control subjects were identified. All but two showed an increase in the 
L:M excretion ratio (Munkholm, Langholz et al. 1994; Halme, Turunen et al. 2000).  
 
The study by Munkholm et al. considered a relatively large sample for such studies  
(Munkholm, Langholz et al. 1994). There were 31 controls and 47 CD patients. The 
L:M analysis technique used was similar to a number of previous studies. Their samples 
were blindly analysed by the laboratory used in a previous, often quoted study that did 
find an increased L:M excretion ratio in CD (Hollander, Vadheim et al. 1986). 
However, the patients they tested had relatively mild disease with 75% having a 
Crohn’s disease activity index (CDAI) of less than 150. In addition most patients were 
not receiving corticosteroids or immunosuppressive agents. Interestingly they did find a 
slight positive correlation between the activity of the disease and the L:M ratio. It is 
possible that the result of this study deviated from that of the majority of similar studies 
because of the clinical activity of the patient group selected. 
 
The study by Halme et al. included a smaller sample of 22 patients with an exacerbation 
of CD and 10 healthy controls (Halme, Turunen et al. 2000). Patients on no medication 
or only on 5-ASA or sulphasalazine as maintenance treatment were included. The 
median L:M ratio was 0.037 (range 0.01 ± 0.260) in patients and 0.030 (range 0.004 ± 
0.063) in controls (N.S.). In a comparison between activity indices and the permeation 
of test solutions, the L:M ratio showed significant correlation with endoscopic activity. 
In this series, 54% of the patients had an elevated L:M ratio, which is comparable with 
results from a previous study which found an increased overall L:M ration in CD 
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(Wyatt, Vogelsang et al. 1993). Thus, in this small study with similar proportions of 
patients with increased L:M ratios to previous positive studies but a relative increase in 
the L:M ratio in CD patients compared to controls which did not reach significance and 
a positive correlation between endoscopically assessed disease activity and L:M ratio, 
there is the possibility that type II error is responsible for the negative finding.
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Table 3. Studies of intestinal permeability in Crohn disease using 
lactulose:mannitol (ordered by result then year) 
 Patient group Number of patients Findings 
Pearson, Eastham 
et al. 1982 
Children 31 controls, 8 CD Increased permeability compared to 
controls 
Ukabam, Clamp et 
al. 1983  
Adults 16 controls, 13 ileal CD, 7 
colonic CD 
Increased permeability compared to 
controls 
Andre, Andre et 
al. 1988 
Adults 100 controls, 47 CD Increased permeability compared to 
controls and permeability increased 
with disease activity 
Katz, Hollander et 
al. 1989 
Adults 29 controls, 25 CD Increased permeability compared to 
controls 
Murphy, Eastham 
et al. 1989 
Children 31 controls, 17 CD Increased permeability compared to 
controls and permeability increased 
with disease activity 
May, Sutherland 
et al. 1993 
Adults 31 controls, 36 CD Increased permeability compared to 
controls 
van Elburg, 
Kokke et al. 1993 
Children 25 controls, 25 CD Increased permeability compared to 
controls 
Wyatt, Vogelsang 
et al. 1993  
Adults control numbers not given, 
72 CD with quiescent 
disease 
Increased permeability compared to 
controls 
Peeters, Geypens 
et al. 1997 
Adults 50 controls, 25 CD Increased permeability compared to 
controls 
Wyatt, Oberhuber 
et al. 1997 
Adults 30 controls, 50 CD Increased permeability compared to 
controls 
Marsilio, D'Antiga 
et al. 1998 
Children 30 controls, 10 CD Increased permeability compared to 
controls 
Puspok, 
Oberhuber et al. 
1998 
Adults 30 controls, 100 CD Increased permeability compared to 
controls 
Soderholm, 
Olaison et al. 
1999 
Adults 29 controls, 39 CD Increased permeability compared to 
controls 
Secondulfo, de 
Magistris et al. 
2001 
Adults 32 controls, 16 CD Increased permeability compared to 
controls 
Fries, Renda et al. 
2005 
Adults controls 64, CD 29 Increased permeability compared to 
controls 
Buhner, Buning et 
al. 2006 
Adults 96 controls, 128 quiescent 
CD,  
Increased permeability compared to 
controls 
Buning, Geerdts et 
al. 2006 
Adults 96 controls, 113 CD 
(CDAI <150) 
Increased permeability compared to 
controls 
D'Inca, Annese et 
al. 2006 
Adults 35 controls, 115 CD Increased permeability compared to 
controls 
Benjamin, 
Makharia et al. 
2008 
Adults controls 22, CD 125 Increased permeability compared to 
controls 
Cuoco, Vescovo 
et al. 2008 
Adults controls 20, CD 13 active 
steroid free 
Increased permeability compared to 
controls 
Vilela, Torres et 
al. 2008 
Adults controls 15, CD 34 Increased permeability compared to 
controls 
Dastych, Dastych 
et al. 2008 
Adults 20 controls, 20 CD active Increased permeability compared to 
controls 
Halme, Turunen et 
al. 2000 
Adults  10 controls, 22 
exacerbation IBD 
No difference in permeability between 
patients and controls 
Munkholm, 
Langholz et al. 
1994 
Adults 31 controls, 47 CD No difference in permeability between 
patients and controls 
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I.1.3.1.4 Lactulose:rhamnose intestinal permeability testing in CD 
A total of 6 studies comparing the lactulose:rhamnose (L:R) ratio in CD patients to 
control subjects were identified. All but one showed an increased in the L:R excretion 
ratio (Munkholm, Langholz et al. 1994), the limitations of this study that might have led 
to this discrepancy were outlined in section I.1.1.1.1. 
 
 Patient 
group 
Number of 
patients 
Findings 
Sanderson, 
Boulton et al. 
1987 
Children 6 control children, 
14 CD 
Increased permeability 
compared to controls 
Katz, 
Hollander et 
al. 1989 
Adults 29 controls, 25 CD Increased permeability 
compared to controls 
Teahon, 
Smethurst et 
al. 1992 
Adults 25 controls, 28 CD Increased permeability 
compared to controls 
Miki, Moore 
et al. 1998 
Children 36 controls, 12 CD Increased permeability in 
active but not quiescent CD 
compared to controls 
Iwata, 
Nakano et al. 
2001 
Adults 20 controls, 92 CD Increased permeability 
compared to controls 
Munkholm, 
Langholz et 
al. 1994 
Adults 31 controls, 47 CD No difference in permeability 
between patients and controls 
Table 4. Studies of intestinal permeability in Crohn disease using 
lactulose:Rhamnose (ordered by result then year) 
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I.1.3.1.5 Iohexol intestinal permeability testing in CD 
Two studies by the same authors used the radiological contrast agent iohexol as a probe 
for the determination of IP (Halme, Edgren et al. 1997; Halme, Turunen et al. 2000). 
They correlated the results of its use to the use of the L:M test and found the two to 
positively correlate. Both studies showed an increased excretion of iohexol by patients 
with CD compared to controls. They found that the urinary excretion of iohexol was 
significantly higher in active disease than in quiescent disease. 
 
 Patient 
group 
Number of 
patients 
Findings 
Halme, 
Edgren et 
al. 1997 
Adults 16 controls, 
40 CD 
Increased permeability compared to controls 
and permeability increased with disease 
activity 
Halme, 
Turunen 
et al. 
2000 
Adults 10 controls, 
16 active CD 
Increased permeability compared to controls 
 Table 5. Studies of intestinal permeability in Crohn disease using iohexol 
 
I.1.3.1.6 Conclusions regarding intestinal permeability testing in CD 
Thus the tests of intestinal permeability most studied in CD are those that use sugars as 
probes and the majority of these studies have shown increases in intestinal permeability, 
particularly in the setting of active disease. The same is true of those studies that used 
51CrEDTA. Not all studies concur and this may reflect differences in levels of disease 
activity, disease location, the methodology used in testing and the test substrate. 
Certainly testing using PEG produces a very different pattern of absorption than the 
other probes used. It seems likely that PEG probes are more useful in demonstrating 
changes in permeability related to colonic disease. 
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While both sugar probes and 51CrEDTA give relatively consistent results in the setting 
of CD, in practice the requirements for the handling of the Chromium isotope make 
sugar probes a more pragmatic tool for the investigation of intestinal permeability in 
CD. It may be that a combination of sugar probes including lactulose, mannitol and 
rhamnose represents the best available approach to the measurement of intestinal 
permeability in CD. 
I.1.3.1.7 Intestinal permeability testing in ulcerative colitis 
Studies of IP in UC are much less numerous and those that exist generally investigated 
smaller numbers of patients than in CD. The evidence for a permeability defect using 
51CrEDTA as the probe is greater than that for those using sugars or PEG as the probe 
(see table Table 6).  
 
Four studies comparing 51CrEDTA excretion in UC and controls were identified. Two 
studies performed in the 1980’s showed no difference between UC patients and controls 
(Bjarnason, O'Morain et al. 1983; Peled, Watz et al. 1985). In the 1985 study by Peled 
et al. the technique itself was called into question by the high rate of positive results 
from the control population (Peled, Watz et al. 1985). Nineteen of 27 patients with 
diseases thought not to affect the integrity of the small bowel had an abnormal test. All 
the patients with UC had normal excretion. In the 1983 study by Bjarnason et al. all the 
control patients had normal excretion of Cr51EDTA, as did the patients with UC, but 
not those with CD (Bjarnason, O'Morain et al. 1983).  
 
Two later studies showed increased IP to 51CrEDTA in UC patients. Berstad et al. 
examined consecutive patients with abdominal pain or diarrhoea. They compared the 3 
found to have UC to those with CD and those without any evidence of organic disease 
on endoscopy, abdominal ultrasonography, or barium X-ray examination of the small 
32 
bowel. The 3 patients with UC appeared to have higher IP than the patients without 
evidence of organic disease. Issenman et al. performed the largest study in UC to date 
using Cr51EDTA as the probe in children and adults. In their 1993 study this group 
examined 24 paediatric and 31 adult patients with active UC and compared them to 26 
paediatric controls with recurrent abdominal pain or chronic non-specific diarrhoea and 
80 adult controls (Issenman, Jenkins et al. 1993). Patients with UC demonstrated 
increased excretion of 51CrEDTA compared to controls. 
 
Three further studies used non-sugar, non-PEG probes in UC patients. Casellas et al. 
used 99mTc labelled DTPA in 10 control adults and 12 adults with UC (Casellas, 
Aguade et al. 1986). They found that excretion was increased in UC patients compared 
to controls and was highest in those patients with active disease. Resnick et al. also 
compared 99mTc-DTPA excretion in 11 controls and 21 adult UC patients, showing a 
significantly greater mean percentage excretion of probe in UC (Resnick, Royal et al. 
1990). Halme et al. used the radiological contrast agent Iohexol as a probe (Halme, 
Edgren et al. 1997). They compared 16 adult controls with 16 UC patients and 
demonstrated increased excretion of Iohexol in patients with UC. 
 
One of three studies that used sugar probes showed a difference between UC patients 
and controls and then only in the subgroup of UC patients with active extensive UC 
(Miki, Moore et al. 1998). Miki et al. compared paediatric UC patients to historical 
paediatric and adult controls. In 6 of 7 patients with active extensive UC the L:R ratio 
was elevated. However, there was no difference between controls and 6 patients with 
inactive extensive UC. Only 1 of 5 patients with active left sided colitis demonstrated an 
increased L:R ratio. 
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None of the three identified studies that used PEG as a probe found a difference 
between controls and UC patients. 
 
In summary, it appears that the IP changes associated with UC are much less impressive 
and less consistent than those seen in CD but that the available studies are small and 
heterogenous in terms of patient group and technique used. The radioisotope probes 
99mTc-DTPA and 51CrEDTA may represent the most sensitive probes to changes in 
permeability and this may reflect their ability to detect changes in colonic permeability.
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Table 6. Studies of intestinal permeability in ulcerative colitis (ordered by 
permeability technique used then result) 
 
 Technique Patient 
group 
Number of 
patients 
Findings in UC 
Bjarnason, 
O'Morain et 
al. 1983 
51 chromium 
EDTA 
Adults 28 controls, 
10 UC 
No difference in 
permeability between 
patients and controls 
Peled, Watz 
et al. 1985 
51 chromium 
EDTA 
Adults 27 control, 3 
UC 
No difference in 
permeability between 
patients and controls 
Issenman, 
Jenkins et al. 
1993 
51 chromium 
EDTA 
Children 26 paediatric 
controls, 80 
adults 
controls, 24 
paediatric 
UC, 31 adult 
UC 
Increased permeability 
compared to controls 
Berstad, 
Arslan et al. 
2000 
51 chromium 
EDTA 
Adults 18 IBS, 3 UC Increased permeability 
compared to controls 
Casellas, 
Aguade et al. 
1986 
99mTc DTPA Adults 10 controls, 
12 UC 
Increased permeability 
compared to controls 
and permeability 
increased with disease 
activity 
Resnick, 
Royal et al. 
1990 
99mTc DTPA Adults 11 controls, 
21 UC 
Increased permeability 
compared to controls 
Halme, 
Edgren et al. 
1997 
Iohexol Adults 16 controls, 
16 UC 
Increased permeability 
compared to controls 
Ukabam, 
Clamp et al. 
1983 
Mannitol and 
Lactulose 
Adults 16 controls, 7 
UC 
No difference in 
permeability between 
patients and controls 
Miki, Moore 
et al. 1998 
Lactulose and 
Rhamnose 
Children 36 control, 18 
UC 
Permeability only 
increased in active 
extensive disease 
compared with 
controls 
Munkholm, 
Langholz et 
al. 1994 
PEG, 
Lactulose, 
Rhamnose 
and Mannitol 
Adults 31 controls, 
52 UC 
No difference in 
permeability between 
patients and controls 
Jenkins, 
Goodacre et 
al. 1986 
PEG Adults 40 control, 7 
UC 
No difference in 
permeability between 
patients and controls 
Zellweger, 
Freiburghaus 
et al. 1990 
PEG Adults 24 controls, 8 
UC 
No difference in 
permeability between 
patients and controls 
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I.1.3.1.8 Pathogenesis of intestinal permeability defects in CD 
Thus the balance of current evidence suggests the epithelial barrier exhibits increased 
permeability in CD and that permeability may be increased in, at least active, UC. The 
exact extent of the pathology underlying this disturbance of epithelial integrity is not 
fully elucidated by current methodology. All the permeability probes used in the studies 
described above measure predominantly the efficiency of the paracellular route. There 
are no clinical measures of transcellular permeability currently available (Gibson 2004). 
In addition molecular studies to date have focussed on the paracellular route. This 
evidence is summarised here. 
 
The tight junction seals the space between adjacent epithelial cells. In intact 
gastrointestinal epithelia it is tight junction permeability that is the rate-limiting step 
that defines overall epithelial permeability (Weber and Turner 2007). Tight junctions 
are composed of multiple proteins that are involved in establishing the epithelial barrier, 
and they selectively determine which molecules are able to traverse the paracellular 
space. The claudin family of proteins has a critical role in selective ion permeability. 
Their involvement in the pathogenesis of the permeability defect of IBD has been 
recently demonstrated. 
 
Prasad et al. used immunohistochemical techniques to examine the expression of 
claudins (CL) 2, 3 and 4 in tissue samples from UC and CD patients and control 
subjects (Prasad, Mingrino et al. 2005). They found that the pore-forming protein CL2 
was strongly expressed along the inflamed crypt epithelium, whilst absent or barely 
detectable in normal colon. In contrast, CL 3 and 4 were present throughout normal 
colonic epithelium and were reduced or redistributed in the diseased surface epithelium. 
They went on to examine the effect of IL-13 treatment of an epithelial cell monolayer 
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model of the gut barrier. IL-13, a pro-inflammatory cytokine, produced no observed 
change in CL 3 and 4 but showed marked increases in CL 2 that correlated with 
reductions in trans-epithelial resistance.  
 
Heller et al. in a study of colonic epithelial cells from UC patients, were also able to 
show increased expression of CL2 in response to increased IL-13 (Heller, Florian et al. 
2005). This, in combination with increased numbers of apoptotic cells, led to a 
reduction in transepithelial resistance. 
 
In another study of tight junction function in IBD Zeissig et al. used electron 
microscopy of epithelium affected by IBD, immunohistochemistry for claudin isoforms 
and in vitro studies of the effect of IBD related cytokines on intestinal cell barrier 
function (Zeissig, Burgel et al. 2007). Freeze-fracture electron microscopy of tissue 
from patients with active IBD showed morphological changes in the tight junctions 
particular to IBD and separate from the effects of gross epithelial damage such as 
ulceration, crypt abscesses or apoptosis. They also showed that CL2 expression was 
increased, particularly in the crypt epithelium, in patients with active disease. 
Additionally the observation that CL2 expression was normal in tissue from patients 
with inactive disease led the authors to conclude that the claudin expression patterns 
were likely to be a consequence rather than a cause of active disease. They were also 
able to demonstrate that CL2 expression was only subtly decreased by Interferon and 
modestly increased by tumour necrosis factor (TNF). Studies of cultured intestinal 
epithelial monolayers have demonstrated that TNF induces increases in permeability 
independent of apoptosis (Bruewer, Luegering et al. 2003).  
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Ultimately results such as those above have led to the conclusion that, while alterations 
in claudin expression might be important in IBD, TNF actually causes intestinal 
epithelial barrier dysfunction by mechanisms distinct from altered claudin isoform 
expression (Weber and Turner 2007). Instead the defect induced appears to relate to 
cytoskeletal mechanisms of permeability increase, in particular increases in epithelial 
cell myosin II regulatory light chain phosphorylation (Zolotarevsky, Hecht et al. 2002). 
I.1.3.2 Defensins and mucus 
The IECs produce a plethora of antimicrobial peptides. In themselves these peptides 
would be ineffective were they not retained in high concentration in the environment 
close to the epithelium by the action of mucus (McGuckin, Eri et al. 2009). The major 
macromolecular component of intestinal mucus is produced by goblet cells. Into this 
other compounds are secreted by the epithelium including phospholipids and 
antimicrobial compounds such as defensins, secreted in granules produced by Paneth 
cells (McGuckin, Eri et al. 2009). 
 
It has long been considered that classical ileal CD results in goblet cell hypertrophy and 
increased, rather than decreased, mucus formation and so is not a result of decreased 
mucus layer function (Dvorak, Osage et al. 1980; Trabucchi, Mukenge et al. 1986). 
This dogma was challenged by the finding that defensin production by Paneth cells is 
reduced in CD (Wehkamp, Harder et al. 2004; Wehkamp, Salzman et al. 2005; 
Wehkamp, Schmid et al. 2005; Wehkamp, Schmid et al. 2007). In addition Paneth cell 
expression of NOD2 was reduced (Lala, Ogura et al. 2003; Ogura, Lala et al. 2003) and 
polymorphisms in the defensin gene were associated with CD (Fellermann, Stange et al. 
2006). The methodology of many these studies relied on polymerase chain reaction 
(PCR) amplification of RNA from tissue biopsies from patients and controls. The 
relative abundance of epithelium decreases during intestinal inflammation. Therefore 
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such studies, based on whole tissue RNA, are fraught with the potential to wrongly 
attribute a decrease in the relative abundance of epithelial specific RNA to decreased 
production of molecules per remaining epithelial cell rather than to decrease in the 
relative abundance of epithelial cells. A recent study which used expression of another 
epithelial-specific gene, villin, as an indicator of relative defensin production 
demonstrated increased rather than decreased defensin expression in non-inflamed ileal 
CD (Simms, Doecke et al. 2008). The authors thus concluded that the evidence did not 
yet support a fundamental decrease in defensin production underlying ileal CD. 
 
In colonic CD the evidence for a reduction in antimicrobial activity is stronger. Nuding 
et al. used a flow cytometric assay to test the antibacterial activity of cationic peptide 
extracts form colonic biopsies. In CD extracts there was decreased antimicrobial effect 
against E. coli and E. faecalis compared to UC. These differences were independent of 
the inflammation status or concurrent steroid treatment (Nuding, Fellermann et al. 
2007). The same group also reported that there was a decrease in the antimicrobial 
protease inhibitors SLPI and elafin in inflamed CD tissue compared with inflamed UC 
tissue (Schmid, Fellermann et al. 2007). 
 
Further, in UC there is a reduction in goblet cells, reduced size of goblet cell thecae, 
decreased MUC2 production (Tytgat, van der Wal et al. 1996; Van Klinken, Van der 
Wal et al. 1999), decreased mucin sulfation (Corfield, Myerscough et al. 1996; Hanski, 
Born et al. 1999; Van Klinken, Van der Wal et al. 1999) and a diminished mucus 
barrier. Whether these changes are primary or a response to inflammation is 
contentious. Similar changes are, however, observed in the unaffected proximal 
intestine of patients with distal UC (McGuckin, Eri et al. 2009) and vacuolisation of the 
endoplasmic reticulum (ER) and Golgi is seen in both inflamed and noninflamed 
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secretory cells in UC, suggesting that ER stress is occurring (Donnellan 1966; 
Gonzalez-Licea and Yardley 1966; Nagle and Kurtz 1967; Delpre, Avidor et al. 1989). 
I.1.3.3 Regulation of reactive oxygen species 
The intestinal mucosa is constantly exposed to reactive oxygen species (ROS) that are 
generated by the luminal contents, oxidized food debris, transition metals such as iron 
and copper, bacterial metabolites, bile acids and salivary oxidants (Rezaie, Parker et al. 
2007). The intestinal mucosa is vulnerable to that oxidative stress and oxidant mediated 
injury plays an important part in the pathophysiology of IBD (Keshavarzian, Morgan et 
al. 1990). Studies in humans have demonstrated increased oxidative stress and 
decreased antioxidant defenses in IBD mucosa (Lih-Brody, Powell et al. 1996; Sido, 
Hack et al. 1998). 
I.1.4 Genetic factors 
A genetic influence on the pathogenesis of IBD has long been evidenced by twin studies 
in IBD. The combined concordance rate for IBD of 36% in monozygotic twins and only 
4% in dizygotic twins was strong evidence for a genetic basis. This was supported by 
familial studies that showed an increased risk of both CD and UC in relatives of patients 
with either of these disorders; the greater risk being in siblings than in other family 
members (Gaya, Russell et al. 2006).  
 
Recent large genome wide association (GWA) enterprises have led to the identification 
of numerous candidate genes. This is turn has focussed attention on hitherto 
unsuspected pathological mechanism in the aetiology of IBD. A particular example is 
that of the IL23/IL17 axis previously described in this chapter (see I.1.2). The 
techniques used in GWA studies and the findings from these studies have been 
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extensively reviewed elsewhere (Gaya, Russell et al. 2006; Kim and Misra 2007; 
Parkes, Barrett et al. 2007; Barrett, Hansoul et al. 2008; Zhang, Massey et al. 2008).  
I.1.5 Environmental Factors 
I.1.5.1 Microbial factors 
There is a dynamic balance between microbes, particularly commensal flora, and the 
host defense response at the mucosal frontier (Xavier and Podolsky 2007). The fact that 
CD and UC occur in the areas of highest intestinal bacterial concentrations and faecal 
flow, and that diversion of that flow can reduce the inflammation of CD (Winslet, Allan 
et al. 1994), as well as the observation that CD and experimental colitis in rodent 
models respond to treatment with antibiotics (Kang, Bloom et al. 2008), suggest that 
this microbe-host interaction may play a pivotal role in the pathogenesis of IBD. How 
this interaction produces disease has not been clearly defined. There are three main 
hypotheses:  
1. A single luminal pathogen, or functionally altered commensal bacteria, produces 
IBD.  
2. An alteration of the microbial composition in the lumen causes disease.  
3. That defective clearance and killing of bacteria leads to immune dysregulation 
and disease.  
The evidence supporting each of these hypotheses is discussed below. 
I.1.5.1.1 Pathogens as the cause for IBD 
Studies of the microbiota in IBD have failed to demonstrate enrichment of an individual 
pathogenic species in IBD but theories regarding the presence of such an organism 
continue to attract attention because of the similarities between CD, UC and enteric 
infections (Packey and Sartor 2009). There are two main organisms that have attracted 
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attention with respect to this theory: Mycobacterium avium subspecies paratuberculosis 
(MAP) and adherent/invasive E. coli (AIEC). 
I.1.5.1.1.1 Mycobacterium avium subspecies paratuberculosis 
MAP causes a spontaneous granulomatous enterocolitis (Johne’s disease) in ruminants, 
making it a credible causative agent for CD (Sartor 2005). However it has proven very 
difficult to either substantiate or invalidate a link between MAP and CD (Packey and 
Sartor 2009).  
 
MAP was first cultured from resected CD tissue in 1984 (Chiodini, Van Kruiningen et 
al. 1984). A number of studies have replicated this finding but the reported detection 
rate has ranged from 0% to 100% (Autschbach, Eisold et al. 2005; Sartor 2005; Behr 
and Schurr 2006). Interest in MAP as a causative agent was regenerated with the 
identification of defective innate immune mechanisms, such as the NOD2 
polymorphism (Sartor 2005; Behr and Schurr 2006). However, no association between 
NOD2 polymorphisms and MAP serology (Bernstein, Wang et al. 2007) or MAP 
culture was seen (Sechi, Gazouli et al. 2005). Credence was added to the theory by an 
uncontrolled report of long-lasting cure of CD by anti-mycobacterial antibiotic 
treatment (Gui, Thomas et al. 1997). However, a well-designed, 2-year prospective trial 
of clarithromycin, rifabutin, and ethambutol has failed to show sustained response 
(Selby, Pavli et al. 2007). 
I.1.5.1.1.2 Adherent/invasive E. coli 
E. coli comprise 99% of invasive bacterial isolates in mucosal biopsies of patients with 
CD as opposed to 42% in patients with UC and 2% in normal controls (Sasaki, 
Sitaraman et al. 2007). Serum antibodies directed against E. coli outer membrane 
protein C (OmpC) are present in 37-55% of patients with CD, in contrast to 5% or less 
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of patients with UC and without IBD. High serum reactivity to E. coli OmpC is 
associated with severe CD with longer disease duration, frequent disease progression, 
small bowel involvement and increased resections (Mow, Vasiliauskas et al. 2004). 
 
AIEC are commensal E. coli that exhibit functional changes that allow them to persist 
and even replicate within macrophages, inducing the secretion of large amounts of TNF 
(Glasser, Boudeau et al. 2001). Three independent studies have demonstrated that AIEC 
selectively colonise the ileum of patients with CD (Sasaki, Sitaraman et al. 2007), 
(Darfeuille-Michaud, Boudeau et al. 2004), (Baumgart, Dogan et al. 2007). In addition 
the prototypic AIEC strain, LF82, induced in-vitro granulomas using blood-derived 
mononuclear cells (Meconi, Vercellone et al. 2007). The mechanisms by which AIEC 
achieve increased epithelial adherence and invasion are still being elucidated. That these 
virulence factors might combine with IBD associated deficits in innate immunity and 
barrier function to promote disease is evidenced by the observation that macrophages 
from NOD2-deficient mice display defective clearance of a murine AIEC strain, with 
prolonged secretion of IL-12/23 p40 and tumour necrosis factor (Packey and Sartor 
2009). 
 
Attempts to define the luminal microbiota in a quantitative fashion have been aided by 
the development of molecular techniques. For example Conte et al. used conventional 
culture techniques for aerobic and facultative-anaerobic microorganisms, and molecular 
analysis (16S rRNA-based amplification and real-time polymerase chain reaction 
assays) for the detection of anaerobic bacterial groups or species in biopsy specimens of 
the ileum, caecum and rectum obtained at colonoscopy. They studied 12 patients with 
Crohn's disease, 7 with ulcerative colitis, 6 with indeterminate colitis and 7 controls 
(Conte, Schippa et al. 2006).  No single pathogen was linked to the presence of IBD. 
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However, there was an overall decrease in some bacterial species or groups belonging to 
the normal anaerobic intestinal flora; in particular, occurrence of Bacteroides vulgatus 
was low in Crohn's disease, ulcerative colitis and indeterminate colitis specimens.  
 
Thus it may be that the intestinal microbiota contributes to disease not by harbouring a 
single pathogenic agent but by subtle alterations in the normal flora that somehow 
promote disease. This concept has been termed dysbiosis. 
I.1.5.1.2 Dysbiosis 
The luminal microbiota is altered in IBD. In both CD and UC there is decreased 
complexity of the commensal bacteria (Packey and Sartor 2009). The most notable 
changes are the reduction in the members of the phyla Bacteroidetes and Firmicutes 
(Backhed, Ley et al. 2005). Faecal and mucosa-associated microbial communities in 
patients with CD and UC are consistently less diverse with increased temporal 
instability (Frank, St Amand et al. 2007; Dicksved, Halfvarson et al. 2008; Martinez, 
Antolin et al. 2008; Ott, Plamondon et al. 2008; Nishikawa, Kudo et al. 2009). The 
abnormal microbiota also correlates with the occurrence of abscesses in patients with 
CD, and IBD patients with dysbiosis undergo surgery at a younger age than those with 
normal microbiota (Frank, St Amand et al. 2007). 
 
Evidence that restitution of the luminal microbiota towards normal is beneficial to 
disease is provided by studies of probiotic preparations in IBD. There is evidence, albeit 
in small clinical trials, that VSL#3 can be efficacious in certain clinical situations 
(Packey and Sartor 2009). Recently particular attention has focussed on 
Faecalibacterium prausnitzii, a major member of the family Firmicutes. This bacteria 
was reduced in patients with CD and the reduction was associated with a higher risk of 
post-resection recurrence of ileal CD (Frank, St Amand et al. 2007; Swidsinski, 
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Loening-Baucke et al. 2008). In a supporting study oral administration of either live F. 
prausnitzii or its supernatant reduced the severity of trinitrobenzene sulfonic acid 
(TNBS) colitis and corrected the associated dysbiosis (Sokol, Pigneur et al. 2008). 
 
Changes in the intestinal microbiota produce changes in the intestinal environment that 
may contribute to disease. The preferred energy substrate of the colonic epithelial cell is 
short chain fatty acids (SCFA) such as butyrate. Clostridia and Bacteroides species 
produce SCFA and decreased concentration of certain Clostridial groups could explain 
the observed decreased SCFA concentration in faecal extracts from IBD patients 
(Marchesi, Holmes et al. 2007). In addition overgrowth of sulfate-reducing bacterial 
species in UC and ileal pouches could enhance hydrogen sulfide production, which in 
turn blocks the utilisation of butyrate by colonocytes (Roediger, Duncan et al. 1993). 
Finally, some commensal bacteria produce chemicals, such as hydrogen sulfide, nitric 
oxide and serine proteases, capable of harming colonocytes and matrix components 
(Roediger, Duncan et al. 1993). 
I.1.5.1.3 Defective clearance and killing of bacteria 
Parallels between the pathophysiology of CD and the gastro-intestinal manifestations of 
chronic granulomatous disease (CGD), a condition caused by defective clearance of 
commensal, opportunistic or pathogenic bacteria, invite speculation that the aetiological 
mechanism in CD might involve an underlying defect in bacterial killing and clearance. 
As outlined in section I.1.1, multiple defects in the mucosal defences have been 
identified in IBD, many of them involving underlying genetic defects.  
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I.1.5.2 Dietary factors 
Aside from the luminal microbiota, the other main luminal constituent is that which is 
ingested. The focus of the proceeding section is to outline the role that dietary factors 
might play in the aetiopathogenesis of IBD. 
I.2 Dietary influences on the aetiology of IBD 
Many methodologies have been employed to examine for a relationship between the 
development of IBD and specific dietary factors. With the obvious exception of breast-
feeding practices, the initial identification of associations has largely been by 
observational studies regarding the pre-illness intake of multiple dietary constituents. 
The important associations discovered by this method are summarised in Table 7 and 
the literature regarding the further elucidation of each of those associations in turn is 
outlined in the section below.  It should be noted that the main methodology employed 
has been case-control studies. These introduce a real risk of recall bias. Only one study 
to date has attempted to overcome this by using a prospective cohort methodology. In 
their study Hart et al. were able to examine a prospective cohort of 260,686 men and 
women resident in the UK, Sweden, Denmark, Germany and Italy (Hart, Luben et al. 
2008). Prospectively collected data on diet was available. In total there were 139 
subjects with incident UC in the cohort. No statistically significant association between 
diet and UC was found but there was a marginally significant positive association with 
increasing percentage intake of energy from total polyunsaturated fatty acids.
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(NA: not applicable) 
Table 7. Studies of pre-illness diet In IBD 
 
 Subjects Metho-
dology 
Dietary Associations 
with UC 
Dietary Associations with 
CD 
Martini and 
Brandes 
1976 
63 CD, 
63 
controls 
Case 
control 
NA Sweets and pastries 
Thornton, 
Emmett et al. 
1979 
30 CD, 
30 
controls 
Case 
control 
NA Refined sugar (negative 
association with dietary fibre, 
raw fruit and vegetables 
Kasper and 
Sommer 
1979 
35 CD, 
70 
controls 
Case 
control 
Sugar, starch and total 
energy 
NA 
Persson, 
Ahlbom et 
al. 1992 
152 CD, 
145 UC, 
305 
controls 
Case 
control 
Fast foods Sucrose and fast foods 
(negative association with 
fibre) 
Japan 1994 101 UC, 
143 
controls 
Case 
control 
Western foods (bread 
for breakfast, butter, 
margarine, cheese, 
meats, and ham and 
sausage)  
NA 
Tragnone, 
Valpiani et 
al. 1995 
104 UC 
and CD, 
104 
controls 
Case 
control 
Total protein, total 
carbohydrate, starch 
and refined sugar 
Total carbohydrate, starch 
and refined sugar 
Shoda, 
Matsueda et 
al. 1996 
CD 
cohort 
Populat
ion 
cohort 
NA Animal protein, increased 
ratio of n-6 to n-3 
polyunsaturated fatty acids 
Reif, Klein et 
al. 1997 
33 CD, 
54 UC, 
144 
controls 
Case 
control 
Sucrose, animal fat, 
cholesterol 
Sucrose 
Sakamoto, 
Kono et al. 
2005 
111 UC, 
128 CD, 
239 
controls 
Case 
control 
Sweets Sugars and sweeteners, 
sweets, fats and oils, fish and 
shellfish, total fat, 
monounsaturated fatty acids, 
and polyunsaturated fatty 
acids vitamin E and n-3 and 
n-6 fatty acids  
Amre, 
D'Souza et 
al. 2007 
130 CD, 
220 
control 
children 
(<=20) 
Case 
control 
NA (Negative association with 
vegetables, fruits, fish and 
dietary fibre) 
Hart, Luben 
et al. 2008 
139 UC  Prospec
tive 
cohort 
study 
No statistically 
significant association 
NA 
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I.2.1 Infant feeding practices  
Breastfeeding has been shown to protect against many immune-mediated diseases such 
as bronchial asthma and atopic dermatitis (Gdalevich, Mimouni et al. 2001), allergic 
rhinitis (Mimouni Bloch, Mimouni et al. 2002), and type 1 diabetes mellitus (Gerstein 
1994). This, combined with the observation that breast feeding may protect infants from 
gastrointestinal infections, (Duffy, Byers et al. 1986; Howie, Forsyth et al. 1990; 
Beaudry, Dufour et al. 1995) suggests it is reasonable to postulate that breastfeeding 
might have an effect on the development of IBD.  
 
The available epidemiological studies of the effect of breastfeeding on the development 
of IBD to 2003 was meta-analysed by Klement et al (Klement, Cohen et al. 2004).  
Together a total of 17 studies giving 2577 patients with UC and 3551 control subjects, 
and 3190 patients with CD and 4026 control subjects, were studied. They found that the 
protective effect of breastfeeding against both UC and CD remained statistically 
significant for all calculated pooled odds ratios (ORs) independent of the quality of the 
studies, with ORs of 0.67 (95% CI: 0.52, 0.86) for CD and 0.77 (0.61, 0.96) for UC in 
breastfed subjects. However, the results for both diseases appeared to be heterogeneous. 
In addition exploration for the possibility of publication bias, using funnel plots, 
indicated a possible publication bias in the studies for CD. 
 
Soon after the completion of the above meta-analysis a further case-control study was 
performed by Baron et al. examining the environmental risk factors prior to the 
development of IBD in a paediatric population (Baron, Turck et al. 2005). They studied 
a total of 222 incident cases of CD and 60 incident cases of UC compared to the same 
number of control subjects matched by sex, age and geographical location. They 
recorded 140 study variables in a questionnaire that covered familial history of IBD, 
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events during the perinatal period, infant and child diet, vaccinations and childhood 
diseases, household amenities, and the family's socioeconomic status. This study 
showed that while breastfeeding had no significant impact on the development of UC, it 
was significantly associated with an increased risk of developing CD (OR 2.1 (95% 
confidence interval 1.3-3.4)). 
 
Klement et al. went on to repeat their meta-analysis using the data from the study of 
Baron et al. They concluded that the study was conducted with the use of excellent 
methods and that it would diminish the significant results of protective breastfeeding on 
CD [Mantel-Haenszel odds ratio (ORMH): 0.62;
 95% CI: 0.27, 1.43] but would not 
affect significantly the summary estimate of the protective association between 
breastfeeding and UC (ORMH: 0.62; 95% CI: 0.43, 0.91). In addition, inclusion of this 
study further increased the high heterogeneity in the CD studies. This finding again 
emphasized the need for further high-quality studies of other population types to fully 
understand the association between breastfeeding and IBD (Klement and Reif 2005). 
I.2.2 Cow’s milk proteins 
In the earlier part of the 20th century a role for cows milk in the pathogenesis of IBD 
was widely propounded (Cashman and Shanahan 2003). In 1989 Koletzko et al. 
reported their controlled study of the association between infant feeding practices and 
IBD (Koletzko, Sherman et al. 1989). They compared 114 patients and their 180 
unaffected siblings from 107 families. Univariate analysis showed that patients with CD 
were less likely to have been breast fed (relative risk 3.6, 95% confidence interval 1.4 to 
9.0, p<0.01), more likely to have received formula food from birth (3.1, 1.3 to 7.4, 
p<0.02), and more likely to have had diarrhoeal illnesses during infancy (2.7, 1.5 to 5.8, 
p<0.02). Multivariate analysis, however, showed that only two factors, lack of breast-
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feeding and episodes of diarrhoeal disease during infancy, were independently 
associated with later development of CD. 
 
In 1990 Glassman et al. went on to investigate the association between cow’s milk 
sensitivity in infancy and the development of IBD (Glassman, Newman et al. 1990). 
They surveyed 78 patients with IBD (35 with CD and 43 with UC) and compared them 
to a control population of 36 children without organic disease. They asked patients and 
controls to report symptoms compatible with cow’s milk intolerance. The incidence of a 
history compatible with cow's milk intolerance was 8.5% (3/35) in patients with CD, 
similar to the 2.8% (1/36) incidence in controls. Patients with UC, however, had a 
significantly greater prevalence of cow’s milk intolerance compared with the other 
patient groups (20.9%, 9/43; p<0.03). In addition, patients with a history of cow's milk 
allergy, who subsequently developed UC, did so at an earlier age (6.68 +/- 2.05 yr vs. 
10.62 +/- 0.74 yr: p<0.02) than those without a history of cow's milk sensitivity. 
However, these results need to be interpreted with reservations because of the difficulty 
in assessing sensitivity to cow’s milk in this retrospective study. 
 
Further evidence for a role of cow’s milk in the pathogenesis of IBD is limited to 
studies of cow’s milk specific antibodies in IBD (see section I.3.2.8). The results from 
such studies vary widely. This may be due to different techniques used for measuring 
antibodies in those studies (Cashman and Shanahan 2003). One commentator has 
concluded that the only recognised value of studies showing elevated levels of serum 
antibodies to cow’s milk proteins is that they provide evidence that the lack of breast 
feeding and increased prevalence of cow’s milk antibodies may be risk factors for the 
later development of IBD (Mishkin 1997). 
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I.2.3 Dietary fat  
The epidemiological support for a role for dietary fat in the aetiology of IBD stems 
largely from the striking association between the increasing intake of animal fat in 
Japanese society and a parallel increase in the incidence of CD. Shoda et al. used data 
that recorded the daily intake of each dietary component using annual prospective 
interviews for 5 consecutive days for between 16500 and 68000 people each year from 
1966 through to 1985 (Shoda, Matsueda et al. 1996). They then compared this to 
incidence data for CD in Japan, obtained from a nationwide multicenter survey of the 
annual numbers of new patients with CD. This data suggests the number of patients 
with IBD in Japan has increased sharply during the past three decades. This increase 
may reflect improved diagnostic and recording practices as well as an increased 
awareness of the disease in recent years. Nonetheless, it does appear true that the actual 
incidence has increased as well (Yamamoto, Nakahigashi et al. 2009). 
 
Univariate analysis showed that the increased incidence of CD was strongly (p < 0.001) 
correlated with increased dietary intake of total fat (r = 0.919), animal fat (r = 0.880), n-
6 polyunsaturated fatty acids (r = 0.883), animal protein (r = 0.908), milk protein (r = 
0.924), and the ratio of n-6 to n-3 fatty acid intake (r = 0.792). It was less correlated 
with intake of total protein (r = 0.482, p < 0.05), was not correlated with intake of fish 
protein (r = 0.055, p > 0.1), and was inversely correlated with intake of vegetable 
protein (r = -0.941, p < 0.001). The multivariate analysis showed that increased intake 
of animal protein was the strongest independent factor with a weaker second factor, an 
increased ratio of n-6 to n-3 polyunsaturated fatty acids (Shoda, Matsueda et al. 1996). 
The eicosanoid biosynthesis pathway and the association of n-3 fatty acids with the 
product of anti-inflammatory cytokines vs. that of n-6 fatty acids with the pro-
inflammatory Arachidonic acid, provides a plausible biological mechanism for such an 
51 
association (see Figure 2). The role of the dietary ratio of n-3 to n-6 polyunsaturated 
fatty acids in IBD is considered in more detail in sections II.1.4.7 and II.2.5. 
 
 
Figure 2. Eicosanoid biosynthesis pathway (adapted from Calder 2004) 
 
A case control study, also conducted in Japan, found that fat intake, among other foods, 
was positively associated with CD (Sakamoto, Kono et al. 2005). They compared 239 
IBD patients (111 UC, 128 CD) to the same number of control subjects matched for sex, 
age and hospital. Using a semi-quantitative food frequency questionnaire they 
retrospectively estimated pre-illness intakes of food groups and nutrients. The intake of 
total fat (OR, 2.86; 95% CI, 1.39 to 5.90), monounsaturated fatty acids (OR, 2.49; 95% 
CI, 1.23 to 5.03), polyunsaturated fatty acids (OR, 2.31; 95% CI, 1.12 to 4.79), n-3 (OR, 
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3.24; 95% CI, 1.52 to 6.88) and n-6 fatty acids (OR, 2.57; 95% CI, 1.24 to 5.32) were 
all positively associated with CD risk. 
 
This data is supported by the 2007 study of Amre et al. (Amre, D'Souza et al. 2007). 
They examined the impact of diet on new onset CD in Canadian children, in a case-
control study. Newly diagnosed patients with CD 20 years old and younger were 
compared to population or hospital controls who were matched for time of diagnosis 
(+/-6 months) and area of residence. Dietary consumption 1 yr prior to disease diagnosis 
was evaluated using a validated food frequency questionnaire, administered within 1 
month of diagnosis. A total of 130 CD patients and 202 controls were studied. The 
consumption of long-chain omega-3 fatty acids (LCN-omega-3) was negatively 
associated with CD (OR 0.44, 95% CI 0.19-1.00, p<0.001). A higher ratio of LCN-
omega-3/omega-6 fatty acids was significantly associated with lower risks for CD (OR 
0.32, 95% CI 0.14-0.71, p=0.02). 
 
Reif et al. observed such an association for UC in a study conducted in Israel (Reif, 
Klein et al. 1997). Quantified dietary histories were obtained from 87 patients with 
recent IBD (54 UC and 33 CD) and 144 controls. A high fat intake was associated with 
an increased risk for UC; this was particularly marked for animal fat (OR 4.09, p=0.02) 
and cholesterol (OR 4.57, p=0.02). 
 
The observation of an association between fat intake and CD is not universal however. 
Tragnone et al. studied the dietary habits of 104 patients with IBD just prior to the onset 
of disease and compared this with the habits of a matched control population in Italy 
(Tragnone, Valpiani et al. 1995). They found no difference in fat consumption between 
IBD patients and controls. Other commentators have, however, pointed out that they 
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failed to correct for total energy intake, and this methodological limitation could have 
biased the results (Geerling, Stockbrugger et al. 1999). 
I.2.4 Margarine consumption 
A series of studies from Germany in the early 1980s suggested an association between 
margarine consumption and CD (Cashman and Shanahan 2003). This finding was also 
seen in UC patients in a multisite, hospital-based, case-control study conducted in Japan 
(EGotRCoIBDiJ 1994). 101 patients who had been diagnosed with UC within the 
previous 3 years were surveyed using self-administered patient questionnaires and 
compared to 143 control subjects. Margarine was positively associated with UC 
(p=0.005). 
 
An international epidemiological study failed to confirm an association between 
margarine consumption and IBD (Sonnenberg 1988). In that study the per capita 
consumption of margarine was correlated with the incidence and mortality of CD from 
different countries and the time trends of mortality from CD. No significant correlation 
was found between margarine consumption and the incidence of CD. The time trends of 
CD in different countries were not matched by similar time trends of margarine 
consumption. 
I.2.5 Refined carbohydrates  
Interest in the association of sugar and refined carbohydrate and the development of CD 
was ignited by the findings of Martini and Brandes in 1976 (Martini and Brandes 1976). 
They compared the nutritional habits of 63 patients with CD using questionnaires and 
compared them to a 63 person control group matched for age, sex and social status. 
There was a significantly higher pre-diagnosis consumption of refined carbohydrates in 
the CD group compared to controls. They, however, found no significant difference in 
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the intake of other foodstuffs such as proteins, fats, vegetables or alcohol. Since then 
there have been numerous studies confirming the observation (Cashman and Shanahan 
2003). 
 
The repeatability of this observation has led some authors to conclude that the most 
consistent, distinct dietary association with IBD is the relationship between increased 
consumption of refined carbohydrates and CD (Cashman and Shanahan 2003). One 
study allowed the estimation of the relative risk of developing CD with a high sugar 
intake. Katschinski et al. used a postal questionnaire to examine the association between 
smoking, added sugar intake and CD (Katschinski, Logan et al. 1988). They questioned 
104 CD patients and 153 community controls. They found that added sugar intake was 
associated with CD, independent of smoking and with a dose response pattern, with a 
relative risk for no added sugar vs. added sugar of less than 50g/day and greater than 
50g/day of 1.0, 1.8 and 4.6 (p<0.005) respectively. However, they found that in 
smokers, the addition of sugar to the diet did not significantly increase the risk of CD 
and thus concluded that the influences of smoking and added sugar may be operating 
through a common mechanism. 
 
Nonetheless, epidemiological studies have not shown a correlation between the rising 
incidence of IBD and any marked change in sugar consumption over the last 50 years 
(Riordan, Ruxton et al. 1998). In addition CD remains extremely rare in countries such 
as Saudi Arabia and Morocco despite a large indigenous intake of sugar (Kirsner and 
Shorter 1982). The differences in diet, therefore, could be interpreted as a consequence 
rather than a cause of the disease, or that other factors are required in combination for 
the development of disease (Cashman and Shanahan 2003). It also remains possible that 
increased refined carbohydrate intake may simply be an expression of the “modern 
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lifestyle” or “urban diet” and is confounded by other risk factors for the development of 
IBD (Russel, Engels et al. 1998; Mahmud and Weir 2001). 
I.2.6 Dietary fibre 
The role of breakfast foods, and by inference cereals, in the pathogenesis of CD was 
brought into the spotlight by the 1977 report of James (James 1977). In that report the 
breakfast habits in adult life of 34 patients with CD were compared with those of 68 
matched controls. An association between the consumption of cornflakes, but not other 
cereals, and CD was reported. This generated a flurry of discussion and further 
descriptive studies, the results of which varied widely but did not coincide with that of 
James (Archer and Harvey 1978; Rawcliffe and Truelove 1978). Since then several 
other studies have failed to show an association between cereal intake and CD 
(Cashman and Shanahan 2003). 
 
The consumption of dietary fibre, however, especially in the form of fruit, has been 
shown to be negatively associated with the risk of IBD (Cashman and Shanahan 2003). 
Reif et al. used quantified dietary histories from 87 patients with recent IBD (54 UC 
and 33 CD) and 144 controls to investigate the association between intake levels of 
various foods and IBD (Reif, Klein et al. 1997). They found a statistically non-
significant trend toward a negative association between a high intake of fruits and IBD. 
Conversely, decreased consumption of fruit, fruit juice and vegetables has been reported 
among IBD patients. Kasper et al. obtained individual dietary histories from 35 patients 
with CD and 70 normal controls (Kasper and Sommer 1979). In the patients with CD 
the mean dietary fiber intake was established as 26.6 +/- 1.4 g/day, compared to 22.3 +/- 
0.9 g/day in the controls (p<0.05). Mayberry et al. interviewed 48 men and 52 women 
with CD and compared them with 100 controls, matched for age and sex (Mayberry, 
Rhodes et al. 1978). They recorded breakfast food intake, but not total fruit and 
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vegetable intake. They found that significantly fewer patients than controls consumed 
fruit or fruit juice for breakfast. 
 
Thornton et al., in an attempt to reduce the recall bias inherent in the above studies, 
interviewed thirty newly diagnosed patients with CD and compared them with 30 
healthy controls, matched for age, sex, social class, and marital status (Thornton, 
Emmett et al. 1979). The patients ate slightly less dietary fibre, and considerably less 
raw fruit and vegetables, than the controls. In a further study by Porro et al. the smoking 
habits, and intake of refined carbohydrates and vegetable fibre were evaluated in 124 
patients suffering from UC, 109 patients with CD, and 250 controls matched by sex and 
age (Bianchi Porro and Panza 1985). A considerable intake of vegetables and fruit 
seemed to reduce the risk for IBD (relative risk (RR) for CD=0.36 and 0.66 
respectively; RR for UC=0.30 and 0.38). 
 
Each of these studies has inherent flaws. Many were subject to recall bias, with patients 
asked to remember their past intake of different food groups. In addition many asked 
specifically about breakfast intake, ignoring intake throughout the rest of the day. None 
were designed to be able to determine the causality of any association between intake 
and IBD.  
 
Nonetheless an association between dietary fibre intake and IBD remains biologically 
plausible as dietary fibre actively contributes to the intestinal anti-inflammatory effect 
associated with an increased production of short-chain fatty acids, mainly acetate, 
propionate and butyrate in the colonic lumen (Galvez, Rodriguez-Cabezas et al. 2005). 
These substances may accelerate intestinal repair, preserving the integrity of the 
intestinal mucosa, and downregulate the exacerbated immune response associated with 
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IBD (Segain, Raingeard de la Bletiere et al. 2000). The production of short-chain fatty 
acids, can also contribute to the inhibition of the production and release of 
proinflammatory cytokines, including IL-6, IL-8, TNF-alpha, and other mediators of 
inflammation such as reactive oxygen and nitrogen metabolites (Rodriguez-Cabezas, 
Galvez et al. 2002). 
I.2.7 Dietary protein  
In their 1985 study Gee et al. compared the dietary intakes of two groups of 
gastrointestinal patients, one group with IBD and the other with functional disorders - 
irritable bowel syndrome, nonulcer dyspepsia, or gastro-oesophageal reflux disease 
(Gee, Grace et al. 1985). They assessed the patients’ diet using 48-hour recalls and 
found an increased mean intake of protein among IBD patients compared with 
functional disorders subjects.  
 
Tragnone et al. also used dietary recall questionnaires in 104 IBD patients in Italy to 
study dietary habits immediately prior to the onset of disease (Tragnone, Valpiani et al. 
1995). They compared IBD patients to healthy subjects matched for age, sex and city of 
residence and found that total protein intake was significantly higher in UC, but not in 
CD patients, than in controls. In contrast, Shoda et al. used prospectively collected 
annual dietary information for a Japanese population between 1966 and 1985 (Shoda, 
Matsueda et al. 1996). On univariate analysis they found a weak correlation between the 
incidence of CD and total protein (r = 0.482, P < 0.05) but a strong correlation with 
increased dietary intake of total fat (r = 0.919). The multivariate analysis showed that 
increased intake of animal protein was the strongest independent factor associated with 
an increased risk of CD. 
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Finally Reif et al., again using dietary recall histories, compared 87 IBD patients (54 
UC and 33 CD) and 144 controls (Reif, Klein et al. 1997). They failed to find an 
association between total protein intake and risk of IBD. 
 
Apart from the Japanese study, these studies were subject to recall bias and the dietary 
histories were based on dietary recall. None of the studies were designed to prove a 
causal relationship. It remains possible an increase in dietary protein might represent a 
response to the disease rather than an aetiological factor. 
I.2.8 Dietary microparticles 
Powell et al. described microparticles resident in phagolysosomes of macrophages at 
the base of human gut associated lymphoid tissue (GALT) (Powell, Ainley et al. 1996). 
They identified three distinct types of microparticle: type I - spheres of titanium 
dioxide; type II - aluminosilicates; and type III - mixed environmental silicates without 
aluminium. The association of such microparticles with non-gastrointestinal disease 
raised the concern that such microparticles might be pathogenic in the gut. 
 
The same group investigated whether one of these microparticles, titanium dioxide 
(TiO2), could alter intestinal cell responsiveness to lipopolysaccharide (LPS) (Powell, 
Harvey et al. 2000). They took colonic biopsy specimens from 28 patients with UC, 21 
with CD, and 36 healthy controls.  These samples were incubated either alone, with 
LPS, with TiO2, or with LPS adsorbed to TiO2. They saw no increase in IL-1 secretion 
when the intestinal organ cultures were challenged with TiO2 or LPS alone, but saw a 
two-to-three-fold increase in IL-1 production with the addition of the TiO2-LPS 
conjugate. They concluded the ultrafine particles were not immunologically inert and 
that they might be important adjuncts in the mediation of the response of the gut 
immune system to luminal antigens. 
59 
 
This group then went on to define the intake of such microparticles in the diets of 91 
CD patients compared to 91 general practice-based controls (Lomer, Hutchinson et al. 
2004). While there was wide variation in intakes of microparticles between individuals 
there was no significant difference between subjects with CD and controls. 
I.2.9 Antioxidant vitamins (C, E and carotenoids) 
In epidemiological studies a negative association was observed between the intake of 
fruits and vegetables, in particular raw fruits and vegetables, and the development of 
IBD (Thornton, Emmett et al. 1979) (Amre, D'Souza et al. 2007). The role fibre intake 
might play in this has been discussed (see section I.2.6). It is also possible that other 
micronutrients found predominately in those foods might play a role. The antioxidant 
vitamins (C, E and the carotenoids) are found in high relative concentrations in these 
foods. There is a strong interaction between oxidative stress and inflammation (Calder 
2009). Oxidants and oxidised cell components, acting through transcription factors such 
as NF-kB, induce production of inflammatory eicosanoids and cytokines (see Figure 3). 
Many of these mechanisms are held in common with IBD. This section briefly outlines 
the evidence to link the antioxidant vitamins to a protective role in IBD. 
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(IkB: inhibitory subunit of NF-kB; IL: interleukin; NF-kB: nuclear factor kappa B; PG: 
prostaglandin; TNF: tumour necrosis factor) 
Figure 3. The interaction between oxidant stress and inflammation (adapted from 
Calder, Albers et al. 2009) 
I.2.9.1 Vitamin C 
The term vitamin C includes ascorbic acid (AA) and dehydroascorbic acid. Vitamin C is 
essential for humans as we are unable to synthesise AA from glucose due to a lack of 
the enzyme gulonolactone oxidase. The main dietary sources of vitamin C in the 
Western diet are fruits and vegetables. The recommended five servings per day of fruits 
and vegetables should provide at least 200 mg of vitamin C, compared to the 
recommended daily intake of 75 to 90 mg/day. Vitamin C plays an important role in 
mechanisms involved in immune function and inflammatory processes, including free 
radical scavenging and protection against lipid peroxidation. In addition to its 
antioxidant action, vitamin C is a cofactor for enzymes involved in the biosynthesis of 
collagen, carnitine and neurotransmitters as well as corticosteroids, the microsomal 
drug-metabolising enzymes and cytochrome P-450 electron transport. It modulates iron 
absorption, transport and storage. AA has also been shown to modulate prostaglandin 
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synthesis. Vitamin C also affects antimicrobial and natural killer cell activities, 
lymphocyte proliferation, chemotaxis and delayed-type hypersensitivity (Calder, Albers 
et al. 2009).  
 
Medline was searched using the terms “vitamin C”, “ascorbic acid”, “ulcerative colitis”, 
“Crohn” and “inflammatory bowel disease”. All articles that compared the intake of 
vitamin C, or the serum, tissue or other levels of ascorbic acid, to control values or 
reference parameters are summarised in Table 8. 
 
All studies show either decreased serum ascorbic acid (SAA) or leucocyte ascorbic acid 
(LAA) in IBD patients. In those studies where vitamin C intake was measured it was 
generally reduced in IBD. There was, however, evidence of normal absorption of 
vitamin C into the mucosa of the small bowel in CD patients. Colonic samples from CD 
and UC patients demonstrated reduced levels of AA in inflamed compared to non-
inflamed tissue. Only one study compared SAA in patients with active vs. inactive CD 
and no difference was seen (Geerling, v Houwelingen et al. 1999). 
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(AA: ascorbic acid; LAA: leucocyte AA; SAA: serum AA; cf: compared with; NA: not 
applicable; Vit C: vitamin C; UC: ulcerative colitis; CD: Crohn disease) 
Table 8. Observational studies of vitamin C in IBD
 Patient group Method Results in UC Result in CD 
Gerson 1975 20 CD, 20 CD on 
vit C supplement 
and 32 controls 
SAA and LAA NA Decreased SAA 
and LAA in CD, 
higher with 
supplements but 
still low cf 
controls 
Linaker 1979 10 CD and 10 
controls 
Vit C intake and 
LAA 
NA Normal intake but 
reduced LAA cf 
controls 
Hodges, Gee et al. 
1984 
47 CD Vit C intake NA Adequate intake 
cf. reference 
parameters 
Imes, Dinwoodie et 
al. 1986 
137 CD Vit C intake and 
SAA and LAA 
NA Lower than 
reference range 
vit C intake and 
low SAA and 
LAA 
Fernandez-
Banares, Abad-
Lacruz et al. 1989 
15 UC and 8 CD 
with acute or 
subacute disease 
and 89 controls 
SAA Decreased SAA 
cf. controls 
Decreased SAA 
cf. controls 
Pettit, Shaffer et al. 
1989 
12 CD and 6 
controls 
Measured 
absorption of 
labelled AA into 
small bowel 
samples 
NA AA absorption 
normal in CD 
Buffinton and Doe 
1995 
17 CD and 13 UC Compared AA in 
inflamed and non-
inflamed colonic 
biopsies 
AA decreased by 
73% 
AA decreased by 
35% in inflamed 
tissue 
Hoffenberg, 
Deutsch et al. 1997 
12 CD and 12 UC 
children and 23 
controls 
SAA Decreased SAA 
cf. controls 
Decreased SAA 
cf. controls 
Geerling, Badart-
Smook et al. 1998 
32 CD and 32 
matched controls 
SAA NA Decreased cf. 
controls 
Geerling, v 
Houwelingen et al. 
1999 
12 active CD, 50 
inactive CD and 
70 controls 
SAA NA Decreased cf. 
controls, no 
signifcant 
difference 
between active 
and inactive CD 
Wendland, 
Aghdassi et al. 
2001 
37 CD and 37 
matched controls 
SAA NA Decreased cf. 
controls 
Filippi, Al-Jaouni 
et al. 2006 
54 CD in 
remission and 25 
controls 
Vit C intake and 
SAA 
NA Decreased intake 
cf. control and 
decreased SAA 
Hengstermann, 
Valentini et al. 
2008 
100 CD, 67 UC 
(majority in 
remission) and 45 
matched controls 
SAA Decreased cf. 
controls (did not 
differentiate UC 
from CD) 
Decreased cf. 
controls (did not 
differentiate UC 
from CD) 
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I.2.9.2 Vitamin E 
Vitamin E is a potent chain-breaking antioxidant that acts mainly in the lipid phase and 
interrupts the chain reaction of lipid peroxidation and, consequently, prevents the 
propagation of free radical-initiated reactions (Calder, Albers et al. 2009). 
 
Medline was searched using the terms “vitamin E”, “tocopherol”, “ulcerative colitis”, 
“Crohn” and “inflammatory bowel disease”. All articles that compared the intake of 
vitamin E, or the serum, tissue or other levels of tocopherols, to control values or 
reference parameters are summarised in Table 9. 
 
The reports of tocopherol levels in IBD are conflicting. Reports of no difference in 
levels in control compared with diseased subjects are balanced by reports of low levels 
in disease. Notably there is even one paper that reports increased levels of alpha-
tocopherol in UC and CD (Hoffenberg, Deutsch et al. 1997).
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(NA: not applicable; vit: vitamin; RBC: red blood cell; cf: compared with) 
Table 9. Observational studies of vitamin E in IBD 
 
 Patient group Method Results in UC Result in CD 
Kuroki, Iida et al. 
1994 
13 CD at 
diagnosis and 12 
controls 
Serum and RBC 
vit E 
NA Serum level 
decreased cf. 
control, RBC 
level no 
difference 
Buffinton and Doe 
1995 
28 CD and 28 UC  Compared alpha-
tocopherol in 
inflamed and non-
inflamed colonic 
biopsies 
No difference in 
inflamed vs. non-
inflamed tissue 
No difference in 
inflamed vs. non-
inflamed tissue 
Hoffenberg, 
Deutsch et al. 1997 
12 CD and 12 UC 
children and 23 
controls 
Plasma alpha- and 
gamma-
tocopherol 
Increased alpha-
tocopherol cf. 
controls, gamma-
tocopherol 
unchanged 
Increased alpha-
tocopherol cf. 
controls, gamma-
tocopherol 
unchanged 
Ramakrishna, 
Varghese et al. 
1997 
19 active UC and 
19 controls 
Plasma vit E No difference 
from controls 
NA 
Bousvaros, 
Zurakowski et al. 
1998 
61 CD, 36 UC 
and 23 controls 
(paediatric and 
young adult) 
Serum alpha-
tocopherol 
Decreased cf. 
controls  
Decreased cf. 
controls 
Geerling, Badart-
Smook et al. 1998 
32 CD and 32 
matched controls 
Serum vit E NA Decreased cf. 
controls 
Geerling, v 
Houwelingen et al. 
1999 
12 active CD, 50 
inactive CD and 
70 controls 
Serum vit E NA No difference cf. 
controls 
Genser, Kang et al. 
1999 
24 CD and 33 
controls 
Alpha- and 
gamma-
tocopherols 
NA Gamma-
tocopherol 
elevated and 
alpha-tocopherol 
no difference cf. 
controls 
D'Odorico, 
Bortolan et al. 
2001 
46 UC, 37 CD 
and 386 controls 
Plasma vit E Decreased cf. 
controls 
Decreased cf. 
controls 
Sampietro, 
Cristaldi et al. 
2002 
20 CD listed for 
surgery and 134 
controls 
Plasma vit E NA Decreased cf. 
control, returned 
to control levels 
following surgery 
Filippi, Al-Jaouni 
et al. 2006 
54 CD in 
remission and 25 
controls 
Vit E intake and 
plasma 
concentration 
NA Decreased intake 
cf. control and 
decreased plasma 
concentration 
Kawakami, Okada 
et al. 2007 
27 UC and 27 
controls 
Serum alpha-
tocopherol 
Decrease cf. 
controls 
NA 
Hengstermann, 
Valentini et al. 
2008 
100 CD, 67 UC 
(majority in 
remission) and 45 
matched controls 
Plasma vit E No difference cf. 
controls (did not 
differentiate UC 
from CD) 
No difference cf. 
controls (did not 
differentiate UC 
from CD) 
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I.2.9.3 Carotenoids 
Carotenoids are coloured pigments found in nature. They are responsible for the typical 
colour of fruits and vegetables as well as some animals. The most prevalent carotenoids 
in the Western diet are alpha-carotene, beta-carotene, lycopene, beta-cryptoxanthin, 
lutein and zeaxanthin. Carotenoids possess immunomodulatory activities in human 
subjects and animals including stimulation of the phagocytic and bacteria-killing ability 
of peripheral blood neutrophils and peritoneal macrophages and of lymphocyte 
blastogenesis, increasing the population of specific lymphocyte subsets and lymphocyte 
cytotoxic activity, as well as stimulation of the production of various cytokines. Beta-
carotene inhibits inflammatory gene expression by suppressing the activation of the 
redox-sensitive transcription factor, NF-kB (Calder, Albers et al. 2009).  
 
Medline was searched using the terms “carotene”, “ulcerative colitis”, “Crohn” and 
“inflammatory bowel disease”. All articles that compared the intake of carotenoids, or 
the serum, tissue or other levels of carotenoids, to control values or reference 
parameters are summarised in Table 10. 
 
All available observational studies but one found that serum carotenoids were reduced 
in UC and CD. Most studies examined serum beta-carotene levels but those that 
investigated a wider range of carotenoids showed similar results among the other 
carotenoids. The carotenoid levels were lower in active disease. One study looked at 
intake and showed that CD patients had a lower intake of beta-carotene than controls 
(Filippi, Al-Jaouni et al. 2006).
66 
(NA: not applicable; cf: compared with) 
Table 10. Observational studies of carotenoids in IBD
 Patient group Method Results in UC Result in CD 
Sharman, Dick et 
al. 1979 
107 UC and 
controls 
Serum 
carotenoids 
Decreased only in 
active UC 
NA 
Fernandez-
Banares, Abad-
Lacruz et al. 1989 
15 UC and 8 CD 
with acute or 
subacute disease 
and 89 controls 
Serum beta-
carotene 
Decreased beta-
carotene cf. 
controls 
Decreased beta-
carotene cf. 
controls 
Hoffenberg, 
Deutsch et al. 1997 
12 CD and 12 UC 
children and 23 
controls 
Plasma beta-
carotene 
Beta-carotene not 
different from 
controls 
Beta-carotene not 
different from 
controls 
Geerling, Badart-
Smook et al. 1998 
32 CD and 32 
matched controls 
Serum beta-
carotene 
NA Decreased cf. 
controls 
Geerling, v 
Houwelingen et al. 
1999 
12 active CD, 50 
inactive CD and 
70 controls 
Serum beta-
carotene 
NA Decreased cf. 
controls and in 
active cf. inactive 
CD 
Genser, Kang et al. 
1999 
24 CD and 33 
controls 
Plasma alpha- and 
beta-carotene, and 
cryptoxanthin 
NA All carotenoids 
decreased cf. 
controls 
Rumi, Szabo et al. 
2000 
28 CD and 23 
controls 
Serum lutein, 
zeaxanthin, alpha-
and beta-carotene, 
alpha- and beta-
cryptoxanthin 
NA Decreased lutein, 
zeaxanthin, alpha- 
and beta-carotene 
D'Odorico, 
Bortolan et al. 
2001 
46 UC, 37 CD 
and 386 controls 
Plasma total 
carotenoids 
Decreased cf. 
controls 
Decreased cf. 
controls 
Wendland, 
Aghdassi et al. 
2001 
37 CD and 37 
matched controls 
Plasma alpha- and 
beta-carotene, 
lycopene and 
beta-
cryptoxanthin 
NA All decreased cf. 
controls 
Filippi, Al-Jaouni 
et al. 2006 
54 CD in 
remission and 25 
controls 
Beta-carotene 
intake and plasma 
concentration 
NA Decreased intake 
cf. control and 
decreased plasma 
concentration 
Kawakami, Okada 
et al. 2007 
27 UC and 27 
controls 
Serum beta-
carotene 
Decrease cf. 
controls 
NA 
Hengstermann, 
Valentini et al. 
2008 
100 CD, 67 UC 
(majority in 
remission) and 45 
matched controls 
Plasma beta-
cryptoxanthin, 
lycopene, alpha- 
and beta-
carotenes and 
sum of 
carotenoids 
Decreased cf. 
controls (did not 
differentiate UC 
from CD). Beta-
carotene lower in 
active than 
inactive disease 
Decreased cf. 
controls (did not 
differentiate UC 
from CD). Beta-
carotene lower in 
active than 
inactive disease 
Maor, Rainis et al. 
2008 
16 active CD, 27 
stable CD and 15 
controls 
Serum beta-
carotene 
NA Decreased in 
active cf. stable 
and both cf. 
control 
Drai, Borel et al. 
2009 
20 CD and 21 
controls 
Plasma 
carotenoids 
NA Decreased cf. 
controls 
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I.2.9.4 Studies of antioxidants in animal models of IBD 
Medline was searched using the terms “carotene”, “vitamin E”, “tocopherol”,  
“vitamin C”, “ascorbic acid”, “ulcerative colitis”, “Crohn” and “inflammatory bowel 
disease”. All studies that examined the effect of antioxidants on an animal model of 
IBD are summarised in Table 11.  
 
The reported studies show a universal benefit of antioxidant treatment in animal models 
of IBD. Two studies showed that antioxidants were particularly beneficial when 
chemically induced colitis was augmented by the administration of iron (Carrier, 
Aghdassi et al. 2002; Reifen, Nissenkorn et al. 2004). 
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 Animal model Intervention Result 
Sato, Kanazawa 
et al. 1998 
TNBS induced 
colitis in rats 
Alpha-
tocopherol 
Decreased colonic damage 
Carrier, 
Aghdassi et al. 
2002 
DSS induced 
colitis in rats 
augmented by iron 
dl-alpha-
tocopherol 
acetate 
Decreased colonic 
inflammation and rectal 
bleeding but did not affect 
oxidative stress 
Lavy, Naveh et 
al. 2003 
Acetic acid 
induced enteritis in 
rats 
Beta-carotene Prevented acid induced 
histological change and 
reduced mucosal 
myeloperoxidase activity 
Ademoglu, 
Erbil et al. 2004 
TNBS induced 
colitis in rats 
Selenium and 
vitamin E 
Combination improved 
histopathology but either 
alone did not 
Reifen, 
Nissenkorn et 
al. 2004 
Iodoacetamide 
induced colitis in 
rats, augmented by 
iron ingestion 
Lycopene and 
beta-carotene 
Weight of ulcerated area 
of colon was reduced by 
lycopene but not beta-
carotene 
Isozaki, 
Yoshida et al. 
2006 
TNBS induced 
colitis in rats 
The water-
soluble vitamin 
E derivative 
TMG injected 
intraperitoneally 
TMG reduced the damage 
score, wet weight of colon, 
peroxidative activity 
Bitiren, 
Karakilcik et al. 
2010 
Acetic acid 
induced colitis in 
rats 
Vit E and 
selenium 
Decreased microscopic 
and macroscopic colonic 
damage and improved 
oxidative status 
(TNBS: trinitrobenzene sulfonic acid; TMG: 2-(alpha-D-glucopyranosyl)methyl-
2,5,7,8-tetra-methylchroman-6-ol; DSS: dextran sulfate sodium) 
Table 11. Studies of antioxidants in animal models of IBD 
 
I.2.9.5 Human studies of antioxidants in IBD 
Medline was searched using the terms “carotene”, “vitamin E”, “tocopherol”,  
“vitamin C”, “ascorbic acid”, “ulcerative colitis”, “Crohn” and “inflammatory bowel 
disease”. All studies that examined the effect of antioxidants on clinical activity of IBD, 
or on oxidative status in patients with IBD, are summarised in Table 12. 
 
In patients with IBD, supplementation with antioxidant vitamins can improve the serum 
levels of antioxidants (Geerling, Badart-Smook et al. 2000; Akobeng, Richmond et al. 
2007). To date studies examining the effect of antioxidant preparations on human 
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disease have been small in size and methodologically limited. One large randomised 
controlled trial is available and did show a benefit but a combination of fish oil, fibre 
and antioxidants was used, making it impossible to divine the benefit exhibited by the 
antioxidant part of the intervention (Seidner, Lashner et al. 2005). A recent pilot study 
of the effect of alpha-tocopherol enemas in UC is encouraging but further randomised 
controlled trials will be necessary before this treatment can be recommended 
(Mirbagheri, Nezami et al. 2008). 
 
 Study 
type 
Subjects Intervention Results 
Hermanowicz, 
Sliwinski et al. 
1985 
Open label 
study 
38 UC Ascorbic acid 6 
months 
No clinical 
benefit 
Bennet 1986 Case 
report 
1 UC Alpha-
tocopherylquinone 
Colonic and 
extra-intestinal 
manifestations 
improved with 
treatment and 
worsened with 
withdrawal 
Aghdassi, 
Wendland et al. 
2003 
RDBPCT 57 CD Vit E (800 iu) and 
vit C (1000mg) or 
placebo for 4 
weeks 
Reduced 
oxidative stress 
measures 
Tsujikawa, 
Kanauchi et al. 
2003 
Open label 
study 
11 CD Chitosan (fibre) 
and ascorbic acid 
for 8 weeks 
No effect on 
disease activity 
Seidner, Lashner 
et al. 2005 
RDBPCT 121 CD Fish oil, soluble 
fiber, vit E, vit C 
and selenium cf. 
carbohydrate 
formula for 6 
months 
No difference in 
DAI but 
reduced 
prednisone 
requirement 
Mirbagheri, 
Nezami et al. 
2008 
Open label 
study 
15 mild to 
moderate 
UC 
d-alpha 
tocopherol enema 
(8000 U/d) for 12 
weeks and 
concomitant 
5ASA or 
immunomodulator 
Average DAI 
reduced after 12 
weeks, 9/14 
(64%) 
completing 
followup in 
remission 
(RDBPCT: randomised double blind placebo controlled trial; DAI: disease activity 
index; 5ASA: 5-aminosalicylic acid) 
Table 12. Studies of antioxidants in IBD 
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I.2.9.6 Conclusions regarding antioxidant vitamins in IBD 
Levels of antioxidant vitamins, in particular ascorbic acid and carotenoids but also 
potentially tocopherols, are reduced in patients with IBD. Supplementation of patients 
with IBD does improve their antioxidant levels and can improve their oxidation status. 
Animal studies of the effect of antioxidant supplementation in animal models of IBD 
have invariably shown benefit. However, high quality studies of this sort in humans are 
lacking and those which are available have combined treatments, limiting our ability to 
draw conclusions as to the benefit of any individual component. Further high quality 
randomised controlled trials of antioxidant therapies in IBD are indicated by the 
positive results to date.  
I.3 Dietary allergy in the aetiology of IBD 
I.3.1 The potential for food allergy to act as a pathogenic 
agent in IBD 
The lack of concordance for IBD in twin studies and the partial penetrance of genetic 
defects associated with IBD suggest an environmental influence in the aetiology of the 
disease. The two main triggers implicated are luminal microbiota and ingested 
substances.  
 
The bowel mucosa acts as a physical barrier to dietary and microbial antigens. 
However, even under normal physiological conditions, intact food antigens can 
penetrate the mucosal barrier via transcellular or paracellular routes (Warshaw, Walker 
et al. 1974; Walker 1986; Sanderson and Walker 1993; Beier and Gebert 1998). The 
integrity of the GI mucosa is further compromised by inflammatory conditions such as 
IBD.  Hence the immune components of the GI tract, principally resident in the lamina 
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propria and Peyer’s patches, are continually exposed to the potentially antigenic 
components of the luminal contents. 
 
Early work suggested an association between IBD and atopic and allergic disease 
(Hammer, Ashurst et al. 1968; Jewell and Truelove 1972; Roberts, Rhodes et al. 1978; 
Pugh, Rhodes et al. 1979). However, other investigaters were unable to substantiate 
those associations (Mee, Brown et al. 1979; Troncone, Merrett et al. 1988). Nonetheless 
the observation has fuelled further investigation into an allergic component in the 
pathogenesis of IBD. This section serves to outline potential allergic mechanisms in the 
pathogenesis of IBD, in particular IgE mediated or Type I allergy and also IgG 
mediated hypersensitivity, and the literature supporting and refuting these. 
I.3.2 Hypersensitivity and IBD 
Hypersensitivity can be described as taking two forms, immediate and delayed. The 
immediate types include type I – anaphylactic, type II – antibody dependent cytotoxic, 
and type III – immune complex mediated. The immediate hypersensitivity most relevant 
to gastro-intestinal disorders and food allergy is type I. In addition there is a fourth type, 
delayed or cell mediated hypersensitivity, often referred to as non-IgE allergy or non-
atopic allergy (Roitt 1997; Kay 2001). 
 
Although there is little direct evidence that IgE mediated hypersensitivity to food 
antigens plays a role in the pathogenesis of IBD, a role for the effector mechanisms of 
hypersensitivity in IBD would raise the possibility that hypersensitivity might be 
implicated in the pathogenesis of IBD. This section briefly discusses the pathogenesis of 
hypersensitivity and then goes on to discuss the evidence of a role for its different 
constituent parts in the aetiopathogenesis of IBD.  
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I.3.2.1 Nomenclature in GI hypersensitivity 
A combined position statement from the European Academy of Allergology and 
Clinical Immunology, and the World Allergy Organization clearly defines the 
appropriate nomenclature to be used when discussing gastrointestinal allergy 
(Johansson, Bieber et al. 2004). The aim of this document was to present a globally 
acceptable nomenclature for allergic diseases, with the ultimate goal of improving 
communication in the field of allergy 
 
In that document hypersensitivity is defined as “objectively reproducible symptoms or 
signs initiated by exposure to a defined stimulus at a dose tolerated by normal persons”. 
Such hypersensitivity to food is termed “food allergy” only when immunologic 
mechanisms have been demonstrated. All other reactions to foods should be referred to 
as “nonallergic food hypersensitivity”.  
 
These definitions were not designed to encompass those gastrointestinal symptoms that 
have not been objectively and repeatedly proven to relate to a defined ingested stimulus. 
In this section and the sections that follow I have used the term “food intolerance” to 
describe those instances where hypersensitivity to food, as evidence by repeated 
objective adverse response to a defined food, has not been proven but nonetheless, an 
adverse response to a food has been reported or observed.  
I.3.2.2  Immediate hypersensitivity 
In the type I reaction previously sensitised mast cells are induced to release 
inflammatory mediators by contact with cross-linked IgE. These mediators result in 
increased vascular permeability, smooth muscle contraction and the classical wheal and 
flare response.  
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The main preformed inflammatory mediators involved in the type I reaction are 
histamine, heparin, neutral protease, eosinophil and neutrophil chemotactic factors, and 
platelet activating factor. These are stored in cytoplasmic granules in the mucosal mast 
cell and are released following cross-linking of IgE antibodies, and more weakly of 
IgG4 antibodies, with IgE receptors on the surface of the mast cell. In addition to 
degranulation, the leukotrienes LTB4, LTC4 and LTD4, the prostaglandin PGD2 and 
thromboxanes are newly synthesized on activation, as well as IL-3, IL-4, IL-5 and IL-6 
and GM-CSF (Roitt 1997). 
 
Preferential accumulation of eosinophils occurs because of the actions of IL-3, IL-5 and 
granulocyte-macrophage colony stimulating factor (GM-CSF). This applies particularly 
to IL-5 which primes eosinophils for enhanced locomotor attractions towards other type 
I inflammatory mediators (Roitt 1997). 
I.3.2.3 Delayed hypersensitivity 
The immunomodulators and pro-inflammatory agents released by mast cell 
degranulation result in granulocyte, lymphocyte and monocyte/macrophage migration 
and activation. This results in a more protracted hypersensitivity response (Dvorak, 
Mihm et al. 1976; Charlesworth, Hood et al. 1989; Gauchat, Henchoz et al. 1993; 
Bischoff 1996). The role of this delayed phase reaction in asthma and atopic eczema is 
well demonstrated (Brostoff, Johns et al. 1977; Metzger, Hunninghake et al. 1985). It 
has also been suggested that a similar mechanism may play a role in food allergy in the 
gut (Crowe and Perdue 1992).  
I.3.2.4 IgE in IBD 
I.3.2.4.1 Total serum IgE  
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Total serum IgE is elevated in a number of conditions that are mediated by type I 
allergy (Grammatikos 2008). If IBD were mediated in a similar fashion it might be 
expected that total serum IgE levels might be elevated in IBD also. Levo et al. looked at 
the serum concentration of IgE in patients with IBD (Levo, Shalit et al. 1986). They 
found that the serum concentration of IgE, as well as the prevalence of patients with 
“high IgE”, was significantly increased in IBD. Among patients with IBD, those with 
CD or those in relapse had the highest levels of IgE. They concluded that, based on 
these findings, allergy might play a pathogenic role in a subset of IBD patients. 
 
Other investigators, however, have not replicated this finding. In their 1977 study Pepys 
et al. found that only 12 of 39 patients with CD and 5 of 20 with UC had elevated serum 
levels of IgE. Their patient group included patients with documented atopy (Pepys, 
Druguet et al. 1977). Mee et al. compared the serum IgE levels of 39 UC and 35 CD 
patients with control subjects (Mee, Brown et al. 1979). They found no difference in 
serum IgE levels between the groups. Troncone et al. found no difference between 
controls and IBD patients, or IBD subgroups, when they measured serum IgE levels in 
122 patients with IBD and 103 age-matched controls (Troncone, Merrett et al. 1988). 
Finally, Brignola et al. studied 50 patients with UC, 50 patients with CD and 100 
healthy controls matched for sex and age (Brignola, Miniero et al. 1986).  There was no 
significant difference in the total serum IgE level between UC, CD and controls. 
I.3.2.4.2 Serum food specific IgE antibodies 
In addition to measuring the total serum IgE in IBD patients, Brignola et al. evaluated 
the presence of food specific IgE antibodies to 10 foods using the radioallergosorbent 
test (RAST). They found that a positive reaction to specific IgE was significantly less 
frequent in controls than in UC and CD. The result was also more often positive in CD 
patients with colonic or ileocolonic involvement than in isolated ileal disease.  
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Frieri et al. found an increase in total serum IgE in only 3 of 11 CD patients (Frieri, 
Claus et al. 1990). They in turn looked for specific IgE antibodies to foods, this time 
using enzyme linked immunosorbent assay (ELISA) for specific IgE antibodies to five 
foods (egg, milk, wheat, soy and corn). In their study all patients had low to negative 
serum IgE levels to all foods. Bartunkova et al. also used ELISA to detect specific IgE 
to nine food allergens (chicken egg white, cow’s milk, peanut, soy bean, apple, walnut, 
gliadin, carrot, and fish) in children with CD, UC and coeliac disease. Only 2 of 23 UC 
and 3 of 21 CD patients tested positive for food specific IgE antibodies. There was no 
difference between any of the groups. Unfortunately both these studies lacked a disease 
free control group with which to make comparisons regarding the significance of these 
results. 
 
Finally Huber et al. considered whether a lack of detectable IgE specific food antibodies 
in serum might relate to the formation of IgG anti-IgE immune complexes, which would 
effectively ‘hide’ the specific IgE present from RAST studies (Huber, Genser et al. 
1998). They examined the serum of 107 patients with CD and 65 healthy controls, 
unmasking specific IgE from anti-IgE autoantibodies by treating the purified immune 
complexes in a low pH environment in order to detect ‘real’ levels of specific IgE in 
RAST immunoassay. They again found no increase in food specific IgE antibodies in 
CD compared to controls.  
I.3.2.4.3 Luminal IgE 
The main secreted immunoglobulin subtype of the intestinal mucosa is IgA. Normally 
very little IgE secretion occurs but variable levels are detectable in the stool of well 
people (Kolmannskog, Florholmen et al. 1986). The absence of serum IgE reactivity in 
IBD reduces the likelihood that specific IgE antibodies play a strong role in the 
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pathogenesis of IBD, but it remains possible that IgE antibodies might play a role at the 
luminal surface that is not reflected in serum studies. Very little information exists 
regarding this possibility, largely because of the difficulty in designing techniques 
capable of examining any involvement. 
 
Total IgE levels in the intestinal lumen are elevated in childhood allergy and parasitic 
disease (Schwab, Raithel et al. 2001). In a study of the excretion of IgE in faeces 
Kolmannskog et al. found that less than 10% of 88 presumably healthy infants, 
children, and adults had detectable IgE in their feces. Conversely 21 of 40 (53%) of 
children with various kinds of allergy had measurable fecal IgE. That was compared 
with the 6 of 25 (24%) adult patients with UC or CD in clinical remission who had IgE-
positive fecal extracts. No information exists regarding the production of specific IgE 
antibodies in the intestinal mucosa. However, there is evidence that IgE dependant 
mechanisms can play a role in altering human IP (Crowe and Perdue 1993) raising the 
possibility that the negative results of serum studies do not preclude a role for IgE 
mediated reactions at the mucosal level. 
I.3.2.5 Mast cells 
The mast cell is the effector cell of type I hypersensitivity. Its role in IBD, however, is 
less well understood. Reports of increased mast cell numbers in IBD date back to 1966 
when Bercovitz and Sommers, using light microscopic techniques, found increased 
numbers of mast cells in the rectal tissue of patients with active UC (Bercovitz and 
Sommers 1966).  
 
Not only are the number of mast cells increased in the mucosa of IBD patients but also 
the function of mast cells are altered in comparison with normal subjects. Lilja et al. 
were able to show that mast cells are an important source of TNF-alpha in all layers of 
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the ileal wall in CD (Lilja, Gustafson-Svard et al. 2000). They looked for TNF-alpha 
immunohistochemically in full thickness specimens of ileal wall from patients with CD 
(histologically normal, n = 9; inflamed, n = 6) and controls (patients with colonic 
cancer, n = 8). In all layers of the ileal wall, and in every specimen investigated, mast 
cells were the main cell type that expressed TNF-alpha immunoreactivity out of the 
TNF-alpha-labelled cells. 
 
Mast cells may also play an important role in the signalling of CD4+ lymphocytes in 
CD. A study by Middel et al. demonstrated increased numbers of IL-16+ mast cells in 
active CD in comparison with UC and controls (Middel, Reich et al. 2001). This 
correlated positively with an increased number of CD4+ lymphocytes, suggesting a role 
for mast cells in the initiation and persistence of the inflammatory process in CD. 
I.3.2.5.1 The Role for therapies directed at the mast cell in IBD 
Many of the therapies effective against IBD do have actions on the mast cell. As 
discussed above mast cells are a source of TNF-alpha in IBD and anti-TNF-alpha agents 
are effective in these diseases (Carter, Lobo et al. 2004). In addition the 5ASA 
preparations, which form the mainstay of UC treatment, are able to inhibit anti-IgE 
induced histamine and PGD2 release from human intestinal mast cells (Fox, Moore et 
al. 1991).  
I.3.2.6 Histamine 
As well as its action in the immediate allergic response as a potent vasoactive agent, 
smooth muscle constrictor, and stimulant of nociceptive itch nerves (Repka-Ramirez 
and Baraniuk 2002), histamine participates in the delayed allergic reaction by activating 
and chemo-attracting neutrophils and eosinophils, and by increasing IL-8 and evoking 
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leukocyte rolling on endothelial cells (He, Peng et al. 1997). Using a variety of 
techniques histamine has been shown to be elevated in the involved tissues of IBD. 
 
Knutson and colleagues used a segmental jejunal perfusions system with a two-balloon, 
six-channel small tube to measure the jejunal secretion rate of histamine in patients with 
CD (n = 15) of the terminal small bowel and in healthy controls (n = 24) (Knutson, 
Ahrenstedt et al. 1990). They found that histamine secretion was significantly increased 
in patients with CD compared with the secretion rate in controls. Moreover, the 
secretion of histamine was related to the disease activity. Similar results were found on 
examination of stool from 62 CD and 24 UC patients compared to 8 healthy controls 
(Bischoff, Grabowsky et al. 1997). Histamine levels in endoscopic gut mucosal biopsies 
and histamine release from those biopsies were also increased in both UC and CD 
(Baenkler, Lux et al. 1987; Horauf, Matek et al. 1989; Fox, Lichtenstein et al. 1993; 
Raithel, Matek et al. 1995). 
 
Systemic production of histamine has also been measured in IBD using urinary levels of 
N-methylhistamine, a stable metabolite of histamine. Increased levels were seen in three 
reports provided by the same group. Initially they examined 41 patients with CD and, as 
controls, 27 persons being worked up for irritable bowel syndrome or food allergy 
(Weidenhiller, Raithel et al. 2000). They measured 24-hour urinary methylhistamine, 
correlating it with urinary creatinine to provide an internal comparator, expressing the 
urinary methylhistamine level as mg/mmol creatinine x m2 body surface area. The 
urinary methylhistamine level was significantly elevated in CD compared to controls. In 
addition there was a higher mean urinary methylhistamine level in active vs. inactive 
CD but this result did not reach statistical significance. The second report, in 2002, 
investigated 55 controls, 56 patients with CD, and in 36 patients with UC (Winterkamp, 
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Weidenhiller et al. 2002). Urinary excretion of methylhistamine was found to be 
significantly elevated in IBD. Patients with active CD and active UC had higher rates of 
methylhistamine excretion than patients in remission or controls. Methylhistamine 
excretion was also significantly correlated with disease activity. The latest paper, 
published in 2007, followed 8 CD patients in remission over a year, comparing them to 
controls (Kimpel et al. 2007). The urinary methylhistamine level remained in the 
normal range throughout follow-up, suggesting no accumulation and degranulation of 
mast cells during inactive phases of CD. 
I.3.2.7 Eosinophils 
As eosinophils are of particular relevance to the late phase allergic reaction, 
characterised by cellular infiltration and tissue destruction (Charlesworth, Hood et al. 
1989), their role in the pathogenesis of IBD might suggest similar processes are 
involved. 
 
Increased numbers of eosinophils are seen in inflamed and non-inflamed colonic tissues 
of IBD patients. Carvalho et al. used eosinophil specific histological staining techniques 
to examine colonic biopsies from 15 CD, 15 UC and 12 irritable bowel syndrome 
control patients (Carvalho, Elia et al. 2003). Increased proportions of eosinophils were 
found in the colon of patients with UC and in inflamed and non-inflamed colon of CD 
patients as compared with controls. 
 
The quantity of eosinophils present in the mucosa may also correlate with the clinical 
activity of disease. In a study in 50 patients with ulcerative proctocolitis who were 
followed for a mean period of 70 months, Heatley and James found that the number of 
eosinophils in the rectal mucosa predicted the clinical course of disease (Heatley and 
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James 1979). They found that patients with a higher mucosal eosinophil count had 
disease that more readily responded to treatment. 
 
In a study designed to examine the pathogenesis of eosinophil infiltration during the 
recurrence of CD in the post-resection neo-terminal ileum, samples were taken from 
nine patients with CD three months after ileocolectomy (Dubucquoi, Janin et al. 1995). 
Tissue eosinophils were studied by histochemical methods and electron microscopy. 
Mucosal expression of IL-5 was also studied using in situ hybridisation. These 
techniques were applied in normal and diseased areas of the neo-ileum. Eosinophil 
infiltration was more pronounced in diseased than in endoscopically normal areas and 
was associated with a high expression of IL-5 mRNA. Ultrastructural analysis showed 
features of eosinophil activation, but no cytotoxic lesions of surrounding inflammatory 
or epithelial cells. The authors concluded that local synthesis of IL-5 and associated 
eosinophil activation might participate early in the mucosal damage of CD. 
 
In addition to increased infiltration of eosinophils in the mucosa of IBD patients there is 
evidence of increased mucosal eosinophil activity in IBD. Hallgren et al. measured the 
concentrations of eosinophil cationic protein (ECP), a specific eosinophil granule 
protein, in jejunal perfusion fluid from ten patients with CD and 14 controls (Hallgren, 
Colombel et al. 1989). While the jejunal segment perfused in patients with CD was 
endoscopically and histologically normal, the perfusion fluid concentration of ECP was 
double that in the control subjects. Another study used segmental perfusion of the 
sigmoid colon and rectum in 18 UC patients and 18 healthy controls to confirm a 10 to 
20 fold increase in ECP, eosinophil protein X (EPX) and eosinophil peroxidase (EPO) 
in colitis patients compared with controls (Carlson, Raab et al. 1999). EPX and EPO, 
like ECP, are potent cytotoxic and neurotoxic mediators derived from eosinophilic 
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granules, which are involved in killing parasites and in tissue destruction during 
inflammatory processes. The same study found increased levels of GM-CSF and IL-8, 
and a correlation between all three eosinophil granule proteins and the levels of IL-
8/GM-CSF in the sigmoid segments of patients with colitis. This correlation suggested a 
role for GM-CSF and IL-8 as eosinophil priming cytokines. 
 
Berstad et al. were able to measure ECP in human stool samples (Berstad, Borkje et al. 
1993). In a study of 10 patients with active CD, 19 with active UC, and 10 healthy 
controls they found elevated levels of ECP in both patient groups as compared to 
controls.  A further study by Bischoff et al. provided evidence of increased eosinophil 
activation in IBD (Bischoff, Grabowsky et al. 1997). They collected stool samples from 
62 CD patients, 24 UC patients and 8 healthy controls. They were able to measure ECP 
and EPX in the stool. Elevated levels of ECP and EPX were seen in patients compared 
with controls. The levels of ECP and EPX did not correlate with activity of disease and 
high levels of ECP and EPX were not specific for IBD, also occurring in other diseases 
associated with inflammation of the intestinal mucosa.  
 
These studies confirm a role for the eosinophil in the pathology of IBD and suggest that 
the eosinophil may be an early player in the development of IBD related mucosal 
inflammation. They do not, however, allow conclusions to be drawn as to the exact role 
of the eosinophil in the aetiopathogenesis of these diseases. 
I.3.2.8 IgG mediated food hypersensitivity 
Whilst raised IgG levels are seen in patients with asthma, hayfever, eczema and atopic 
dermatitis, (Shakib, McLaughlan et al. 1977; Gwynn, Smith et al. 1978) the published 
data regarding IgG mediated immune reactions in food hypersensitivity is contradictory 
(Galant, Bullock et al. 1973; Wraith, Merrett et al. 1979). In fact it has been suggested 
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that IgG production may be a normal immunological response to dietary antigens 
(Barnes, Barton et al. 1983; Merrett, Burr et al. 1983; Johansson, Dannaeus et al. 1984; 
Husby, Oxelius et al. 1985). However, increased levels of food-specific IgG and IgG4 
antibodies have been demonstrated in atopic eczema and respiratory allergy (Merrett, 
Barnetson et al. 1984; Shakib, Brown et al. 1986; Okahata, Nishi et al. 1990; Barnes, 
Lewis-Jones et al. 1993). 
 
Raised levels of specific IgG antibodies to a limited range of foods have also been 
reported in IBD. In the first study of its kind, Davidson et al. were able to show that 
antibodies to maize were detectable, using an immunofluorescent technique, in 14% of 
controls, 33% of CD patients, and in 50% of UC patients (Davidson, Lloyd et al. 1979). 
They found similar levels in patients with coeliac disease and concluded, “The similar 
incidence of antibodies in the IBD and coeliac groups suggests absorption of dietary 
antigen secondary to an increased mucosal permeability”.  
 
Other authors have since promoted this conjecture, but it is interesting to note that a 
Medline search reveals no study that directly compares any measure of IP with food-
specific IgG antibody production in IBD. The evidence that does exist regarding IgG 
reactivity to luminal antigens and IP relates to IgG antibodies to yeast. In their 2003 
study Harrer et al. examined the relationship between serum levels of anti-
Saccharomyces cerevisiae antibodies (ASCA) and IP at a given time and the probability 
of increased ASCA serum levels with increased IP in patients with CD (Harrer, 
Reinisch et al. 2003). They did not find a statistically significant association between 
ASCA IgG antibodies and IP and concluded, “elevated serum levels of anti-S. 
cerevisiae antibodies do not seem to result primarily from a defect of the gut barrier”. 
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In a further study of food specific IgG antibodies in IBD Knoflach et al. measured 
serum IgG, IgM and IgA antibodies to five major proteins of cow's milk, casein, bovine 
serum albumin, alpha-lactalbumin, beta-lactoglobulin A, and beta-lactoglobulin B, 
using enzyme-linked immunosorbent assay in 51 patients with UC, 49 with CD, and 20 
age-matched controls (Knoflach, Park et al. 1987). IgG and IgM antibodies to cow's 
milk proteins were significantly elevated in patients with IBD as compared to controls. 
These increased titres seemed to be specific and not due to a polyclonal 
immunoglobulin activation, as naturally occurring blood group antibodies were not 
elevated. In addition there was a correlation between disease activity and antibody titers. 
 
Similar results were observed by Paganelli et al. on measuring the class-specific 
antibody response to the cow's milk antigen beta-lactoglobulin in sera from patients 
with UC and CD (Paganelli, Pallone et al. 1985). IgG antibodies were higher in active 
cases but antibody titres did not correlate with disease duration. 
 
A slightly wider range of food-specific IgG antibodies was tested by Frieri et al. in their 
1990 study (Frieri, Claus et al. 1990). They evaluated 11 CD patients by measuring 
serum IgG4 levels to five food proteins (egg, milk, wheat, soy, and corn) using a 
sensitive enzyme monoclonal antibody assay. They found an increased IgG4 humoral 
response to egg protein only. 
 
Although little data exists regarding the prevalence of IgG antibodies to a wider range 
of foods in IBD, there is some information in the setting of IBS. Zar et al. examined the 
patterns of IgG4 food-specific antibody positivity in patients with IBS compared with 
controls (Zar, Benson et al. 2005). They measured IgG4 titers to 16 common foods 
(milk, eggs, cheese, wheat, rice, potatoes, chicken, beef, pork, lamb, fish, shrimps, soya 
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bean, yeast, tomatoes, and peanuts) in one hundred and eight IBS patients and 43 
controls. They found that subjects with IBS had significantly higher titres of antibodies 
to wheat, beef, pork and lamb than controls.   
 
The same group have reported an uncontrolled study of the effect of an exclusion diet 
based on IgG4 titres on IBS symptoms and rectal sensitivity and compliance (Zar, 
Mincher et al. 2005). They studied 25 patients with IBS, measuring IgG4 titres to the 16 
foods mentioned above. Foods with titres >250 microg/l were excluded for 6 months. A 
statistically significant improvement was reported in pain severity, pain frequency, 
bloating severity, satisfaction with bowel habits and effect of IBS on life in general, at 3 
months. This symptom improvement was maintained at 6 months.  
 
Atkinson et al. were able to show similar results using non-subtype IgG food-specific 
antibodies in a randomised, sham controlled study of IBS patients (Atkinson, Sheldon et 
al. 2004). A total of 150 outpatients with IBS were randomised to receive, for three 
months, either a diet excluding all foods to which they had raised IgG antibodies or a 
sham diet excluding the same number of foods but not those to which they had 
antibodies. After 12 weeks, the true diet resulted in a 10% greater reduction in symptom 
score than the sham diet. 
 
While the exclusion diets were open, patients and investigators were blinded as to the 
results of IgG testing. Potential confounding factors in this study include the fact that 
IgG antibodies to wheat, milk, whole egg and yeast were common amongst subjects 
with IBS and so were commonly excluded in the true exclusion diet compared with the 
sham diet. These foods are widely reported as causing food intolerance in IBS and may 
be associated with worsening of IBS symptoms by non-immunological mechanisms. 
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Critics of the study concluded, “regardless of IgG antibody status, the dietary 
restrictions in one group were not controlled for by the other group” and “it is therefore 
difficult to assess whether a diet excluding these foods would have led to symptomatic 
improvement in all patients regardless of their antibody status” (Mawdsley, Irving et al. 
2005; Sewell 2005). 
 
Following the above studies, and the experiments that make up this thesis, Bentz et al. 
published their experience with IgG antibody guided diets in CD (Bentz, Hausmann et 
al. 2010). In an initial observational pilot study they examined 20 healthy volunteers 
without a history of food intolerance and 79 CD patients with different disease status. 
Forty-seven of them had clinical and endoscopic signs of acute inflammation (i.e. 
diarrhea and mucosal ulcerations). Twenty-four CD patients had chronically active 
disease and 8 were in remission. They used the ImuPro300 test (Evomed, Darmstadt, 
Germany) to detect food specific IgG antibodies in serum. Disease activity was assessed 
by the patient’s medical record.  
 
They found a significant difference in serum IgG antibodies between CD patients and 
healthy controls (p < 0.0001, t test). The ten most frequently measured IgG antibodies in 
CD patients were against processed cheese (84%), yeast (83%), agave syrup (78%), 
camembert cheese (76%), poppy seeds (74%), aloe vera (74%), bamboo sprouts (73%), 
kamut (durum wheat, 70%), unripe spelt grain (69%) and wheat (60%). More CD 
patients showed reactions against the evaluated food components than healthy controls, 
i.e. 35% of healthy controls had IgG antibodies against wheat in contrast to 60% of CD 
patients. Moreover, 39% of CD patients had IgG antibodies against hazelnut in contrast 
to only 15% of healthy controls. This was even more pronounced in IgG antibodies 
against linseed, where 70% of CD patients and only 10% of healthy controls showed 
86 
IgG antibodies. The same was seen with processed cheese (60% of healthy controls vs. 
84% of CD patients). The most frequently detected IgG antibodies in healthy controls 
were against yeast (66%), Aspergillus niger (60%), whey (60%), processed cheese 
(60%), bamboo sprouts (55%), paprika spice (55%), crawfish meat (50%), cottage 
cheese (45%), yoghurt (45%) and zander (45%). 
 
In the proceeding interventional study 40 CD patients were evaluated in a randomised, 
double blind, cross over, sham diet controlled fashion. Each diet was followed for 6 
weeks. Similar to the Atkinson et al. study in IBS the specific and sham diets were 
based on similarity of the excluded food components. If, for example, IgG against 
hazelnut was detected, then almond was excluded in the sham diet; if cauliflower IgG 
was found, broccoli was excluded. Sixteen male and 24 female subjects were 
randomised but, in a non-intention to treat analysis, only 23 patients were included in 
the final analysis because of a high dropout rate (n=17) from the treatment first and 
sham first groups.  
 
There was a significant reduction in the daily stool frequency by 11% in the active diet 
compared to the sham diet group (p = 0.004, 95% CI: 4%, 18%). However, the effect 
was confounded by a significant increase in stool frequency of 9% in the second 
intervention phase of the study, regardless of type of diet (p = 0.025, 95% CI: 1%, 18%; 
fig. 2 ). Only those patients who first followed the specific diet had a significant 
reduction in stool frequency. The group of subjects who first followed the sham diet had 
no significant change in their stool frequency.  
 
This study demonstrated that IgG antibodies against a number of food antigens are 
elevated in patients with CD in contrast to healthy controls. An improvement in some 
87 
IBD symptoms was observed in patients eliminating foods to which they were found to 
exhibit elevated IgG antibodies. Forty-eight percent of patients in the intervention group 
had an improvement in stool frequency and general well-being (total score). Only 9% of 
patients described the opposite effect. However, the high drop out rate meant that an 
intention to treat analysis would have shown much less effect than that seen in the per-
protocol analysis performed. In addition the 40 patients initially included in this study 
were on different medications, allowing no control for the confounding effect of 
different medication regimens on IgG food antibody results or course of disease. As 
with the Atkinson et al. study in IBS, it could also be argued that the sham diet was too 
similar to the specific diet, as the definition of specific and sham diet was based on the 
similarity of excluded food components. There may be some cross-reactivity of the 
respective antigens, which could explain some effects of the sham diet on IBD 
symptoms. Finally, the study did not include a washout phase at the cross-over point, 
which may have led to some transmission of effects into the sham arm of the study.  
 
Although these studies exhibit methodological problems, their findings challenge the 
dogma that IgG antibodies to food are non-specific and of no relevance to GI disease.  
The possibility exists that IgG antibodies to food might be useful in guiding dietary 
management of those GI diseases that are responsive to dietary manipulation. 
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Chapter II Current evidence and 
recommendations for the use of 
dietary manipulation in the 
management of IBD  
II.1 Crohn Disease 
II.1.1 Attitudes 
hile there is no evidence that specific immune mediated reactions to food 
play a role in most patients with either CD or UC, (Bischoff, Mayer et al. 
2000) it is commonplace for patients with GI disorders to believe that something in their 
diet has caused their condition (Crowe 2001; Joachim 1999). Some studies have 
claimed that food intolerances are common in CD and have found that when food 
intolerances are detected, patients on an exclusion diet maintain remission significantly 
longer than those on an unrestricted diet (Jones, Dickinson et al. 1985; Riordan, Hunter 
et al. 1993). However, when these patients are subjected to double-blind food 
challenges only 15% show a positive response (Pearson, Teahon et al. 1993). 
 
That both newly diagnosed and chronically affected patients with CD have significant 
nutritional inadequacies is clear. Malnutrition is often reported, especially in CD 
patients with active disease (Harries and Heatley 1983; Fernandez-Banares, Abad-
Lacruz et al. 1989; Fernandez-Banares, Mingorance et al. 1990; Janczewska, Bartnik et 
al. 1991; Stokes 1992; Kuroki, Iida et al. 1993; Royall, Greenberg et al. 1995; Teahon, 
Pearson et al. 1995; Zurita, Rawls et al. 1995; Azcue, Rashid et al. 1997; Capristo 
1998). In addition several nutritional and functional deficiencies, especially of 
antioxidants, in patients with longstanding CD in remission, have been described 
(Geerling, Badart-Smook et al. 1998). Serum vitamin B12 concentrations are 
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significantly lower in CD than controls even at the time of diagnosis (Geerling, Badart-
Smook et al. 2000).  
 
The degree to which these nutritional deficiencies are related to malabsorption and 
inflammation versus dietary deficiencies is not clear. It does seem likely that dietary 
exclusions which do not positively influence disease activity might have a negative 
effect on nutritional status and thus a negative effect on wellbeing. Certainly patients 
with CD do avoid those foods to which they report intolerance (Joachim 1999). No 
consensus statements regarding the nutritional advice that should be given to CD 
patients exist, in particular with respect to exclusion of foods from the diet. In the 
following section the current evidence, where any exists, for those dietary 
manipulations commonly practised in CD are discussed. 
II.1.2 Milk and dairy products 
The possible mechanisms for dairy intolerance in CD are multiple and include lactose 
malabsorption (LM) due to lactase inactivity secondary to mucosal disease, the long-
chain triacylglycerol content of milk, or allergy to milk proteins (see Table 13). Milk 
has always featured highly in the list of foods investigated for IBD related food 
intolerances, originating in the early part of last century with the theory that milk allergy 
might contribute to the pathogenesis of IBD (Truelove 1961; Binder, Gryboski et al. 
1966). This was later replaced by the recognition that in large part the GI symptoms 
produced by milk relate to malabsorption of lactose (Saavedra and Perman 1989) and, 
specifically in CD, might relate to the presence of long-chain triacylglycerol content as 
evidenced by improved response to enteral diets excluding these fats in CD (Middleton, 
Rucker et al. 1995). 
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There is some data to show that dairy intolerance (as reported by patients) occurs in CD 
patients more commonly than controls. In a questionnaire study of 33 patients with CD 
and 27 patients with UC Joachim et al. determined those foods which patients reported 
as affecting them positively and compared them to those that affected them negatively. 
Dairy products were reported as affecting both disease groups negatively (Joachim 
1999). Using similar methodology Triggs et al. examined a Caucasian CD population in 
New Zealand (Triggs, Munday et al. 2010). They reported similar rates of dairy 
intolerance. Interestingly, it seemed the greater the fat content of the dairy product, the 
higher the frequency of reports of intolerance. Von Tirpitz et al. asked 49 patients with 
CD specifically about dairy intolerance (von Tirpitz, Kohn et al. 2002). 46.9% of the 
disease group reported milk intolerance compared to 16.6% of controls. However, the 
H2 lactose breath test was positive in just 70% of the patients reporting milk 
intolerance. The mechanism and data surrounding LM in CD is discussed further below 
(see section II.1.2.1).  
 
Very little data exists regarding the veracity of milk allergy as an aetiological 
mechanism in CD. The majority of data that is available concentrates on the use of 
classical allergy tests (including skin prick and RAST tests) and also on the incidence of 
non-IgG food-specific antibodies in detecting immune sensitisation to food antigens. 
Direct testing for allergy as a mechanism is fraught in the gastrointestinal tract. While 
double blind placebo controlled food challenge is perhaps the gold standard for 
detecting food hypersensitivity, it is not specific for the mechanism of hypersensitivity 
and in no way rules out non-immune mechanisms (Bischoff and Crowe 2005). Novel 
methods for detecting immune reactivity to foods in the gut have yielded results in CD 
(Bischoff, Herrmann et al. 1996; Van Den Bogaerde, Cahill et al. 2002). This topic is 
considered separately in detail in section V.1.1 
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Additionally it may be that any effect of milk ingestion on CD activity is not only 
mediated by sugar content in the form of lactose, or protein as a potential allergen, but 
also by the fat constituent. This is supported to an extent by studies manipulating the 
type of fat given to CD patients receiving therapy with enteral nutrition and is discussed 
in detail below (see section II.1.4.6). 
 
Potential 
Mechanisms for 
Milk Intolerance 
in CD 
Evidence for a role in CD 
Long chain 
triacylglycerols 
There is an improved response to enteral diets excluding these 
fats in CD (Middleton, Rucker et al. 1995) the greater the fat 
content of the dairy product, the higher the frequency of reports 
of intolerance (Triggs, Munday et al. 2010) 
Allergy to milk 
protein 
Despite the initial interest in a mechanism for milk allergy in 
IBD (Truelove 1961; Binder, Gryboski et al. 1966) there is 
little direct evidence of a role for milk allergy in CD 
Lactase inactivity The activity of duodenal lactase has been shown to be reduced 
only in active disease (von Tirpitz, Kohn et al. 2002) 
Other mechanisms 
for Lactose 
Malabsorption 
Disease location and activity, small bowel transit time and 
previous surgery are implicated (Pironi, Callegari et al. 1988; 
Mishkin, Yalovsky et al. 1997)  
Table 13. Summary of the evidence for a role of each potential mechanism for 
dairy intolerance in CD 
 
II.1.2.1 Lactose malabsorption in Crohn Disease  
Disaccharide lactose, the principal carbohydrate of animal milks, requires the enzyme 
lactase to split it into glucose and galactose. Undigested lactose passes to the colon 
where fermentation produces hydrogen and short-chain fatty acids that can cause 
abdominal distension, pain, and sometimes diarrhoea (Scrimshaw and Murray 1988). 
The term LM is widely used for an arbitrarily defined “significant” increase in breath 
hydrogen (H2) (10-20 ppm) after an oral lactose challenge (King and Toskes 1983; 
Saavedra and Perman 1989). This is based on an equally arbitrary 50g lactose challenge 
that is only applicable to the hereditary form of LM, which is not associated with any 
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organic gastrointestinal disorder (Mishkin 1997).  It also fails to include the variable 
fraction of the population (10-20%) who do not excrete appreciable H2 during colonic 
fermentation, which can lead to false-negative results in the breath test (Corazza, 
Strocchi et al. 1993). On the other hand, a positive hydrogen breath test may just be an 
indicator of bacterial overgrowth (Mishkin 1997). 
 
 
Figure 4. Lactase converts lactose to galactose and glucose in the small intestine 
 
The frequency of LM in patients with CD, particularly those with active disease, 
appears to be higher than that in the normal population (Littman, Cady et al. 1968; 
Pironi, Callegari et al. 1988; Mishkin, Yalovsky et al. 1997; von Tirpitz, Kohn et al. 
2002; Barrett, Irving et al. 2009). However, reports are contradictory (Gudmand-Hoyer 
and Jarnum 1970; Park, Duncan et al. 1990; Banos Madrid, Salama Benerroch et al. 
2004). It is still only a small proportion (8% in one study) that experience symptoms of 
intolerance when challenged with milk (Pironi, Callegari et al. 1988) and most of these 
patients consume some dairy product without any significant discomfort (Mishkin 
1997). The available evidence is summarised in Table 14. 
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Authors Country Crohn disease Controls   Diagnostic method 
    Number 
of 
patients 
Lactose 
Malab-
sorption 
Number Lactose 
Malab-
sorption 
Lactose 
tolerance 
test 
Determination 
of mucosal 
enzyme activity 
Chalfin and 
Holt 1967 
USA  5 3 (60%)      +   
Littman, 
Cady et al. 
1968 
USA  11 5 (45%)  93 18 (19%) +  + 
Gudmand-
Hoyer and 
Jarnum 
1970 
Denmark  71 4 (6%)  700 3-7%  +  + 
Kirschner, 
DeFavaro 
et al. 1981 
USA 50 17(34%) 40 “similar to 
IBD” 
+ 
 
Pironi, 
Callegari et 
al. 1988 
Italy 37 18 (49%) 67 11(16%) + 
 
Park, 
Duncan et 
al. 1990 
Scotland 62 2(3%) 13 (IBS 
patients) 
1(8%) 
 
+ 
Huppe, 
Tromm et 
al. 1992 
Germany 124 21(17%)     +   
Mishkin, 
Yalovsky et 
al. 1997 
Canada 121 48(40%) 158  46(29%) +   
von Tirpitz, 
Kohn et al. 
2002 
Germany 49 23(47%) 24 4(17%) + + 
Banos 
Madrid, 
Salama 
Benerroch 
et al. 2004 
Spain 18 3(17%) 25 5(20%) +   
Barrett, 
Irving et al. 
2009 
Australia 92 39(42%) 71 13(18%) +  
Table 14. Studies of lactose malabsorption in Crohn disease 
 
II.1.2.2 Mechanisms of lactose malabsorption 
There are many mechanisms for LM. In the general population the two main risk factors 
for LM are related to reduced levels of duodenal lactase. They are ethnicity, with very 
high rates in Asians and Native Americans (DiPalma and Narvaez 1988); and age, with 
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decreasing levels of duodenal lactase occurring with older age (Welsh, Poley et al. 
1978; Rao, Bello et al. 1994). 
 
However, in CD other mechanisms may also be important and the activity of duodenal 
lactase has been shown to be reduced only in active disease (von Tirpitz, Kohn et al. 
2002). There is the suggestion that disease location influences the frequency of LM in 
CD with a higher incidence in proximal small bowel disease than terminal ileal and 
terminal ileum than colonic disease in turn (Mishkin 1997). Disease activity and 
previous surgery have also been discussed as determinants of LM (Pironi, Callegari et 
al. 1988; Mishkin, Yalovsky et al. 1997). In addition it may be that many CD patients 
who are positive for  LM have a small bowel transit time that is significantly shortened 
(Mishkin, Yalovsky et al. 1997). 
II.1.2.3 Lactose or dairy restriction in the treatment of CD 
Much of the evidence for dairy avoidance in CD is embedded in studies that examined 
diets with multiple food exclusions. The majority of positive results stem from studies 
from one centre that examined the ability of dietary exclusion to maintain a remission 
induced by therapy with an elemental diet. Once those CD patients were in remission, 
30% managed to stay in remission with avoidance of dairy products and other offending 
foods identified using elimination diets (Jones, Dickinson et al. 1985; Jones 1987; 
Riordan, Hunter et al. 1993). Although two other studies have confirmed these results, 
the benefit was much less than that seen in the original studies (Giaffer, Cann et al. 
1991; Pearson, Teahon et al. 1993). It is not possible to extrapolate from these studies 
the degree to which dairy avoidance contributed to the results. 
 
The only available evidence for a diet excluding milk alone is a dated case series in 
which three CD patients, who were milk drinkers with lactose malabsorption proven on 
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enzyme testing and blood sugar response to lactose challenge, experienced a total 
cessation of diarrhoea with a lactose-free diet. In addition nine patients without evident 
lactose malabsorption were treated with a lactose free diet and the diet was beneficial in 
three patients, as judged from the number of bowel movements and their feeling of well 
being (Gudmand-Hoyer and Jarnum 1970) 
 
Nanji et al. made an interesting observation in their epidemiological study of the 
association between geographic incidence of CD and LM (Nanji and Denardi 1986).  
They found a strong negative correlation (-0.93, p<0.01) between the incidence of CD 
and LM over 13 countries. The authors propose that the mechanisms by which such 
protection occurs include: a) production of short chain fatty acids and lactate; b) 
increase in intestinal transit time; and, c) reduction in production of noxious substances 
that may be partially responsible in the pathogenesis of IBD.  
 
Very little evidence exists regarding physician practice in the use of dairy exclusion in 
IBD.  Mishkin reported the results of a survey conducted in > 100 physicians and 
nutritionists attending a Canadian IBD conference in 1995 (Mishkin 1997). 40% 
indicated that they advised their IBD patients to avoid dairy products.  
 
Dairy products are an important source of calcium and other nutrients and a reduction in 
their intake might have significant consequences for the patient with CD (Mishkin 
1997). This possibility is supported by a study of 38 patients with CD who underwent 
bone densitometry. Bone mineral densities of the spine were significantly decreased in 
those with reported milk intolerance (z-score, -1.33 ± 0.92 vs. -0.19 ± 0.95; p=0.002). 
Bone densities of the femoral neck also tended to be decreased in patients with milk 
intolerance, although this result did not reach significance (z-score, -1.26 ± 0.67  
96 
vs. -0.76 ± 0.95; not significant) (von Tirpitz, Kohn et al. 2002). 
 
The available evidence, therefore, suggests that there may be an increased rate of 
detectable LM in the CD population but that the clinical significance of this is not clear. 
Evidence to support the recommendation of empiric dairy exclusion to patients with CD 
is lacking.  
II.1.3 Carbohydrates 
II.1.3.1 Simple sugars 
An interest in the role of sugar in the evolution of CD was fuelled by the observation of 
Thornton et al. that newly diagnosed CD patients ate more refined sugar than controls 
(Thornton, Emmett et al. 1979). Further case control studies have shown an increased 
relative risk of CD for patients with a high intake of sucrose and total intake of 
carbohydrate (see Table 15).  
 
Persson et al. performed a postal questionnaire of 152 CD patients asking about their 
food intake 5 years previously (Persson, Ahlbom et al. 1992). They showed a relative 
risk of 2.6 for CD in patients who had a high intake of sucrose. Reif et al. obtained 
dietary histories in 33 patients with CD of recent onset. (Reif, Klein et al. 1997). Again 
a high sucrose consumption was associated with an increased risk for CD.  
 
104 UC and CD, 104 controls et al. studied the dietary habits of 104 IBD patients 
immediately prior to the onset of disease using a recall questionnaire (Tragnone, 
Valpiani et al. 1995).  They found that patients with CD have a high intake of total 
carbohydrate, starch and refined sugar. This result was corroborated in a study by 
Geerling et al. who took a dietary history in 23 CD patients within 6 months of initial 
97 
diagnosis (Geerling, Badart-Smook et al. 2000). They also found a higher mean daily 
intake of carbohydrates in CD patients compared to controls. 
 
 Study 
methodology 
Sample size Result 
Thornton, Emmett 
et al. 1979. 
Case-control, 
retrospective 
interview 
30 CD and 30 
controls 
Median refined 
sugar intake CD 
122 vs. controls 65 
g/day (p<0.002) 
Persson, Ahlbom et 
al. 1992 
Case-control, 
retrospective postal 
questionnaire 
152 CD and 305 
controls 
RR 2.6 for CD if 
>55g/day sucrose 
intake 
Tragnone, Valpiani 
et al. 1995 
Prospective cohort 
study 
104 UC and CD, 
104 controls 
High intake of total 
carbohydrate, 
starch and refined 
sugar 
Reif, Klein et al. 
1997 
Case-control, 
retrospective 
interview of 
patients with recent 
onset CD 
33 CD and 144 
controls 
OR 2.85 for CD if 
high sucrose 
consumption 
Geerling, Badart-
Smook et al. 2000 
Case-control, 
contemporary 
dietary interview 
23 CD and 23 
controls 
Total carbohydrate 
(en%) CD 51% vs. 
controls 46% 
(p<0.05) 
(RR: relative risk; OR: odds ratio; en%: percentage of energy intake) 
Table 15. Studies of sugar consumption in Crohn disease 
 
In the study by Geerling et al. the total carbohydrate intake expressed as a percentage of 
energy was significantly higher in patients with active disease compared to those in 
remission. It has been suggested that the above observations of an association between 
CD and carbohydrate intake might simply represent a consequence of active disease 
(Riordan, Ruxton et al. 1998) 
 
A study by Heaton et al. retrospectively compared 32 CD patients treated with 
conventional therapy plus a fibre-rich, unrefined-carbohydrate diet to 32 matched 
patients who had received no dietary instruction. There were fewer hospital admissions 
and surgical interventions in the diet treated patients (Heaton, Thornton et al. 1979). 
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Ritchie et al. followed this up with a controlled, multicentre study of 162 patients given 
the above diet compared to 190 patients given a diet unrestricted in sugar and low in 
fibre (Ritchie, Wadsworth et al. 1987). They found no difference between the groups in 
terms of the relapse rate over 2 years. 
 
Certainly it seems that patients with CD consume more refined sugar and have a higher 
total carbohydrate intake that controls. However, it is not clear that this association is 
causal and the available evidence does not suggest that restricting refined sugar intake 
in patients with CD results in an improvement in disease outcomes.  
II.1.3.2 FODMAPs 
The variable evidence of a role for lactose malabsorption in CD has led in recent years 
to interest in other fermentable carbohydrates. Incomplete absorption of fructose is 
relatively common in the normal population and has been identified as a possible 
precipitant of functional gastrointestinal symptoms (Simren and Stotzer 2006). In a 
study by Barret et al. 91 patients with CD were tested for fructose malabsorption using 
a hydrogen breath test (Barrett, Irving et al. 2009). They found that fructose 
malabsorption was more common in CD than in controls (61% vs. 34%, p<0.05). 
 
Other rapidly fermented and osmotically active carbohydrates may be malabsorbed and 
contribute to gastro-intestinal symptomatology. These poorly absorbed short-chain 
carbohydrates have been termed the Fermentable Oligo-, Di-, Mono-saccharides and 
Polyols (FODMAPs) (Gibson and Shepherd 2005). They include oligosaccharides, 
disaccharises, and polyols (see Table 16). 
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Fructose Fructans Lactose Galacto-
Oligosaccharides  
Polyols 
Honey 
Apples 
Mango 
Pear 
Watermelon 
High fructose 
corn syrup 
Corn syrup 
solids 
Artichokes 
(globe and 
jerusalem) 
Asparagus 
Beetroot 
Chicory 
Dandelion leaves 
Garlic (in large 
amounts) 
Leek 
Onion  
Raddicio lettuce 
Spring Onion 
(white part) 
Wheat (in large 
amounts) 
Rye (in large 
amounts) 
Inulin 
Fructo-
oligosaccharides. 
Milk  
Icecream 
Custard 
Dairy desserts 
Condensed 
and 
evaporated 
milk 
Milk powder 
Yoghurt 
Margarine 
Soft unripened 
cheeses  
(eg. Ricotta, 
Cottage, 
Cream, 
Marscarpone). 
Legume beans 
(eg. baked beans, 
kidney beans, 
bortolotti beans) 
Lentils 
Chickpeas 
Apples 
Apricots 
Avocado 
Cherries 
Longon 
Lychee 
Nectarines 
Pears  
Plums Prunes 
Mushrooms 
Sorbitol  
Mannitol 
Xylitol  
Maltitol 
Isomalt  
Table 16. Common examples of the FODMAP foods (adapted from Gearry, Irving et 
al. 2009) 
 
Gearry et al. conducted a retrospective phone interview survey of 52 CD patients who 
had been identified as having previously received dietary advice for probable functional 
gastro-intestinal symptoms in quiescent CD (Gearry, Irving et al. 2009). The dietary 
advice given included the exclusion of dietary FODMAPs. They found that up to 70% 
of patients were adherent to the diet. They found that more than half of the patients with 
abdominal pain, diarrhoea and bloating reported improvement following dietary advice. 
 
The evidence to date is not sufficient to warrant empiric exclusion of FODMAPs from 
the diet of CD patients suspected of having functional symptoms. Large scale 
comparative studies do, however, seem indicated. 
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II.1.4 Enteral and parenteral nutrition  
CD patients benefit from treatment with parenteral or enteral formula nutrition. Such 
treatment has not been shown to have a particular role for the management of UC 
(Dickinson, Ashton et al. 1980; Seidman 1989; Sitzmann, Converse et al. 1990). The 
mechanisms by which such treatment might benefit CD patients are not clear but 
possibilities include exclusion of deleterious dietary substances (eg. lactose, fat), resting 
the bowel, altering the microflora of the gut, altering the balance of beneficial to 
harmful precursors in foods (eg n3- vs. n6-polyunsaturated fatty acids), nutritional 
improvements, or perhaps reducing the antigenic load presented to the immune 
mechanisms of the bowel. These potential mechanisms, and the evidence to support 
them, are discussed in detail in the ensuing section. 
 
Potential 
mechanism of 
effect for enteral 
nutritional 
Evidence for a role in CD 
Bowel rest and 
reducing the 
antigenic load 
TPN is not superior to EN (Lochs, Meryn et al. 1983; 
Greenberg, Fleming et al. 1988), however total EN may be 
more effective than partial EN (Johnson, Macdonald et al. 
2006) suggesting removal of something from the diet and 
resting the gut may play a role 
Altering the enteric 
microflora 
EN can change the intestinal microbiota (Pryce-Millar, Murch 
et al. 2004; Lionetti, Callegari et al. 2005; Schneider, Girard-
Pipau et al. 2006), the mechanism by which this might then 
affect disease is not clear 
Altering metabolic 
precursors 
The main example of this is the alteration of the n-3 to n-6 
fatty acid ratio (see II.1.4.7 n3 vs. n6 polyunsaturated fatty 
acids) 
Nutritional 
improvements 
Suboptimal levels of micronutrients impair mucosal healing 
and defence (Gassull 2004) and improvements in nutritional 
status is important in achieving and maintaining remission 
(Royall, Jeejeebhoy et al. 1994) 
Direct anti-
inflammatory effect 
A decrease in the production of inflammatory cytokines is 
observed when inflamed mucosa is incubated with formula 
(Meister, Bode et al. 2002), the mechanism for this is unclear 
Table 17. Summary of potential mechanisms for an effect of enteral nutrition in 
Crohn disease 
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Initial investigations into dietary intervention in CD centred on the use of enteral 
feeding using elemental diets consisting of amino acids rather than peptides as the 
nitrogen source, and varying amounts and types of fats. Polymeric (whole protein) 
drinks have the advantage of lesser cost as well as enhanced taste and palatability, 
thereby improving tolerance and compliance (Day, Whitten et al. 2008). They have 
been shown to be equally efficacious to elemental enteral nutrition (EN) (Gonzalez-
Huix, de Leon et al. 1993; Royall, Jeejeebhoy et al. 1994; Verma, Brown et al. 2000; 
Zachos, Tondeur et al. 2001; Zachos, Tondeur et al. 2007). While 5 metaanalyses have 
concluded that steroid therapy is more efficacious than enteral feeding for attaining 
remission of CD (Fernandez-Banares, Cabre et al. 1995; Griffiths, Ohlsson et al. 1995; 
Messori, Trallori et al. 1996; Zachos, Tondeur et al. 2001; Zachos, Tondeur et al. 
2007), it remains true that the remission rate obtained with enteral feeding is 
approximately 60%, and higher than the 20-30% placebo response (Singleton, Hanauer 
et al. 1993; Lochs 2007). It appears that the benefit might be greater in children than 
adults and meta-analysis of the paediatric studies (not including any adult studies) using 
EN for CD has ascertained that EN and steroids were of equal efficacy in the induction 
of remission in children with active CD (Heuschkel, Menache et al. 2000; Dziechciarz, 
Horvath et al. 2007). 
 
Even if steroid is more effective than EN at attaining clinical remission, there is 
evidence it may not be so efficacious in healing the mucosa. Yamamoto et al. treated 28 
patients with EN and saw endoscopic healing in 44% and improvements in 78% of 
patients (Yamamoto, Nakahigashi et al. 2005). This is in keeping with a study of 37 
children randomised to polymeric EN vs. corticosteroids in which 74% of the children 
given EN had mucosal healing compared to only 33% in the steroid group (p<0.05) 
(Borrelli, Cordischi et al. 2006). 
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In addition to induction of remission, EN can be used to maintain remission. This has 
been achieved either by giving enteral formula as intermittent intensive periods of 
exclusive feeding via a NG tube (Belli, Seidman et al. 1988), or using supplements of 
formula in addition to an ongoing standard diet (Harries, Jones et al. 1983; Verma, 
Kirkwood et al. 2000; Esaki, Matsumoto et al. 2005; Yamamoto, Nakahigashi et al. 
2005; Takagi, Utsunomiya et al. 2006). An additional benefit of EEN is the nutritional 
improvement seen during and following therapy in many clinical studies (Sanderson, 
Udeen et al. 1987; Azcue, Rashid et al. 1997; Gavin, Anderson et al. 2005). EEN also 
has specific benefits on bone nutrition (Day, Whitten et al. 2008). Additionally EN is 
associated with few side effects, principally loose, unformed motions and flatulence, but 
also nausea and constipation (Borrelli, Cordischi et al. 2006; Day, Whitten et al. 2006). 
Finally, it has been shown to improve QOL scores in children treated with EN for active 
CD (Afzal, Van Der Zaag-Loonen et al. 2004). 
II.1.4.1 Direct effects on the epithelium 
That EN itself may have a direct effect at the epithelial level is supported by data 
demonstrating that, although corticosteroids fail to induce epithelial healing 
(Modigliani, Mary et al. 1990; Landi, Anh et al. 1992), in the course of inducing 
clinical remission EN does result in epithelial healing (Afzal, Davies et al. 2005; Fell, 
Paintin et al. 2000; Yamamoto, Nakahigashi et al. 2005; Berni Canani, Terrin et al. 
2006).  
 
Suboptimal levels of micronutrients may participate in this process due to defects in 
tissue repair mechanisms or via impaired defence (Gassull 2004). In addition recent data 
suggest EN may have a direct effect on inflammatory processes in the epithelium 
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(Meister, Bode et al. 2002; Fell, Paintin et al. 2000; Yamamoto, Nakahigashi et al. 
2005; de Jong, Leach et al. 2007). 
II.1.4.2 Improvement in nutritional status 
Improvement in nutritional status and correction of micronutrient deficiencies are 
considered key factors for the effect of enteral nutrition and may be associated with an 
effect on disease activity (Lochs 2006). Improvement in nutritional status appears to be 
important not only in achieving but also in maintaining remission. (Royall, Jeejeebhoy 
et al. 1994). 
II.1.4.3 Resting the bowel from the mechanical effects of digestion 
One theory for the beneficial effects of both TPN and EN in CD was that of “resting” 
the bowel, although exactly what the mechanism underlying this might be was never 
elucidated. Only two studies have been performed to investigate the validity of this 
hypothesis, and those in the 1980’s. In those studies no advantage of total parenteral 
nutrition (TPN), or total enteral nutrition compared with partial parenteral nutrition 
(PN) in addition to standard food, was found (Lochs, Meryn et al. 1983; Greenberg, 
Fleming et al. 1988). Hence it was concluded that bowel rest is not necessary, enteral 
nutrition should be preferred, and patients might eat ad libitum in addition to enteral 
nutrition. It is interesting to note that despite this fact all later studies put patients on 
‘‘bowel rest’’ whilst on enteral nutrition.  
 
The waters are somewhat muddied by a recent randomised controlled study that showed 
that total EN was superior to partial EN, with 50% of calories provided as EN and 50% 
as normal diet (Johnson, Macdonald et al. 2006). While this study seems supports the 
bowel rest hypothesis, the study was not designed to test this hypothesis. It fails to 
control for the beneficial nutritional effects provided by total EN versus relying on oral 
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food intake to provide 50% of the daily caloric requirements. Thus the difference 
between the groups is as likely to be explained by a lack of nutritional repletion, or a 
reduced exposure to potential intrinsic anti-inflammatory effects of EN, in the partial 
EN group. 
II.1.4.4 Altering the gut flora – A prebiotic effect for EN? 
That the expression of CD is modulated to some degree by the intestinal flora is well 
established (Shanahan 2004). It seems reasonable therefore that the effects of EN might 
be mediated by alterations in that flora. It has been shown that EN, albeit a fibre 
enriched formula, given to healthy individuals is capable of altering the intestinal flora 
and the characteristics of the bacterial metabolic activity (Schneider, Girard-Pipau et al. 
2006). In CD EN leads to alterations in the bacterial flora present on mucosal surfaces 
(Pryce-Millar, Murch et al. 2004) and produces large changes in the faecal flora patterns 
(Lionetti, Callegari et al. 2005). It remains unclear how treatment with EN modulates 
changes in faecal or mucosa-associated flora. It could be because of prebiotic properties 
of the formula used for EN or because EN alters the micro-environment in the colon, 
perhaps as a result of alterations in pH, short-chain fatty acids or changes in bacterial 
growth factors (Day, Whitten et al. 2008). 
II.1.4.5 Reducing the antigenic load presented to the immune 
mechanisms of the bowel  
One of the driving theories behind the emergence of enteral and parenteral therapy for 
CD was that they removed a potential source of antigenic load confronting the immune 
cells in the lamina propria of the gut (Stenson and Alpers 1997). No studies have 
directly addressed this hypothesis. However, studies attempting to define whether bowel 
rest is an important factor give some information. As described above, in these studies 
PN was compared to PN plus formula and food ad libitum (Lochs, Meryn et al. 1983) or 
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PN to EN alone to partial PN and oral food (Greenberg, Fleming et al. 1988) (see 
II.1.4.3 Resting the bowel from the mechanical effects of digestion). No significant 
differences were found, suggesting that introducing food to the lumen has no deleterious 
effect. This is further supported by studies showing equivalence between elemental and 
polymeric EN (Gonzalez-Huix, de Leon et al. 1993; Royall, Jeejeebhoy et al. 1994; 
Verma, Brown et al. 2000; Zachos, Tondeur et al. 2001; Zachos, Tondeur et al. 2007).  
 
However, any immune response to food antigens might be expected to be dose 
dependent and there are likely to be significant differences in the antigenic load to the 
intestine between a normal diet and a polymeric diet or a PN regimen with additional 
oral food. This conjecture is supported by a recent study that compared patients on 
exclusive enteral EN to those receiving approximately 50% of their intake as formula 
with the remainder as a normal diet, ie. a greater proportion of calories as whole food 
than the previous studies. The exclusive EN group had a remission rate of 42%, which 
was superior to that of the partial EN group (remission in 15%: P < 0.035) (Johnson, 
Macdonald et al. 2006).  
 
One must also consider that TPN might have deleterious effects on the GI immune 
system. TPN has been shown to induce atrophic changes in Peyer’s patches, with a 
decrease in number of CD4+ T cell subsets and immunoglobulin A-containing cells in 
the intestinal mucosa of rats (Tanaka, Miura et al. 1991). Total parenteral nutrition also 
resulted in inhibition of lymphocyte transport through intestinal lymphatics, suggesting 
the importance of oral nutrition in maintaining immunological function in general, and 
GALT function in particular. This further confounds the ability to extrapolate the effects 
of oral food vs. TPN in terms of direct effects on the GI immune system. 
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II.1.4.6 The Role of the amount and type of fat 
Although the protein source in EN does not appear to impact on effectiveness in the 
treatment of CD (Gonzalez-Huix, de Leon et al. 1993; Royall, Jeejeebhoy et al. 1994; 
Verma, Brown et al. 2000; Zachos, Tondeur et al. 2001; Zachos, Tondeur et al. 2007), 
the effects of the type and amount of fat used in the diet has proven important, and the 
optimal formulation for the induction of remission in CD has been elusive.  
 
More than 90% of dietary fat is triglycerides, which are made up of fatty acids and 
glycerol. Short-chain fatty acids have four or six, medium-chain fatty acids have eight 
to 12, and long-chain fatty acids have 14 to 22 carbon atoms. Fatty acids with one 
double bond are monounsaturated, while those with more are polyunsaturated. The 
predominant monounsaturated fatty acid in the diet is oleic acid. The predominant 
dietary polyunsaturated fatty acid (PUFA) is linoleic acid, an essential fatty acid. The 
position of the first double bond in a PUFA is designated by the omega (n-) number. 
The two main families of PUFAs are n-6 and n-3 (Gorard 2003). 
 
Middleton et al. in 1995 performed meta-analysis of the existing data that showed that 
the response rate to enteral feeding in CD is inversely correlated with the amount of fat 
in the feed, in particular long chain triglycerides (LCT) (Middleton, Rucker et al. 1995). 
Subsequently Bamba et al. showed that the efficacy of an elemental diet in inducing 
remission in Crohn disease is impaired by the addition of LCTs (Bamba, Shimoyama et 
al. 2003).  In addition Middleton et al. went on to show that adding medium chain 
triglycerides (MCT) to the feed did not impair therapeutic efficacy (Middleton, Rucker 
et al. 1995). This is supported by the results of Sakurai et al. who obtained the same 
response from elemental feeds with low fat and polymeric feeds with 25% energy as fat, 
mainly in the form of MCTs (Sakurai, Matsui et al. 2002). Finally, Khoshoo et al. 
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obtained similar responses in adolescents with Crohn disease when using a peptide-
based feed containing 9% energy as fat, of which 45% was MCT, and a peptide feed 
containing 33% energy as fat, of which 70% was MCT (Khoshoo, Reifen et al. 1996). 
 
The mechanisms by which fat administration might affect disease expression in CD are 
multiple. Various saturated and unsaturated fatty acids can modulate the immunological 
role of lymphocytes both in vitro and in vivo (Erickson 1986; Palmblad and 
Gyllenhammar 1988). Theories as to the mechanisms for this include effects on 
lymphocyte migration, lymphocyte proliferation, and changes in receptor affinity and 
signalling of lymphocytes; as well as effects on other cell types of the GI immune 
system, oxidative mechanisms and GI immunoglobulin production. Most of the 
evidence regarding these mechanisms applies to animal models and how important each 
might be in the mediation of CD remains to be determined. The evidence to support 
each of these proposed mechanisms is summarised in the proceeding text. The possible 
pro- and anti-inflammatory effects of the two main PUFA types, n-3 and n-6, are 
discussed in detail in the following section (see section II.1.4.7). 
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Potential 
mechanisms for 
an effect by fats 
Evidence for an effect 
Lymphatic 
lymphocyte 
transportation 
LCTs are transported with lymphocytes in the lymphatic system 
and so could affect lymphocyte transportation (Miura, Sekizuka 
et al. 1987) 
Lymphocyte 
trafficking 
Fat absorption can affect the expression of adhesion molecules 
on the lymphocyte (Tsuzuki, Miura et al. 1997; Fujiyama, 
Hokari et al. 2007) 
Lymphocyte 
proliferation 
Lipoproteins are required for lymphocyte proliferation and the 
type of fat available to lymphocytes can affect their proliferation 
(Cuthbert and Lipsky 1989; Miura, Imaeda et al. 1993) 
Lymphocyte 
receptor affinity 
and signalling 
Unsaturated fatty acids are incorporated into the lymphocyte 
cell membrane and can effect changes in membrane fluidity, 
changes in receptor affinity to cytokines and effects on signal 
transduction (Goppelt, Kohler et al. 1985; Shinomura, Asaoka 
et al. 1991; Zurier 1993; Suchner, Senftleben et al. 1995) 
Effects on other 
immune cells 
Oleic acid stimulates fibroblasts (Zugaza, Casabiell et al. 1995) 
and long chain fatty acids enhance the secretion of cytokines 
from intestinal epithelial cell lines (Hirokawa, Miura et al. 
1997) 
Effects on 
immunoglobulin 
production 
Intestinal IgA secretion is stimulated by oleic acid in the rat 
(Imaeda, Miura et al. 1993) 
Table 18. Potential mechanisms for an effect on disease of the amount and type of 
fat ingested  
 
II.1.4.6.1 Lymphatic lymphocyte transportation 
Both long-chain fatty acids and lymphocytes utilize intestinal lymphatics as the major 
pathway for transport from the intestinal mucosa to the systemic circulation, whereas 
medium chain fatty acid is mostly transported via the portal system. Thus associated 
changes in lymphocyte transport in the lymphatic system might be greater with 
administration of LCTs than MCTs. In one study this effect was demonstrated to cause 
a significant increase in lymphocyte flux in the mesenteric collecting lymphatics after 
administration of olive oil (Miura, Sekizuka et al. 1987). 
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II.1.4.6.2 Lymphocyte trafficking 
Lymphocytes interact with endothelium and cross endothelial linings of post-capillary 
venules (PCV), especially in Peyer’s patches, where morphologically distinct venules 
called high endothelial venules (HEV) are recognized as sites of lymphocyte traffic. 
Extravasation of lymphocytes through HEV involves multiple steps; primary interaction 
(rolling), activation-dependent adhesion (sticking) and transmigration. Adherence of 
lymphocytes to PCV of Peyer’s patches is mediated by a variety of lymphocyte 
adhesion molecules, including L-selectin, CD44, LFA-1 and the a4b7 integrins (Miura, 
Tsuzuki et al. 1998).  
 
That fatty acid exposure and the fatty acid composition of lymphocyte membranes can 
affect patterns of lymphocyte migration has been demonstrated in a number of studies. 
(Novo, Fonseca et al. 1987; Twisk, Detering et al. 1991; Twisk, Rutten et al. 1992; 
Tsuzuki, Miura et al. 1997). In one of those studies potential mechanisms were 
examined and it was found that olive oil absorption enhanced expression of both a4-
integrin and L-selectin on lymphocytes. Nearly complete inhibition of the olive oil-
stimulated lymphocyte–PCV interactions by a combination of a4-integrin- and L-
selectin-specific antibodies suggested that dual upregulation of a4-integrin and L-
selectin after fat absorption largely accounts for the associated lymphocyte adhesion in 
Peyer’s patches (Tsuzuki, Miura et al. 1997). 
 
A recent study into T-lymphocyte adherence to microvessels of the small intestinal 
mucosa showed that this was significantly enhanced after butter (long chain, saturated 
fatty acid) ingestion. This enhancement was due to an increase in expression levels of 
adhesion molecules of the intestinal mucosa (Fujiyama, Hokari et al. 2007). 
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II.1.4.6.3 Lymphocyte proliferation 
Lipoproteins are needed for lymphocyte proliferation in vitro (Cuthbert and Lipsky 
1989). Hence the amount and type of lipoprotein available to lymphocytes in vivo might 
affect their proliferation (Miura, Tsuzuki et al. 1998). This is supported by experiments 
showing that absorption of long-chain fatty acids, specifically oleic acids, stimulates 
mitogen-induced blast transformation of lymphocytes in intestinal lymphatics, whereas 
MCTs do not (Miura, Imaeda et al. 1993). Another group have shown that  
triacylglycerols containing PUFA inhibit lymphocyte proliferation, while 
triacylglycerols containing saturated fatty acids do not (Cuthbert and Lipsky 1989).  
II.1.4.6.4 Changes in lymphocyte receptor affinity and signalling 
Unsaturated fatty acids are readily taken up by lymphocytes and incorporated into 
phospholipids and triglycerides (Goppelt, Kohler et al. 1985; Cuthbert and Lipsky 
1989).  They then have direct effects on immunocompetent cells, some of which do not 
depend on the eicosanoid actions discussed further below. These include changes in 
membrane fluidity, changes in receptor affinity to cytokines, and also direct interactions 
of the PUFA with intracellular signal transduction and by acting as signal transducers 
themselves, affecting such cellular enzymes as cyclases or protein kinase C (Goppelt, 
Kohler et al. 1985; Shinomura, Asaoka et al. 1991; Zurier 1993; Suchner, Senftleben et 
al. 1995). 
II.1.4.6.5 Effects on other cell types of the GI immune system 
There is evidence that fat absorption might affect other GI cell types. In one series of 
experiments the monounsaturated fatty acid, oleic acid, stimulated fibroblasts exposed 
to endothelial growth factor to enter the replicative cycle more quickly and exhibit 
earlier cell division (Zugaza, Casabiell et al. 1995). In contrast long chain fatty acid has 
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been shown to enhance the secretion of cytokines during experiments on intestinal 
epithelial cell lines (Hirokawa, Miura et al. 1997). 
II.1.4.6.6 Effects on oxidative mechanisms 
The potential effects of different fatty acids in inflammatory states are demonstrated by 
experiments on neutrophils pretreated with TNF. TNF augmented superoxide 
production in response to PUFA and mono-unsaturated fatty acids, such as oleic acid, 
but not to saturated fatty acids (Li, Ferrante et al. 1996).  
II.1.4.6.7 Effects on gastrointestinal immunoglobulin production 
Finally, there is a documented effect of fatty acids on intestinal IgA production in the 
rat small intestine. Release of IgA into the intestinal lumen is stimulated by absorption 
of oleic acid and transport of IgA into the lymphatics is decreased (Imaeda, Miura et al. 
1993). 
II.1.4.7 n3 vs. n6 polyunsaturated fatty acids 
More recently attention has focussed on the individual fatty acids (FA) that make up the 
fat content of feeds. Polyunsaturated fats (PUFA) can be made up of two main subtypes 
of FA, n-3 and n-6. n-6 FAs are derived from Linoleic acid and are precursors for 
Arachidonic acid. Arachidonic acid forms an important part of the pro-inflammatory 
pathway via its conversion to Thromboxane A2 and Leukotrienes. In contrast n-3 FAs 
consist primarily of Linolenic acid, which has been shown to exert an anti-inflammatory 
effect (Caughey, Mantzioris et al. 1996). It has been speculated that increasing the 
amount of n-3 FA in feeds, relative to n-6, may exert a greater anti-inflammatory effect 
in CD. 
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(COX: cyclo-oxygenase; HETE: hydroxyeicosatetraenoic acid; HPETE: 
hydroperoxyeicosatetraenoic acid; LOX: lipoxygenase; LT: leukotriene; PG: 
prostaglandin; TX: thromboxane) 
Figure 5. Eicosanoid biosynthesis (adapted from Calder, Albers et al. 2009) 
 
Support for this concept comes from the link between increased intake of n-6 FAs and 
increasing incidence of CD in Japan (Shoda, Matsueda et al. 1996).  In addition patients 
with CD have lower concentrations of n-3 PUFAs in plasma phospholipids and adipose 
tissue compared with controls (Geerling, Stockbrugger et al. 1999).  
 
Whiting et al., using a (SCID) mouse model of chronic colitis that resembles Crohn 
disease, compared standard diet or a diet enriched in n-3 PUFAs (Whiting, Bland et al. 
2005). Animals fed n-3 FAs had similar immune cell infiltration, but significantly 
reduced disease scores, reduced neutrophil infiltration and lower mucosal levels of pro-
inflammatory cytokines (TNF-a, IL-1b and IL-12). Expression of epithelial tight 
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junction protein ZO-1 – a marker of intestinal permeability – was also better preserved, 
suggesting improved epithelial barrier function. The authors interpreted their findings as 
demonstrating that n-3 PUFAs reduce inflammation by reducing myeloid cell 
infiltration and activation, which, in turn, means lower levels of cytokines and less 
damage to the barrier. 
 
In a randomised controlled trial Bamba et al. showed that the addition of LCT with high 
n-6 FA levels did decrease the effectiveness of enteral feeding in CD (Bamba, 
Shimoyama et al. 2003). A multi-centre European study (Gassull, Fernandez-Banares et 
al. 2002), which was stopped early because of a low remission rate in one of the 
enterally fed groups, muddies the waters somewhat. It did not compare n-3 to n-6 
enriched feeds but did compare a high n-6 feed to a feed composed almost solely of 
monounsaturated fatty acids (MUFA). Of compliant patients treated with a diet high in 
linoleate (n-6 PUFA) and low in oleate (MUFA), 67% achieved remission compared 
with only 27% of those compliant with a formula low in linoleate and high in oleate. 
This suggests that the magnitude of response to enteral nutrition is influenced by lipid 
composition, but the relative importance of specific fatty acids might not so clearly 
relate to n-3 to n-6 ratio alone.  
 
Finally, in a recent study of nutritional supplementation in combination with steroids in 
CD, both the n-6 and n-3 enriched nutritional supplements were able to improve 
nutritional status, and clinical and biochemical markers (Nielsen, Nielsen et al. 2007). 
II.1.4.8 Maintenance using exclusion diets 
Following the induction of remission of CD by the use of an elemental diet or other 
enteral feeding regimen, remission can be maintained by the avoidance of foods to 
which intolerance has been demonstrated (Jones, Dickinson et al. 1985; Riordan, 
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Hunter et al. 1993). However the oral food challenges which inform dietary exclusion 
remains cumbersome and unreliable (Pearson, Teahon et al. 1993) and the regimens 
used need to be individualised.  
II.1.4.9 Implications of a role for enteral nutrition in CD 
The research outlined in the above section suggests that multiple mechanisms combine 
to produce a benefit for enteral nutrition in CD and that no one molecular mechanism is 
responsible for all the effects seen. That mechanical rest for the gut may play a role 
seems likely but this effect may be less than the role of the significant changes in the 
luminal content that occur with enteral nutrition. While enteral nutrition may well have 
direct anti-inflammatory effects on the mucosa and change the bowel flora in an 
advantageous manner, it remains plausible that a part of the effect of EN on active CD 
comes from the reduction or removal of antigenic substances from the lumen. 
II.1.5 Short chain fatty acids 
Studies of a role for SCFAs in the treatment of CD have been lower in number and have 
largely followed similar studies in UC (see Chapter III.2.4 Dietary fibre and short chain 
fatty acids). In their study of 17 CD patients and 6 healthy controls Segain et al. 
cultured intestinal biopsy specimens with and without butyrate (Segain, Raingeard de la 
Bletiere et al. 2000). They were able to show that butyrate decreased proinflammatory 
cytokine expression in inflamed tissue and that that change was mediated by the 
inhibition of NFkappaB activation and IkappaBalpha degradation. 
 
Di Sabatino performed the first in vivo study of butyrate treatment in CD (Di Sabatino, 
Morera et al. 2005). Thirteen patients with mild-moderate ileocolonic CD were given 
enteric-coated butyrate tablets for a total of 8 weeks. Crohn disease activity index and 
endoscopic and histological scores were assessed at the beginning and end of treatment. 
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Seven (53%) patients entered clinical remission and a further two had a partial response. 
Endoscopic and histological scores were significantly improved at the end of treatment. 
One patient withdrew from the study and three did not experience clinical improvement.  
 
While these results are encouraging further large scale controlled trials will be required 
before oral butyrate for CD could be recommended in clinical practice. 
II.1.6 Dietary fibre 
Concerns that dietary fibre might exacerbate IBD, and in particular cause obstruction in 
CD, was largely discounted by work done in the 1980s. Levenstein et al. in 1985  
randomly assigned 79 patients with non-stenosing Crohn disease to normal or low 
residue diet and saw no difference between groups (Levenstein, Prantera et al. 1985). 
Following this Ritchie et al. randomised 352 patients with inactive or mildly active 
Crohn disease to a diet containing either little or no sugar and high unrefined 
carbohydrate or unrestricted in sugar and low in fibre (Ritchie, Wadsworth et al. 1987). 
Again there was no difference between the groups.  
 
Thus it seems unlikely that fibre in the diet of CD patients is detrimental, but neither is 
there evidence to support the use of a high fibre diet in the treatment of CD. 
II.1.7 Yeast  
A role for yeast in the pathogenesis of CD was suggested by an early study that showed, 
in patients with CD of the ileum, decreased capacity of the leukocytes to phagocytose 
yeast (Krause, Michaelsson et al. 1978). Further indirect evidence comes from studies 
on occupational distribution of Crohn disease prevalence and mortality. Analyses of 
occupational mortality from Crohn disease in England and Wales (Sonnenberg 1990) 
have shown a proportional mortality ratio for bakers close to 3.5 times greater than that 
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for managers in retail (who had the second highest ratio of all professions). Another 
study from Germany showed that, among all professions in men, bakers have the 
highest odds ratio for Crohn disease (Sonnenberg 1990). 
 
There is one clinical study of 19 patients looking at the effect of yeast exclusion and 
exposure on CD (Barclay, McKenzie et al. 1992). This involved patients continuing 
their usual diet during the 1st month (base-line period), but during the next 2 months 
dietary yeast was excluded except that during 1 month patients took baker's yeast 
capsules while for the other month they took placebo capsules. The mean of each 
patient's maximum CDAI during yeast exclusion was significantly lower than those 
during the base-line and baker's yeast inclusion periods. Patients with elevated yeast 
antibodies tended to develop a higher CDAI while receiving baker's yeast. These results 
suggest that dietary yeast may affect the activity of Crohn disease but larger studies are 
required to confirm this finding. 
II.2 UC 
II.2.1 Attitudes 
The majority of patients with UC believe that certain foods affect the activity of their 
disease, and restrict their diets accordingly (Ballegaard, Bjergstrom et al. 1997; Green, 
Issenman et al. 1998; Joachim 1999; Jowett, Seal et al. 2004). The frequency and 
pattern of food intolerance does not differ between patients with CD and UC 
(Ballegaard, Bjergstrom et al. 1997). A wide range of foods are cited as causing 
symptoms. Most commonly these are vegetables, fruit, milk products, liver, diet drinks 
and artificial sweeteners, high fibre foods, spicy foods, corn and corn products, nuts, 
chocolate, cheese, wheat, and tomato sauces (Ballegaard, Bjergstrom et al. 1997; Green, 
Issenman et al. 1998; Joachim 1999).  
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Ballegaard et al. performed a postal survey of 53 CD, 69 UC patients and 70 healthy 
controls, asking whether the participants had problems with any particular food item 
and, if so, to describe the symptoms experienced from it (Ballegaard, Bjergstrom et al. 
1997). Food intolerance was equally common in CD (66%) and UC (64%), compared to 
14% of controls. The pattern of foods to which intolerance was reported and the 
symptoms reported were similar for UC and CD patients. 
 
In a later study Joachim et al. questioned 33 CD and 27 UC patients about their 
consumption of 122 different foods (Joachim 1999). They asked subjects to rate their 
reaction to each food. In contrast to the study by Ballegaard et al. they found that there 
was a higher number of foods that caused problems for people with CD than UC. 
 
As well as reporting intolerances to foods, patients with UC do alter their diet in 
response to those intolerances. In one study 80% of paediatric UC patients, who altered 
their diets to avoid foods that they felt worsened their condition, reported subjective 
symptomatic improvement as a result (Green, Issenman et al. 1998). Forty-nine UC 
patients responded to a questionnaire enquiring about changes they had made to their 
diets as a result of their disease and the effect this had had on the disease. Lactose-free, 
nonspicy, low acid, additive-free, caloric supplement and low fibre diets were used by 
more than 15% of UC patients. UC patients commonly avoided corn and corn products, 
nuts, milk and bran. More than 20% of UC patients also avoided tomato, chocolate, 
cheese, wheat, tomato sauces and fruit juice. The authors claimed, “of the 55 UC 
patients who had modified their diet, 44 (80%) reported a benefit”. The discrepancy 
between the denominator for this result and the total number of respondents may signify 
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that the there were actually a total of 55 dietary changes amongst the 49 UC patients 
surveyed. 
 
 Conversely, a prospective study using an objective measure of disease activity found 
dietary beliefs did not modify the risk of relapse, as much as adversely affect nutrient 
intake (Jowett, Seal et al. 2004). In this 1-year cohort study nutrient intake was assessed 
using a food frequency questionnaire and relapse defined using the simple clinical 
colitis activity index. Food beliefs, demographics and disease characteristics were also 
recorded. Of the one hundred and eighty-three patients studied 52% relapsed. 68% of 
patients held dietary beliefs and reported having altered their diet because of this, most 
commonly by avoiding milk and dairy products. No reported behaviour reduced the risk 
of relapse but patients who avoided dairy products did have a significantly lower intake 
of calcium. That dietary beliefs can affect nutritional status in UC is further evidenced 
by a study of patients with UC in whom the median calcium intake was significantly 
lower in those patients who reported avoiding milk and dairy products (Bernstein, 
Ament et al. 1994). 
 
Jowett et al. also examined the types of dietary advice received by UC patients and their 
adherence to it. The minority of patients (33%) had received advice. It was more 
common for those who believed that food was important to their disease to have 
received dietary advice compared to those that did not think food was important (40% 
vs. 17%).  The advice received most commonly came from dietitians, then hospital 
doctors and general practitioners. It consisted of a variety of recommendations, and the 
minority of patients were following the advice received (Jowett, Seal et al. 2004).  
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As with CD, analysis of the nutritional status of recently diagnosed UC patients shows 
that body weight and body mass index are significantly lower in UC patients than 
controls and that there are differences in intake of carbohydrate, protein, calcium, 
phosphorus, and riboflavin between patients and controls, and also major differences in 
the serum concentrations of several nutrients (beta-carotene, magnesium, selenium and 
zinc) in UC patients compared to controls (Geerling, Badart-Smook et al. 2000). 
However, the decrease in serum antioxidants of UC patients may be explained by 
increased consumption of antioxidants by inflamed tissue rather than by impaired 
digestion and absorption of nutrients. The effects of disease on body protein, body fat 
and hydration state were corrected within 12 months by curative colectomy in a separate 
study (Christie and Hill 1990). The degree to which these nutritional deficits might 
relate to the dietary manipulation effected by patients and their advisors is difficult to 
evaluate.  
 
Thus it appears that patients with UC commonly experience food intolerances and 
commonly alter their diet based on these intolerances. In addition, patients who alter 
their diets do report improvement in their disease. However, the real efficacy of such 
practices has not yet been clearly defined, although there remains a real possibility of 
deleterious nutritional effects.  
 
Non-dietary disease factors are likely to be statistically more important than dietary 
factors. In their study of dietary effect on risk of relapse, Jowett et al. demonstrated a 
greater magnitude of effect of previous disease activity on relapse rate than that of the 
greatest dietary contributor, red meat (odds ratio 9.30 vs. 5.19 respectively). However, 
nutrient intake cannot be ignored as a modifiable factor in disease activity. Patients 
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already commonly modify their diet in response to its perceived effect on their disease, 
and, when asked, see this as an area of great research interest (Jowett, Seal et al. 2004). 
 
No consensus statement as to appropriate use of dietary modification in the treatment of 
UC has been published. The impact of food on the course of disease has been examined 
only for a small number of specific dietary factors, including milk, meat, sulphate 
containing foods, fish oils, fat and dietary fibre. The current evidence regarding dietary 
manipulation in UC is summarized below. 
II.2.2 Milk 
The perception that dairy products have a negative effect in UC dates back to studies 
from the 1960s, conducted by Truelove’s group. They described a marked symptomatic 
and histological improvement for a small group of UC patients on a milk-free diet 
(Truelove 1961). Five patients were described who had a clear temporal relationship 
between the reintroduction of milk to the diet and the onset of clinical and histological 
exacerbation of disease. 
 
In the controlled trial that followed from the same group, patients on a milk free diet 
were found to be less likely to relapse than controls (Wright and Truelove 1965). 
Patients were randomly assigned to either a low fibre, dairy free diet or a “dummy” diet 
in which they were instructed to exclude a variety of items, such as fried foods, 
condiments, and icecream. In addition all patients received “standard medical therapy” 
which included oral prednisone. Relapse was defined as diarrhoea with an average of 
four or more stools a day for at least a week and with macroscopic blood present, 
together with sigmoidoscopic evidence of diffuse inflammation. There were a total of 
26 patients in the milk free diet group and 24 in the “dummy” diet group. The milk free 
diet group experienced fewer relapses than the “dummy” diet group. These results only 
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reached statistical significance if an one-tailed Chi-square test was used rather than a 
two-tailed test. 
 
These studies, by today’s standards, can be considered to have clear methodological 
defects (Jowett, Seal et al. 2004; Taxonera and Mendoza 2004). That said, the concept 
remains in force amongst patients with UC, who commonly adhere to a lactose free diet 
(Bernstein, Ament et al. 1994; Jowett, Seal et al. 2004). However, the evidence is that 
the prevalence of lactose malabsorption (as determined using hydrogen breath testing) is 
similar to (Gudmand-Hoyer and Jarnum 1970; Busk, Dahlerup et al. 1975; Bernstein, 
Ament et al. 1994; Ginard, Riera et al. 2003; Banos Madrid, Salama Benerroch et al. 
2004) or even lower than controls (Huppe, Tromm et al. 1992; Mishkin, Yalovsky et al. 
1997) when the risk is adjusted for ethnic group. Not even during flares in disease do 
patients with UC appear to have a higher rate of LM (Bernstein, Ament et al. 1994; 
Rosinach, Maurer-Pons et al. 2002)(see Table 19).
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Authors Country Ulcerative colitis Controls Diagnostic method 
  Number 
of 
patients 
Lactose 
Malab-
sorption 
Number Lactose 
Malab-
sorption 
Lactose 
tolerance 
test 
Determ-
ination of 
mucosal 
enzyme 
activity 
Binder, 
Gryboski et 
al. 1966 
USA  39 19 (49%) 37 18 (49%)  +  
Cady, Rhodes 
et al. 1967 
USA 32 15(47%) 122 38(31%)  + 
Newcomer 
and McGill 
1967 
USA  24 2 (8%) 100 6 (6%)  +  + 
Chalfin and 
Holt 1967 
USA  9 4 (44%)    +  
Littman, 
Cady et al. 
1968 
USA  29 13 (45%)  93 18 (19%) +  + 
Kojecky and 
Matlocha 
1968 
Czechos-
lovakia  
18 9 (50%)    +  + 
Montgomery, 
Frazer et al. 
1968 
England  11 2(18%)     + 
Gudmand-
Hoyer and 
Jarnum 1970 
Denmark  85 8 (9%)  700 3-7%  +  + 
Busk, 
Dahlerup et 
al. 1975 
Denmark 120 11 (9%)    + + 
Kirschner, 
DeFavaro et 
al. 1981 
USA 20 3(15%) 40 “similar 
to IBD” 
+  
Huppe, 
Tromm et al. 
1992 
Germany 53 2 (3.8%)   +  
Bernstein, 
Ament et al. 
1994 
USA 29 13(44%) 14 5(36%) +  
Mishkin, 
Yalovsky et 
al. 1997 
Canada 139 18(13%) 158 46(29%) +  
Ginard, Riera 
et al. 2003 
Spain 52 13 (25%) 34 11(32%) +  
Banos 
Madrid, 
Salama 
Benerroch et 
al. 2004 
Spain 24 4(17%) 25 5(20%) +  
Table 19. Studies of lactose malabsorption in ulcerative colitis 
(Adapted from Gudmand-Hoyer et al.) 
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That mechanisms other than LM might play a role in UC has received less research 
attention. In a dated study of 21 patients with ulcerative colitis, none of whom had 
lactose malabsorption, a milk-free diet was beneficial in five patients, as judged from 
the numbers of movements and their feeling of well being (Gudmand-Hoyer and 
Jarnum 1970). In another study an increased number of basophils degranulated in the 
presence of cows' milk in UC patients, but normal responses occurred in patients with 
CD (Smart, Danis et al. 1986). 
 
It seems therefore that a subset of patients with UC do believe intake of dairy products 
contributes to their disease. However, there is no data to suggest that lactose 
malabsorption plays a more important role in this than it does in the general population 
and no further mechanisms by which milk might contribute to symptoms in UC have 
been elucidated in the literature. 
II.2.3 Meat and sulphates 
Concerns that a diet high in red meat might predispose to UC are raised by epidemiological 
data from Japan, a country in which increasing rates of UC have been paralleled by an 
increased intake of red meat (Kitahora, Utsunomiya et al. 1995). Prospective data is limited, 
but in a study by Jowett et al. a high meat, protein, or alcohol intake was associated with an 
increased risk of UC relapse (Jowett, Seal et al. 2004).  The biological plausibility of such 
observations are supported by animal experiments demonstrating that sulphated dextrans, but 
not dextrans without sulphur, are able to induce experimental colitis in rodents (Ohkusa 1985). 
The presence of faecal sulfides is directly related to the intake of red meat (Magee et al. 2000). 
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Figure 6. Faecal sulfide content as a function of dietary meat protein intake (from 
Magee et al. 2000) 
 
Clinical data to support limiting the intake of sulphur amino acids is limited to a pilot study of 4 
patients with chronic UC and 4 with acute UC, in which all patients experienced clinical 
improvement (Roediger, Duncan et al. 1993). Current evidence therefore suggests an 
association between the intake of red meat and other sulphate containing foods, and the 
incidence of ulcerative colitis. While there is experimental data to suggest a biological 
mechanism, there are no controlled clinical trials demonstrating the utility of dietary avoidance 
of sulphate containing foods.  
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II.2.4 Dietary fibre and short chain fatty acids 
N-butyrate, a SCFA produced by the colonic fermentation of some forms of fibre, is the 
preferred respiratory fuel of the colonocyte (Roediger 1980). Butyrate has also been 
shown to inhibit both the production of some cytokines and the activation of the 
transcription factor NFkB (Segain, Boureille et al. 1997; Wu, Huang et al. 1997; Luhrs, 
Gerke et al. 2002; Sanderson 2004). These findings have fuelled investigation into the 
role of SCFAs in the management of UC. The results of clinical studies performed using 
SCFA preparations are summarised in Table 20.
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(RDBPCT: randomised, double-blind, placebo controlled trial; SCFA enema = sodium 
acetate, sodium propionate and sodium butyrate; ITT: intention to treat analysis) 
Table 20. Studies of short chain fatty acids in the treatment of ulcerative colitis
 Preparation Design Patients Results 
Senagore, 
MacKeigan et 
al. 1992 
SCFA enema vs. 
corticosteroid 
enema vs. 
mesalamine 
enema 
Open label Proctitis (SCFA enema 
n=14, corticosteroid 
n=12, 5ASA n=19) 
Recovery in 12/14 SCFA, 
10/12 corticosteroid and 
17/19 5ASA treated 
patients 
Scheppach, 
Sommer et al. 
1992 
Butyrate enema RDBPCT 
cross-over 
(8 weeks) 
Distal UC unresponsive 
to standard therapy 
(n=10) 
Reduced stool frequency, 
bleeding and 
inflammation 
Steinhart, 
Brzezinski et 
al. 1994 
Butyrate enema Open label Distal UC unresponsive 
to standard therapy 
(n=10) 
60% response 
Vernia, 
Marcheggian
o et al. 1995 
SCFA enema RDBPCT 
(6 weeks) 
Mild to moderate distal 
UC (n=40) 
Improvement in 14/20 
treatment vs. 5/20 placebo 
patients 
Patz, 
Jacobsohn et 
al. 1996 
SCFA enema Open label 
(6 weeks) 
Distal UC unresponsive 
to standard therapy 
(n=10) 
50% clinical and 
endoscopic response 
Steinhart, 
Hiruki et al. 
1996 
Butyrate enema RDBPCT 
(6 weeks) 
Distal UC (n=38) Clinical improvement in 
37% butyrate treated and 
47% placebo treated 
patients 
Scheppach 
1996 
SCFA enema vs. 
butyrate enemas 
vs. saline 
placebo 
RDBPCT 
(6 weeks) 
Active distal UC 
(n=47) 
Trend toward 
improvement with active 
treatment but no statistical 
differences 
Breuer, 
Soergel et al. 
1997 
SCFA enema vs. 
placebo 
RDBPCT 
(6 weeks) 
Distal UC (n=103) Improvement in 33% 
SCFA vs. 20% placebo 
treated patients (p=0.14) 
Vernia, 
Monteleone 
et al. 2000 
Oral sodium 
butyrate tablets 
plus oral 
mesalazine vs. 
mesalazine plus 
placebo 
RDBPCT 
(6 weeks) 
Mild to moderate UC 
(n=30) 
Remission in 7 butyrate 
vs. 5 placebo treated 
patients and improvement 
in 4 butyrate vs. 5 placebo 
treated patients 
Vernia, 
Annese et al. 
2003 
Butyrate and 5-
ASA enema vs. 
5-ASA enema 
alone 
RDBPCT 
(6 weeks) 
Distal UC refractory to 
topical 5-ASA and 
cortisone (n=51, 24 
butyrate vs. 27 placebo) 
Remission in 6 butyrate 
vs. 1 placebo treated 
patients and improvement 
in 12 butyrate vs. 13 
placebo treated patients 
Assisi 2008 Mesalazine, 
butyrate and 
inulin tablets 
Open label UC unresponsive to 
mesalazine (n=216) 
110/216 (51%) clinical 
and endoscopic remission 
(ITT) 
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The treatment of UC with SCFA preparations has given contradictory results, with early 
results being encouraging, but the results from more recent, larger studies disappointing.  
Subgroup analysis of the largest of the studies to date did suggest that despite there 
being no therapeutic value of SCFA enemas for the whole group studied, patients with a 
short period of disease activity prior to treatment, and those who used more of the 
treatment, were more likely to benefit (Breuer, Soergel et al. 1997).  
 
Anecdotal reports of clinical improvement of UC with a high fibre diet fuelled a 1978 
report from Davies and Rhodes who took patients with UC in remission and either 
continued them on Sulphasalazine (n=15) or withdrew Sulphasalazine after initiation of 
a high-fibre diet (n=24).  Four patients could not tolerate the diet and were withdrawn. 
At the end of 6 months 15 of 20 patients who continued on the high fibre diet had 
relapsed as compared to 3 of 15 patients who continued Sulphasalazine. 
 
In 1991 Hallert et al. described their placebo-controlled cross-over experience with 
Ispaghula husk in UC in remission (Hallert, Kaldma et al. 1991). Twenty-nine patients 
with UC in remission but with ongoing disturbance of bowel habit were studied. The 
trial analysis was not on an intention to treat basis and only the results of patients who 
completed treatment were considered. They found a statistically significant rate of 
symptomatic improvement in Ispaghula treated patients.  
 
The hypothesis upon which the above studies were based stemmed from evidence that 
patients with quiescent UC were subject to irritable bowel syndrome-like symptoms. 
However, the advent of evidence for a role of SCFA in maintaining the health of the 
colonocyte, and initial data suggesting a role for topical SCFA in the treatment of UC, 
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led to the conjecture that oral ingestion of substrates promoting the production of SCFA 
in the colon might be beneficial in UC. 
 
The first of these studies, by Fernandez-Banares et al, found no difference in the 
efficacy of Plantago Ovata vs. Mesalamine, or a combination of the two, for the 
management of UC in remission (Fernandez-Banares, Hinojosa et al. 1999). In an open 
label randomised clinical trial 105 patients with UC in remission were randomised to 
receive one of the above treatments. The primary outcome measure was maintenance of 
remission at 12 months. The rate of treatment failure was 40% in the Plantago ovata, 
35% in the mesalamine and 30% in the combined treatment groups. A significant 
increase in faecal butyrate was observed with Plantago ovata administration. 
 
Mitsuyama et al. used germinated barley foodstuff (GBF) to treat 10 patients with mild 
to moderate UC who had been unresponsive to or intolerant of standard treatment. In 
this open label study there was a clinical and endoscopic improvement in the patients 
treated at the end of 4 weeks (Mitsuyama, Saiki et al. 1998). This improvement was 
associated with an increase in stool butyrate concentrations and in luminal 
Bifidobacterium and Eubacterium (the bacteria responsible for converting fermentable 
fibre to SCFA) levels. 
 
The follow up study was again open label and examined 18 patients with mild to 
moderate UC who were randomly allocated to receive either standard therapy alone 
(n=7) or standard therapy plus GBF (n=11) (Kanauchi, Suga et al. 2002). After 4 weeks 
of treatment, the GBF-treated group showed a decrease in clinical activity score 
compared with control (p<0.05). A group of 21 patients was further followed to 24 
weeks whilst on open label treatment (Kanauchi, Mitsuyama et al. 2003). Again the 
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treatment group showed a decrease in clinical activity index compared to the control 
group (p<0.05).  
 
Hanai et al. then went on to use GBF for the treatment of 59 patients with UC in 
remission (Hanai, Kanauchi et al. 2004). They compared patients on conventional 
therapy (n=37) with patients treated with conventional therapy plus GBF (n=22). At 12 
months the clinical activity index was better in the GBF treatment group. 
 
In a study examining the advice given to patients with UC, they most commonly 
recalled being told to take a high fibre diet, but the advice was not consistent and a 
minority were told to have a low fibre diet (Jowett, Seal et al. 2004). Interestingly, those 
patients who reported taking a high fibre diet because they felt it helped their disease 
did not have a significantly greater intake of dietary fibre compared to those who did 
not believe high fibre helped (Jowett, Seal et al. 2004). In another study patients with 
UC consumed significantly less fibre than control subjects (Rosman-Urbach, Niv et al. 
2006). 
 
Recently interest has focused on the anti-inflammatory properties of SCFAs and dietary 
fibre outside of luminal disease (North, Venter et al. 2009). These agents act on 
multiple inflammatory pathways, not all of which are particular to the gut (see Figure 
7). 
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Sites of action 
of current IBD 
therapies 
 
Figure 7. The mechanisms through which dietary fibre may influence 
inflammation (adapted from North, Venter et al. 2009) 
 
A biological mechanism for benefit is provided by the demonstration that dietary fibre 
in UC can safely increase the amount of luminal butyrate (Fernandez-Banares, Hinojosa 
et al. 1999; Hallert, Bjorck et al. 2003). However, larger scale placebo controlled trials 
are required to ensure the finding that the addition of fermenting fibre to conventional 
remission maintenance strategies robustly improves outcome. In addition, placebo 
controlled trials of fibre for the treatment of active UC are required before this treatment 
can be recommended. 
II.2.5 Fish oils 
As discussed in section II.1.4.7 a dietary intake high in n-3 fatty acids, such as are found 
in fish oil preparations, may have anti-inflammatory effects. The evidence to support a 
role for the use of fish oil preparations in UC are summarised in Table 21. 
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 Study description Subjects Results 
Lorenz, Weber et al. 
1989 
7 month, double-
blind, placebo 
controlled cross-over 
study 
Active UC (n=10) Non-significant 
trend towards an 
improvement in 
clinical activity in 
the fish oil treated 
group 
Aslan and 
Triadafilopoulos 
1992 
8-month, double-
blind, placebo-
controlled, crossover 
trial 
Eleven patients 
with mild to 
moderately active 
UC 
A reduction in the 
mean disease 
activity index of 
56% for patients 
receiving fish oil 
compared to 4% 
for those on 
placebo 
Stenson, Cort et al. 
1992 
4 month randomised, 
double-blind, 
placebo-controlled 
crossover trial 
24 patients with 
active UC 
Histological 
improvement and 
weight gain in 
treatment group, 
no improvement 
in placebo group 
Hawthorne, 
Daneshmend et al. 
1992 
randomised, double 
blind, placebo-
controlled study 
96 patients with 
UC, 56 of whom 
were in relapse at 
enrolment and 40 
in remission 
For those patients 
who entered the 
trial with active 
disease there was 
a significant 
reduction in 
corticosteroid use 
but only a trend 
toward achieving 
remission 
Almallah, Ewen et 
al. 2000 
6 month randomised, 
double blind study 
of fish oil or 
sunflower oil 
placebo 
18 patients with 
active proctitis 
Significant 
reduction in the 
clinical activity 
score for the fish 
oil compared to 
the placebo group 
Table 21. Randomised controlled studies of fish oil in active UC 
 
Lorenz et al. were able to show that dietary n-3 fatty acids were incorporated into 
plasma and enteric mucosa phospholipids at the expense of n-6 fatty acids (Lorenz, 
Weber et al. 1989). Almallah et al. demonstrated a possible mechanistic effect in the 
form of a significant reduction in the circulating numbers and activity of natural killer 
and lymphokine-activated killer cell activities (Almallah, El-Tahir et al. 2000). 
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A Cochrane review of this subject found a level of inconsistency, in particular regarding 
reporting of outcome measures, between the above studies that obviated meta-analysis 
(De Ley, de Vos et al. 2007). Their conclusion was that the available information is 
insufficient to make recommendations for practice regarding the use of fish oils in 
active UC. 
 
Studies that have used fish oil as maintenance therapy for UC in remission have, 
however, been largely negative. In the trial conducted by Hawthorne et al. described 
above, there was no significant difference in the rate of relapse of those in remission 
between the fish oil treated and placebo groups (Hawthorne, Daneshmend et al. 1992).  
In a study by Greenfield et al. 24 patients with stable UC were randomised to receive 
fish oil (n=16) or olive oil placebo (n=8) (Greenfield, Green et al. 1993). The only 
clinical effect of active treatment was an improvement in stool consistency. Stool 
frequency, rectal bleeding, disease relapse, sigmoidoscopic appearance and rectal 
histology were unchanged between the treatment groups. 
 
A relapse prevention study by Loeschke et al. randomised 64 patients with UC in 
remission, both on and off steroids, to fish oil or placebo. After 3 months of treatment 
all 5-ASA preparations were stopped and clinical disease activity was monitored for 
two years. The relapse-free survival was improved in the fish oil group only during 
months 2 and 3. By 2 years the relapse rate was similar for both groups. 
 
Mantzaris et al. allocated 40 patients with UC in remission to be treated either with fish 
oil (n=22) or olive oil placebo (n=18), in a randomised fashion (Mantzaris, Archavlis et 
al. 1996). There was no difference in relapse rates at one year between the two groups. 
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Recent meta-analysis from the Cochrane group of 3 of the above studies was unable to 
show a clear benefit for fish oils alone in the maintenance of UC (Turner, Steinhart et 
al. 2007). 
 
Other studies have compared fish oil treatment to active controls. Dichi et al. compared 
fish oil head-to-head with sulphasalazine in a randomised, cross-over study of 10 
patients with mild to moderate active UC. The fish oil group fared significantly worse 
than the sulphasalazine group in terms of clinical, endoscopic and histological activity 
of disease.  
 
Barbosa et al. performed a randomised controlled cross-over study comparing 
sulphasalazine alone with the combination of sulphasalazine and fish oil in 9 patients 
with mild or moderate UC. Although they were able to show a reduction in plasma 
oxidative stress with fish oil treatment, this did not translate into an improvement in 
disease activity as measured by laboratory indicators, and sigmoidoscopy and histology 
scores. 
 
A further open label study examined the use of seal oil, administered via nasoduodenal 
feeding tube, for the treatment of UC (Arslan, Brunborg et al. 2002). Five patients were 
treated for 10 days with a benefit in terms of disease activity.  
 
Interest in the action of n-3 FAs and fibre as described above has logically led to the 
investigation of combinations of these supplements in the management of IBD, in 
particular in UC. Seidner et al. compared a combination of fish oil, soluble fibre and 
antioxidants in the management of mild to moderate UC. They were able to demonstrate 
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a reduction in the use of steroid therapy in the treatment group, clinical response was 
similar for treatment and placebo control (Seidner, Lashner et al. 2005).  
 
Thus it seems unlikely that fish oil preparations constitute a beneficial approach to the 
maintenance of remission in UC. The possibility remains that larger, parallel group, 
double-blind, placebo controlled studies might find a benefit for fish oil over placebo in 
the treatment of active UC. However, the limited available evidence suggests it likely 
fish oil will remain inferior to standard 5-ASA therapy for the treatment of such 
patients. 
II.3 Conclusions 
The only conclusion the above Chapter allows is that there remains a lack of consensus 
on the dietary management of IBD. This is explicable by the uncertainty of the 
underlying science regarding the effect of dietary factors on disease development and 
the influence of dietary change over disease course. In the light of this I wanted to 
ascertain a baseline status of current practice. Much information exists regarding how 
patients view the interaction of diet with their disease, but there is very little descriptive 
data regarding the approach gastroenterologists take to the interaction between diet and 
disease. The proceeding Chapter describes a survey study, conducted in both the United 
Kingdom and New Zealand, designed to ascertain how gastroenterologists approach 
dietary management and manipulation in IBD and to compare that with their dietary 
management in irritable bowel syndrome, another common gastroenterological 
condition . 
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Chapter III Survey of United Kingdom and New 
Zealand gastroenterologists’ 
practice regarding dietary advice 
and food exclusion in irritable bowel 
syndrome and inflammatory bowel 
disease 
III.1 Introduction 
n 1950 Loveless (Loveless 1950) and Graham (Graham, Wolf et al. 1950) 
synchronously demonstrated an association between food and gastro-intestinal 
symptoms in adults. Since then food intolerance has commonly been reported in the 
general population, and 20-45% of the adult population believe that they suffer from 
adverse reactions to food (Burr and Merrett 1983; Crowe and Perdue 1992; Shanahan 
1993; Young, Stoneham et al. 1994). However, double-blind food elimination and 
challenge is positive in only a small proportion of these people.  
 
It has long been thought that food intolerance plays at least some role in the production 
of symptoms in irritable bowel syndrome (IBS) (Crespo and Rodriguez 2003; Sicherer 
2003). The perception of food intolerance is common amongst patients with IBS, 20-
65% of patients attribute their symptoms to adverse food reactions (Nanda, James et al. 
1989; Dainese, Galliani et al. 1999) and patients commonly experiment with 
elimination diets or alternative therapies before seeking medical help (Smart, Mayberry 
et al. 1986). Recent studies have shown the ability of an exclusion diet guided by the 
results of testing for IgG antibodies to foods in the serum to improve the symptoms of 
patients with IBS (Atkinson, Sheldon et al. 2004; Zar, Mincher et al. 2005). 
 
I 
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The association between symptoms of IBD and diet has also received much attention 
(Jones, Dickinson et al. 1985; Riordan, Hunter et al. 1993; Crowe 2001). It is 
commonplace for patients with GI disorders to believe that something in their diet has 
caused their condition (Crowe 2001). Some studies have claimed that food sensitivities 
are common in CD and have found that when food intolerances are detected, patients on 
an exclusion diet maintain remission significantly longer than those on an unrestricted 
diet (Jones, Dickinson et al. 1985; Riordan, Hunter et al. 1993). However, when these 
patients are subjected to double-blind food challenges only 15% show a positive 
response (Pearson, Teahon et al. 1993). 
 
Despite these associations the available evidence is insufficient for strong 
recommendations regarding the use of exclusion diets in these conditions to be made 
and current guidelines for the management of IBD and IBS give very little specific 
recommendation regarding testing for food intolerance/allergy nor the treatment of it 
(Carter, Lobo et al. 2004; Spiller, Aziz et al. 2007). No information exists as to how 
commonly exclusion diets are used in practice or what forms of advice are given. This 
study aimed to determine what current practice regarding dietary advice, in particular 
advice about food exclusion, is amongst gastroenterologists in the United Kingdom 
(UK) and New Zealand (NZ). 
III.2 Collaborators 
The author performed all data collection and analysis. Dr A Emmanuel and Dr S Bloom 
assisted with study and questionnaire design. 
 
III.3 Ethical approval 
Advice was sought from the chair of the Joint UCL/UCLH Committees On The Ethics 
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Of Human Research. It was their opinion that committee approval was not needed for 
the conduct of this study. 
III.4 Subjects 
This survey aimed to question the majority of adult gastroenterologists in NZ and the 
UK. Both countries have professional gastroenterological societies with high rates of 
membership by practising gastroenterologists [the British Society of Gastroenterologists 
(BSG) and the New Zealand Society of Gastroenterologists (NZSG)], although the 
exact proportion of gastroenterologists who are members is not known. Both societies 
maintain lists of active members, providing the only reliable route for identification of a 
large body of practising gastroenterologist in each country.  
 
Both societies also contain many members who are not practising adult 
gastroenterologists. All respondents were questioned regarding the nature of their 
practice. All but those currently practising as gastroenterologists in adult medicine were 
excluded from the analysis. In addition the list of non-responders was examined for 
non-adult gastroenterologists by means of qualification, e.g. those holding FRCS and 
FRCPath qualifications were excluded, and location of practice, e.g. those practising 
only in a paediatric setting were excluded. This differentiation proved straightforward in 
NZ, where the number of practising gastroenterologists is lower. However, it remains 
probable that non-adult gastroenterologists are represented in the final numbers of non-
responders in the UK audit, thus increasing the apparent non-response rate in that 
survey. 
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III.5 Methods 
Gastroenterologists are no strangers to surveys of practice. A Medline search using the 
terms “gastroenterologist” and “survey” returned 10 published, large scale, practice 
surveys in the year 2008 alone. Mandal et al. and Eaden et al. have extensively 
reviewed the aspects that are essential to maintaining the quality of survey work in this 
area (Eaden, Mayberry et al. 1999; Mandal, Eaden et al. 2000). They are careful to 
point out that, while survey techniques can produce speedy results usually without 
significant capital investment, questionnaires cannot be easily constructed and used 
without training. Careful attention to reliability and validity is needed. The ideas from 
these review articles are heavily drawn upon in the proceeding discussion. Each aspect 
of the survey design process for this study is outlined below and the compromises and 
solutions decided upon are discussed. 
III.5.1 Question type 
Closed questions may unduly lead the respondent, yet open questions give responses 
that may be difficult to analyse in a quantitative fashion. Semi-closed questions can 
provide a compromise for both the investigators and the respondents; besides providing 
answer choices, they give the subject a freedom to include additional information. For 
this reason two main question types, dichotomous and multiple choice, were used in this 
survey but ample opportunities for additional open responses were provided. 
III.5.2 Survey medium 
The choice of survey medium depends on the type and the size of the population to be 
studied as well as its geographical distribution. In this survey the desire was that a large 
population over a wide geographical distribution be included. This precluded face-to-
face or over-the-telephone interviews, leaving mail out and Internet based surveys as the 
applicable tools. 
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Internet based techniques allow researchers to conduct surveys through self-
administered questionnaires and data can be collected using the World Wide Web or 
through electronic mail. The main advantages of this method are: 1. cheapness, as it 
needs no postage, printing, packaging, interviewer or telephone call; 2. it is quick – it 
takes only few seconds to send and return messages; 3. sending a repeat message, 
reminder or clarification is easy; 4. recipients can easily and quickly complete 
proformas and return the data with a keystroke; 5. easy access to respondents 
throughout the world which removes geographic barriers.  
 
The disadvantages are: 1. there remains a concern that the internet community is not yet 
representative of the general population and this will lead to selection bias; 2. 
respondents have generally had a higher education and higher household income; 3. if 
the survey is done through e-mail, access to the e-mail addresses of potential 
respondents is necessary; 4. impersonation of patients or other subjects will be difficult 
to exclude.  
 
At the time of their review Mandal et al. concluded that data collected through the 
Internet should be interpreted with caution because of these selection biases (Mandal, 
Eaden et al. 2000). However, this tool has received increasing popularity of use in 
healthcare related research (Braithwaite, Emery et al. 2003). Recently, Lusk et al. 
evaluated determinants of response to Internet-based surveys in a sample (n = 5600) of 
Texas healthcare professionals (Lusk, Delclos et al. 2007). Participants were given the 
option of responding by mail or over the Web. Overall, Web-based responses 
represented a consistent 9% to 10% of the total responses. Missing questionnaire items 
were significantly higher among Web responders. In the final multivariate logistic 
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regression, only male gender (OR = 2.09, 95% CI = 1.56-2.80) and younger age 
remained significantly associated with response over the Internet, suggesting that there 
is a significant and perhaps growing minority of health professionals who would prefer 
to respond over the internet and that the selection biases one could expect might be 
mostly gender and age based.  
 
Mail surveys are also quick, cheap and free of interviewer influence. The major issues 
are of non-response bias, response quality and item non-response. In addition they allow 
only limited control over whether the intended respondent or someone else completes 
the form. Incorrect addresses and temporary absence of the respondent at the time of the 
survey  (e.g. holiday) will also affect response rates.  
 
Both the BSG and NZSG lists include email addresses for the majority of members, 
allowing a Web-based approach. However, it was recognised that the age range in both 
societies is wide and that, as evidenced by the results of Lusk et al. (Lusk, Delclos et al. 
2007), sole use of a Web-based approach would have been likely to produce non-
response bias, at least in terms of age of respondents vs. non-respondents. For this 
reason a two-pronged approach was chosen where all society members would first be 
emailed. Then, in subsequent rounds, those not responding and those without listed, 
functioning email addresses would additionally be contacted by conventional mail. 
III.5.3 Questionnaire design 
The main principles of questionnaire design, as set out by Stone, were adhered to (Stone 
1993). 
1. Clear and appropriate objectives for the study were set with a well-defined end-
point.  
2. Questions were designed to be unambiguous. 
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3. The questions were designed to be appropriate to the social and educational 
background of the respondent. 
4. Consultant gastroenterologists were approached as it was felt they would be 
most willing and able to answer accurately. 
5. The potential for external events to bias the answer was considered. Thus the 
decision to use two forms of survey medium. In addition the decision to use an 
incentive strategy was very carefully considered (discussed in section III.5.5) 
and only embarked upon when it was felt that overcoming non-response bias 
might outweigh the bias introduced. In addition the effect of the incentive on the 
pattern of response was analysed in a sensitivity analysis. 
6. Approval from the Chair of the Joint UCL/UCLH Committees On The Ethics 
Of Human Research was sought.  
 
III.5.3.1 Length of questionnaire 
Available evidence suggests that the length of a survey directly contributes to non-
response. Mandal et al. and Eaden et al. have suggested that one A4 page is an 
appropriate length of survey (Eaden, Mayberry et al. 1999; Mandal, Eaden et al. 2000). 
A study by Jepson et al. showed that there might be a threshold length for surveys, 
beyond which non-response rates increase (Jepson, Asch et al. 2005). In a pilot study 
they administered questionnaires of 30 different lengths (849 to 1,867 words), by mail, 
to 192 physicians in April 1999. This was followed by a study involving surveys of 16 
different lengths (564 to 988 words) sent to 1,700 physicians between June 1999 and 
January 2000. They concluded there appeared to have been a threshold of 
approximately 1,000 words. Questionnaires above the threshold had lower response 
rates than those below it (38.0% vs. 59.4%). However there was no direct association, 
on logistic regression analysis, between word count and response. 
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Attempts to confine the questionnaire for this survey to one A4 page did not allow 
identical surveys to be administered for IBS and IBD with clear layout. Although the 
focus of this thesis is food intolerance testing in IBD, I was very interested to 
investigate how current practice compared between IBD and IBS, two diseases with 
very different evidence bases regarding food intolerance and its management. For this 
reason it was decided the questionnaire would be extended to two A4 sheets. However, 
at 833 words, the final word count was kept below 1000.  
III.5.3.2 Layout of questionnaire 
The level of compliance and quality of response depends on the initial questions, thus 
emotional content should be avoided at the beginning of the questionnaire and the first 
few questions should be simple, objective and interesting. More sensitive items are 
better placed later. This is known as a ‘funnel approach’ (Mandal, Eaden et al. 2000). In 
addition the overall questionnaire should move from topic to topic in a logical manner 
with all questions on one topic being completed before the respondent moves to the 
next.  
 
These principles were carefully applied in the design of the questionnaire for this study. 
Initial questions were regarding the nature of the respondents’ practice and the resources 
available to them, prior to asking direct questions about their personal management. The 
two parts to the questionnaire, practice in IBS and IBD, were carefully separated by a 
header statement in the Web-based and mail-out versions and by separate pages in the 
mail-out version. 
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III.5.4 Questionnaire pilot study 
Mandal et al. summarise the characteristics of a pilot study (Mandal, Eaden et al. 2000). 
Pilot studies should address the following:  
1. Validity of the data (extent to which an instrument measures what it is supposed 
to measure) 
2. Reliability of the data  (extent to which the questionnaire can give consistent 
results) 
3. Whether the understanding was similar for all respondents 
4. Non-response to one or more questions 
5. Uninterpretable responses to any question 
6. Researcher bias in question design 
7. Whether the questionnaire and the covering letter adequately explain the purpose 
of the study. 
 
Test–retest examines the ability of a questionnaire to produce identical responses when 
given to the same person on two separate occasions. However, if the test–retest is done 
too quickly the result may be confounded by memory.  
 
Within this study a pilot study was conducted with 14 consultant gastroenterologists in 
the London region. 14 gastroenterologists were emailed and requested to complete an 
online survey.  They were then requested to repeat the survey 4 weeks later.  In the light 
of their comments the questionnaire was modified. The responses to both pilot 
questionnaire rounds were used to assess the test-retest reliability of the survey, by 
comparing each item and identifying items as unreliable if the correlation coefficient 
was below 0.5 using Pearson's correlation coefficient (r) for continuous variables and by 
calculating Phi (f) for dichotomous variables.  
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III.5.5 Avoiding non-response bias 
Mandal et al. have summarised the factors associated with response rates greater than 
90% (Mandal, Eaden et al. 2000): 
1. Motivation and interest in the subject matter. 
2. The nature of the sponsor, for example sponsorship by a professional body.  
3.  A relatively short and non-contentious questionnaire that includes a description 
of purpose and benefits of the study. 
4. Notification by mail or telephone. 
5. A handwritten note attached to the questionnaire. 
6. A supporting letter from the patient’s general practitioner.  
 
Attention was paid to those aspects that could be addressed in this study. It was 
presumed that gastroenterologists, by and large, would exhibit interest in what is 
recognised as an aspect that is of great interest to their patients in the management of 
two of the commonest diseases that they treat. In addition the covering letter sought to 
promote that interest by clearly stating the objectives of the study and recapping the 
absence of similar data or authoritative recommendations regarding practice in this area. 
In the NZ study a hand-written note accompanied all second mail out letters from the 
author. Although sponsorship from the professional bodies was not available, the use of 
the mailing list from that body was mentioned.  
 
One of the major advantages of Internet-based surveys is the ease of repeated reminders 
to potential respondents. In work by Braithwaite et al. looking at the response of UK 
general practitioners (GPs) to an electronic survey, this strategy was associated with a 
doubling of the initial response rate after a total of five reminders and response rates 
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very similar to those reported in studies of mail-out surveys of UK GPs (Braithwaite, 
Emery et al. 2003). 
 
Monetary incentives can also increase response rates substantially, especially if they are 
prepaid (Mandal, Eaden et al. 2000). In this study it was decided that response rate 
would be monitored in the initial email rounds and if unexpectedly low response rates 
were occurring an incentive in the form of a prize would be offered. The effect of this 
on the responses would be monitored using sensitivity analysis of responses before and 
after the offering of a prize. 
III.5.5.1 Sensitivity analysis 
After each successive wave of contact with a group of potential respondents the 
researcher should run a sensitivity analysis. Its purpose is to ascertain how different 
non-respondents would need to be from respondents to alter the significance of the data 
supplied by current respondents. If the most extreme foreseeable answers by the non-
respondents would not alter the decision no further efforts are needed. If the non-
respondents could alter the decision then the researcher should examine the trend over 
the first, second and third mailings. The attributes of the non-respondents are assumed 
to be similar to a projection of the trend between early and late respondents.  
 
In this study the responses from early vs. late respondents, which also made up the 
groups offered vs. not offered an incentive, and also email vs. conventional mail 
respondents, where analysed for significant differences in their replies to any question. 
III.5.6 Statistical methods 
Sensitivity analysis comparing mail rounds was performed by calculating the 95% 
confidence intervals for each response within each mail round. Confidence intervals 
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were compared between rounds to examine for statistically significant differences in 
response between mail rounds. Assessment of questionnaire test-retest reliability was 
performed in a pilot study using Pearson’s correlation coefficient (r) for continuous 
variables and by calculating Phi (f) for dichotomous variables. Paired proportions were 
compared using the McNemar test. 
 
Web-based survey data were collected using the tool provided by the UK based online 
market and research systems provider Problemfree Ltd. at their website 
www.Freesurveysonline.com. Data were collated in Microsoft® Excel 2003 (Microsoft 
Inc). Statistical analysis was carried out using SPSS™ 14.0 (SPSS Inc). 
III.6 Results 
III.6.1 Pilot study (UK) 
In a pilot study to assess questionnaire design and reliability 14 gastroenterologists were 
emailed and requested to complete an online survey. Eight (57%) replied to the initial 
request, of whom six (43%) replied to a request to repeat the survey 4 weeks later.  In 
the light of their comments the questionnaire was modified. The responses of the six 
respondents to both questionnaire rounds were used to assess the reliability of the 
survey, by comparing each item and identifying items as unreliable if the correlation 
coefficient was below 0.5 using Pearson’s correlation coefficient (r) for continuous 
variables and by calculating Phi (f) for dichotomous variables. Correlation coefficients 
could not be calculated for some dichotomous variables as they generated identical 
responses from all participants in either mail round.  
 
Four items considered in the final analysis were shown to be unreliable using these 
criteria. These questions were: 
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1. Physicians please indicate the percentage of time spent in gastroenterology 
versus medicine. 
2. Please indicate which patients with IBS you are most likely to give or send for 
dietary advice: Difficult to control IBS?  
3. If you do ask patients to exclude foods please indicate the types of foods: Yeast? 
4. Please indicate which patients with IBS you are most likely to give or send for 
dietary advice: Constipation predominant? 
 
All other items gave a correlation coefficient greater than 0.5 where one could be 
calculated (see Appendix 1.  Correlation coefficients for two rounds of survey pilot 
study).
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III.6.2 United Kingdom national survey 
Altogether there were three email invitations at intervals of approximately six weeks. A 
single conventional mailout was made to all BSG members who had no email address 
listed or whose listed email address was non-functioning. In addition, following all 
email rounds, all BSG members who did not respond to email requests were sent a 
conventional mail request. Eighty-nine potential subjects were excluded because a 
response was received stating they were not eligible for the survey. This included non-
adult gastroenterologists, retired gastroenterologists, deceased members, members with 
no clinical practice and members on maternity leave. Two members responded 
declining to participate and were excluded.  
 
This gave a total of 983 potential respondents, 834 of whom appeared to have 
functioning email addresses, in that no reply from the email server was received stating 
that delivery was not possible. This, of course, does not mean that all the members 
emailed received the email or indeed read the email. Those members with non-
functioning or no email address were sent a questionnaire by first class post. In addition, 
all members with an apparently functioning email address who did not reply to the 
email requests were sent a questionnaire by first class post. Following a response rate of 
only 17% to the first email round it was evident that response rates were likely to fall 
below predicted and an incentive, in the form of entry in a prize draw for all 
respondents, was offered at all subsequent mailings. In total there were 363 replies, 
constituting 37% of the 983 potential respondents identified (Figure 8). 
 
149 
 
Figure 8. Number of responses received at each mail round 
 
III.6.2.1 Sensitivity analysis  
Early vs. late respondents, which also made up the groups offered vs. not offered an 
incentive, were not found to differ significantly in their replies to any question, nor were 
email vs. conventional mail respondents. 
III.6.2.2 Respondent demographics  
The median percentage of time spent in gastroenterological practice was 80% (range 5% 
to 95%) with 98.6% of respondents having access to dietetic services, equal numbers 
having access to general dietetic services and specialist gastroenterological dietetic 
services. Respondents were asked how much dietetic resource (in hours) was allocated 
to their service and the median was 6 hours (range 0 to 100) but 172 respondents were 
unable to or did not answer this question.  
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49% of respondents were involved in a specialist IBD clinic whereas only 8.5% were 
involved in a specialist IBS clinic. Overall, respondents reported seeing similar numbers 
of IBS and IBD patients in outpatient clinics with the majority of respondents seeing 
between 20 and 60 IBS and IBD patients in a month ( 
Figure 9). 
 
 
Figure 9. Number of IBD and IBS patients seen by gastroenterologists per month 
 
III.6.2.3 Dietary advice 
Clinicians reported giving specific dietary advice to patient with IBS more commonly 
than IBD. The majority of respondents (84%) reported giving advice to more than 25% 
of patients with IBS, whereas this was the minority (27%) in IBD (p=0.001) (Figure 
10). The proportion of patients sent for dietetics referral was similar for both groups of 
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patients, the majority of respondents reporting that they refer less than 25% of IBD and 
IBS patients to see a dietitian. 
 
 
Figure 10. Percentage of IBS and IBD patients given dietary advice 
 
Respondents were also more likely to give advice specifically about dietary exclusion to 
IBS than IBD patients. The majority of respondents reported giving advice to more than 
25% of their IBS patients (87%) compared to the majority who reported giving advice 
about dietary exclusion to less than 25% of their IBD patients (61%, p<0.001). The 
foods respondents most commonly advised patients to avoid were similar for IBD and 
IBS, fibre being common in both. Wheat and dairy exclusion were also commonly 
recommended in both conditions, however these recommendations were more common 
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in IBS than IBD (66% vs 20% of respondents for wheat (p<0.001) and 70% vs. 45% for 
dairy (p=0.001). 
 
Figure 11. Percentage of IBD and IBS patients given dietary exclusion advice 
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Figure 12. Foods recommended to IBD and IBS patients for exclusion 
 
A low utilisation of allergy testing was reported in both IBD and IBS. In both 
conditions the majority of respondents reported no or very little (0-25% of patients) use 
of allergy testing (97% in IBD and 89% in IBS) (Figure 13). Where allergy tests were 
used they were most commonly “open food exclusion and rechallenge” (14% of 
respondents in IBD and 23% in IBS) and RAST (14% in IBD and 18% in IBS). There 
was also a small proportion who reported using skin prick testing (4% in IBD and 6% in 
IBS) and the Yorktest IgG antibody test (3% in IBD and 8% in IBS) (Figure 14). 
Respondents reported being most likely give dietary advice to, or send for dietary 
advice, patients with small bowel Crohns disease (84% of respondents), difficult to 
control IBD (46%), diarrhoea predominant IBS (59%) and difficult to control IBS 
(59%). 
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Figure 13. Percentage of IBD and IBS patients sent for allergy testing 
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(RAST: radioallergosorbent test; DBPCFC: double-blind placebo-controlled food 
challenge) 
Figure 14. Allergy tests recommended to IBS and IBD patients  
 
When asked whether participants agreed that dietary exclusion was an effective strategy 
in IBD, responses were mixed with only a small proportion agreeing strongly (7%) and 
the rest either agreeing a little (32%), neither agreeing or disagreeing (20%), disagreeing 
a little (20%) or disagreeing a lot (21%). When asked the same question in IBS the 
majority of respondents reported either agreeing strongly or agreeing a little (71%). 
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Figure 15. Response to the question "do you think dietary exclusion is an effective 
strategy" for IBD and IBS patients 
 
III.6.3 New Zealand national survey 
Altogether there were five email mailings at intervals of approximately two weeks. Two 
conventional mailouts were made to all NZSG members who had not responded two 
weeks after the final mail round. The two mail rounds were separated by approximately 
four weeks. Fifty-five potential subjects were excluded because a response was received 
stating they were not eligible for the survey. This included non-adult 
gastroenterologists, retired gastroenterologists, deceased members, members not 
currently practising or practising outside of NZ.  
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This gave a total of fifty-four potential respondents, all of whom appeared to have 
functioning email addresses, in that no reply from the email server was received stating 
that delivery was not possible. After five email rounds a total of forty-three members 
had responded. The remaining eleven were sent a mail-out reminder letter, to the first 
round of which six replied and to the second round, two.  
 
Thus in total there were fifty-one replies, constituting 94% of the fifty-four potential 
respondents identified (Figure 16). 
 
 
Figure 16. Number of responses received at each mail round 
 
III.6.3.1 Sensitivity analysis  
Because of the high response rate for the NZ survey non-response bias is very unlikely 
and sensitivity analysis was not required. 
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III.6.3.2 Respondent demographics  
The median percentage of time spent in gastroenterological practice was 93% (range 
10% to 100%) with 96% of respondents having access to dietetic services, the greater 
proportion (67%) having access to general dietetic services versus specialist 
gastroenterological dietetic services (29%). Respondents were asked how much dietetic 
resource (in hours) was allocated to their service and the median was four hours (range 
0 to 20) but 30 respondents were unable to or did not answer this question.  
 
31% of respondents were involved in a specialist IBD clinic whereas 18% were 
involved in a specialist IBS clinic. Respondents reported seeing greater numbers of IBS 
than IBD patients in outpatient clinics with the overwhelming majority of respondents 
seeing 20 to 40 IBS patients per month (Figure 17). 
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Figure 17. Number of IBD and IBS patients seen by gastroenterologists per month 
 
III.6.3.3 Dietary advice 
Clinicians reported giving specific dietary advice to patients with IBS more commonly 
than IBD. 90% of respondents reported giving advice to more than 25% of patients with 
IBS, whereas this was much lower (55%) in IBD (p<0.001) (Figure 18). The proportion 
of patients sent for dietetics referral was similar for both groups of patients, the 
overwhelming majority of respondents reporting that they refer less than 25% of IBD 
and IBS patients to see a dietitian.
160 
 
Figure 18. Percentage of IBS and IBD patients given dietary advice 
 
Respondents were also more likely to give advice specifically about dietary exclusion to 
IBS than IBD patients. The majority of respondents reported giving advice to more than 
25% of their IBS patients (77%) compared to the majority who reported giving advice 
about dietary exclusion to less than 25% of their IBD patients (86%, p<0.001). The 
foods respondents most commonly advised patients to avoid were similar for IBD and 
IBS, fibre being common in both. Wheat, sugar and dairy exclusion were also 
commonly recommended in both conditions, however these recommendations were 
more common in IBS than IBD (45% vs 14% of respondents for wheat (p<0.001), 47% 
vs 20% for sugar (p=0.001) and 55% vs. 26% for dairy (p=0.001) (Figure 19).
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Figure 19. Percentage of IBD and IBS patients given dietary exclusion advice 
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Figure 20. Foods recommended to IBD and IBS patients for exclusion 
 
A low utilisation of allergy testing was reported in both IBD and IBS. In both 
conditions the majority of respondents reported no or very little (0-25% of patients) use 
of allergy testing (82% in IBD and 89% in IBS) (Figure 21).  Where allergy tests were 
used they were most commonly “open food exclusion and rechallenge” (14% of 
respondents in IBD and 29% in IBS) and RAST (4% in IBD and 14% in IBS). There 
was also a small proportion that reported using skin prick testing (4% in IBD and 6% in 
IBS) and skin patch testing (2%in IBD and 4% in IBS) (Figure 22). Respondents 
reported being most likely to give dietary advice to, or send for dietary advice, patients 
with small bowel Crohn disease (71% of respondents), difficult to control IBD (59%), 
diarrhoea predominant IBS (49%) and difficult to control IBS (69%). 
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Figure 21. Percentage of IBD and IBS patients sent for allergy testing 
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(OFER: open food exclusion and rechallenge; RAST: radioallergosorbent test; 
DBPCFC: double-blind placebo-controlled food challenge) 
Figure 22. Allergy tests recommended to IBS and IBD patients  
 
 
When asked whether participants agreed that dietary exclusion was an effective strategy 
in IBD, responses were mixed with only a small proportion agreeing strongly (2%) and 
the rest either agreeing a little (41%), neither agreeing or disagreeing (16%), disagreeing 
a little (16%) or disagreeing a lot (26%). When asked the same question in IBS the 
majority of respondents reported either agreeing strongly or agreeing a little (84%) 
(Figure 23). 
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Figure 23. Response to the question "do you think dietary exclusion is an effective 
strategy" for IBD and IBS patients 
 
III.7 Discussion 
This is the first study to examine the attitudes of gastroenterologists to dietary 
manipulation in IBD and IBS. The use of the BSG membership list as a source for UK 
gastroenterologists is likely to have included the majority of UK gastroenterologists. 
However it will have also included a number of non-practicing and non-
gastroenterologist members, who are unlikely to have replied, thus contributing to the 
high non-response rate. This was not the case for the NZ survey. 
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Although the response rate for the UK survey was low at 37% it is still a large survey of 
UK gastroenterologists, including 363 British gastroenterologists. This sample size is 
comparable to the sample size of previous such surveys including that of Eaden et al. in 
2000 who reported a response rate of 83% of UK Gastroenterologists with a sample size 
of 341 (Eaden, Ward et al. 2000). We believe our sample is likely to be representative 
of gastroenterological practice in the UK because of the size of the sample and the fact 
that sensitivity analysis showed no significant difference in demographics or responses 
between early and late email responders, email and conventional mail responders, nor 
responders offered an incentive and those not. The internal validity of the questionnaire 
used was not directly tested during the pilot study. The questionnaire was, however, 
shown to be reliable using test-retest methods. The questionnaire’s validity is supported 
by the comparability of responses between the two countries. 
 
This is the first such survey of gastroenterologists conducted using email as the 
communication method. It could, therefore, be argued that this contributed to the poor 
response rate in the UK. However, the first round response rate to a conventional mail 
questionnaire sent to UK gastroenterologists without email addresses listed gave an 
identical response rate, suggesting this was not the case. 
 
Access to dietetic support was almost universal. However, utilisation was low in both 
groups. This is in keeping with the recent UK national audit of IBD services (UK IBD 
Audit Committee 2008). In that study 204 of 207 sites reported access to GI dietetic 
support with a median number of dietetic hours per week of eight (range 0-24). In our 
study the median reported hours of GI dietetics service in the UK was six hours (range 0 
to 100) and in NZ four hours (range 0 to 20). 
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This survey clearly demonstrates that practice regarding dietary manipulation in the UK 
and NZ differs between IBD and IBS, and that practice in NZ and the UK is very 
similar. Patients with IBS are more likely to be given dietary advice by the 
gastroenterologist and are more likely to be given advice regarding dietary exclusion 
than IBD patients. Both groups of patients are equally likely to be sent for dietetic 
consultation and receive allergy testing, although the rates of utilisation of both are low. 
Where dietary exclusion was recommended, in both conditions, the commonest 
exclusions recommended were fibre, dairy and wheat, as well as sugar in NZ but not the 
UK.  
 
Where allergy testing was used this was most commonly “open exclusion and 
rechallenge” and RAST. It must be noted that both in the UK and NZ such testing 
services are not routinely available in the public healthcare setting. In addition the NICE 
guidelines on the management of IBS in primary care state, “There are no objective 
tests available to identify food intolerance and few to confirm food allergy” (NICE 
2008). Those patients most likely to receive dietary advice are those with small bowel 
Crohn disease, difficult to control IBD, diarrhoea predominant IBS and difficult to 
control IBS. 
 
Finally, overall most respondents agreed strongly or a little that dietary exclusion was 
effective in IBS. When asked the same question for IBD the level of agreement was 
much lower and very few respondents agreed strongly.  
 
This data suggests that there is a role for dietary manipulation and exclusion in the 
modern care of IBD and IBS, particularly IBS, but that the advice given is largely 
empiric and mostly comprises the exclusion of fibre, dairy and wheat. Particularly in 
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IBS the level of confidence in this approach is high. These results would suggest that 
further research in this area is likely to be supported and utilised by the 
gastroenterological community.
169 
 
Chapter IV Food specific IgG antibodies and 
patient perceived food intolerance in 
inflammatory bowel disease 
IV.1 Introduction 
s the previous Chapter demonstrated, gastroenterologists are generally uncertain, and 
frequently contradictory, in their approach to dietary intervention in IBD. By contrast, 
several lines of work have shown that patients frequently have a strong belief in the role 
of dietary factors in their disease (Ballegaard, Bjergstrom et al. 1997). When patients 
with IBD were surveyed regarding the frequency and pattern of food intolerance there 
existed no significant difference in findings between UC and CD (Ballegaard, 
Bjergstrom et al. 1997). Food intolerance was reported at a significantly higher rate in 
patients with both UC and CD compared with normal controls. Very little information 
exists comparing intolerance to individual foods in patients with IBD compared to 
controls. 
 
While food intolerance appears to play a role in the symptomatology of IBD, testing for 
specific allergic or other mechanisms of intolerance has proven very difficult. As 
discussed previously classical allergy testing is not reliable for the detection of GI food 
hypersensitivity (see section I.3.2.4). One reason for this may be that hypersensitivity in 
the gut is mediated by local, rather than systemic, processes (Shanahan 1993; 
Bruijnzeel-Koomen, Ortolani et al. 1995; Crowe 2001). For example IgE levels in stool 
and intestinal juices do not correlate with IgE levels in blood (Belut, Moneret-Vautrin et 
al. 1980; Kolmannskog and Haneberg 1985; Andre, Andre et al. 1995). The other 
possible explanation for this discrepancy is that an IgE-independent mechanism, such as 
IgG mediated reactions, immune complex disease or lymphocyte-triggered reactions are 
involved (Bischoff, Mayer et al. 2000). 
A 
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IgG antibodies to a limited number of foods have been shown to be more prevalent in 
IBD than in controls and there is evidence to support a role for exclusion diets guided 
by IgG levels in other GI disorders. However, IgG antibodies to foods are also found in 
people without GI disease and authors have dismissed IgG antibodies to foods as being 
a non-specific phenomenon, perhaps related to changes in intestinal permeability (see 
section I.3.2.8). 
 
The primary aim of this study was to describe the self reported sensitivity to specific 
foods in IBD patients compared to controls. The secondary aim was to investigate the 
pattern of positivity of food specific IgG antibodies in IBD compared to controls, and to 
describe the association between food specific IgG antibodies and patient perceived 
food intolerance. 
IV.2 Collaborators 
The author completed the study design and analysis and performed the patient 
recruitment and sample collection. Dr Anton Emmanuel and Stuart Bloom, of 
University College London, assisted with trial design and analysis. Yorktest 
Laboratories Ltd completed the food specific IgG antibody testing.  
IV.3 Ethical approval 
This study was carried out in accordance with the declaration of Helsinki. It was 
approved by the University College London (UCL) / UCL Hospitals Joint 
Research Ethics Committee and written informed consent was obtained from all 
participants. 
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IV.4 Subjects 
Patients diagnosed with ulcerative colitis or Crohn disease and controls aged 18 years 
and over were eligible to enter the study.  As a significant proportion of patients with 
IBD receive some form of immunosuppressive therapy at some point in the course of 
their illness, patients on stable doses of immunosuppressant medication were not 
excluded from this study. Patients with other autoimmune disease or documented 
immune deficiency were excluded. Control subjects with diagnosed GI disease or 
symptoms suggesting significant GI disease were also excluded. The cases for this case-
control study were identified from the UCLH IBD clinic register. All had confirmed 
diagnoses of UC or CD based on clinical, endoscopic and histological observations.  
 
In order to avoid bias generated by advertising for control subjects, or selecting them 
from hospital clinic populations that might exhibit undiagnosed gastrointestinal or other 
immune conditions, the control group chosen consisted of patients presenting for 
assessment of thyroid lumps. All patients were biochemically euthyroid. They were 
approached for participation in this study when they attend for assessment in the UCLH 
thyroid nodule clinic. 
 
Sequential patients with quiescent UC or CD were enrolled from the UCLH IBD clinic. 
Quiesence was determined by physician assessment of current symptomatology. 
Control patients were enrolled from the UCLH thyroid nodule clinic and had normal 
thyroid biochemistry and no history of GI disease.  
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IV.5 Methods 
IV.5.1 Blinding 
From the point of initial clinic assessment patient samples and questionnaires were 
identified only by linked anonymised labelling, in order to provide blinding and protect 
subject data. Laboratory staff performing antibody testing were unaware of subject 
details.  
IV.5.2 Self-reported food intolerance 
No validated questionnaire for the determination of food intolerances in IBD exists. 
Locke et al (Locke, Zinsmeister et al. 2000) asked IBS patients about food sensitivity 
and allergy as a part of a validated questionnaire for the identification of risk factors for 
IBS. They first asked the subjects if they were allergic or sensitive to any foods. If yes, 
the subject was asked to indicate the types of foods to which they thought they were 
allergic or sensitive, and whether they had a rash or swelling of the lips and throat. The 
reliability of the questionnaire as a whole was reported but not that for the food 
sensitivity questions particularly.  
 
Eggesbo et al (Eggesbo, Halvorsen et al. 1999) administered a validated questionnaire 
to parents asking whether they perceived their children to have intolerances to foods 
including vomiting, abdominal pain or diarrhoea as well as extra gastrointestinal 
symptoms.  
 
In the absence of other validated tools we based our questionnaire on these techniques 
(see Appendix 3. Questionnaire regarding food sensitivities). For each of the 92 foods to 
be tested for IgG, each subject was asked to report gastro-intestinal (GI) intolerance in 
the form of bloating, abdominal pain, diarrhoea, constipation, heartburn or other 
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symptoms using a tick-box questionnaire. They were considered to be positive for 
perceived GI intolerance to that food if they reported any one of these symptoms. 
IV.5.3 Blood testing for food-specific IgG 
Blood was taken and sent, with only a numerical identifier, to YorkTest Laboratories 
Ltd (York, UK) where an ELISA test was performed to detect the presence of IgG 
antibodies specific to a panel of 92 different food extracts. This test has been described 
previously elsewhere using a smaller panel of 29 food antigens (Foster, Knowles et al. 
2003; Atkinson, Sheldon et al. 2004).   
 
Plates were coated with food antigens (Antigen Laboratories, Inc., Missouri, USA) 
diluted in carbonate/bicarbonate buffer. Plates were incubated at 4 ºC overnight with 
100 µl of extract per well. Plates were subsequently blocked with 400 µl per well of 
0.1% phosphate buffered saline/0.5% sucrose/1% fish gelatin, at room temperature for 1 
hour. The blocking buffer was then decanted and the plates were left at 37 ºC overnight.  
 
Serum samples were diluted in PBST/3% polyvinyl pyrolidone 10 kD to 1/50, 1/150, 
and 1/450 with each dilution applied to an allergen panel. After washing, anti-human 
IgG horse radish peroxidase conjugated was applied to each well for 10 min. 3,3’,5,5’-
Tetramethylbenzidine substrate was applied to each well for 10 min. The reaction was 
stopped using 50 µl per well of 0.5 M sulphuric acid and the plates were read using a 
Dynex ELISA plate reader at 450 nm. The mean absorbance of each test specimen was 
compared to the absorbance of a positive control serum using 0 arbitrary unit (AU) and 
25 AU standards prepared from a serum with a high IgG titre to a cow’s milk allergen 
extract. A 50 AU positive control was used to confirm that the slope formed by the 0 
and 25AU standards was sufficiently precise and accurate. The test results were 
obtained from the 1/150 dilution of the specimen. Where a high specimen background 
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was observed, the test results were obtained from the 1/450 dilution. The threshold for a 
positive (reactive) result was arbitrarily set as 10 AU. Test results were scored as 
positive or negative only, relative to this cut off.  
IV.5.4 Statistical considerations 
Insufficient information exists on the prevalence of IgG antibodies to foods in differing 
populations to allow calculations of sample size required to yield adequate  statistical 
power.  A minimum sample size of 75 patients: 25 with UC, 25 CD, 25 controls was 
chosen. Analysis was performed on the SPSS statistical package. Results are reported 
using proportion of patients positive for the primary and secondary outcome measures. 
Comparisons between groups were made using Fisher's exact (2-sided) tests. 
Correlations were analysed using Spearman’s rank correlation test. 
IV.6 Results 
Over a six month period 77 patients were enrolled (25 with UC, 28 with CD and 24 
with thyroid nodules). Of the patients with CD 10 had disease isolated to the colon, 2 
had disease isolated to the small bowel, 15 had ileocolonic disease and 1 had perianal 
disease. Of the patients with UC 12 had distal disease (up to and including the splenic 
flexure), 11 had pan-colonic disease and in 2 patients the exact extent was unknown. 
Because of recruitment problems with control patients with thyroid nodules one less 
patient than planned could be recruited in the trial period. Cases were not matched with 
controls but the distribution of age and sex between the three groups were well 
matched: the proportion of females in the UC, CD and control groups were 52%, 54% 
and 58% respectively (p=NS chi-squared). The mean age (and range) in these three 
groups were also well matched, respectively 36 (19-59), 35 (22-56) and 36 (20-61). 
 
175 
All patients were assessed by the referring physician to have quiescent disease. Fifty-
one out of 53 patients with inflammatory bowel disease had contemporary serum C-
reactive protein measurements available, all of which were normal (less than 10mg/dL). 
Serology for coeliac disease using anti-gliadin and anti-endomysial antibodies was 
available in all patients, no patient demonstrated positive antibodies. A total of 4 (14%) 
patients with CD and 16 (64%) patients with UC were receiving therapy with 5-ASAs, 
and 3 (11%) with CD and 3 (12%) with UC were receiving either azathioprine or 6-
mercaptopurine. None were taking corticosteroids. 
 
All control patients had been assessed with thyroid ultrasound, and where appropriate 
fine needle aspiration, no patient had abnormal thyroid function tests and no patient was 
found to have thyroid carcinoma. 
IV.6.1 Patient reported food sensitivity 
CD and UC patients reported gastro-intestinal sensitivity to a greater number of foods 
than controls (median (range)): 3(0,33), 4(0,29), 0(0,20) respectively, p=0.05 CD vs 
control, p<0.01 UC vs control) (Figure 24).  
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Figure 24. Box and whisker plots of the number of foods with self-reported 
sensitivity in patients with UC, CD and control, showing that inflammatory bowel 
disease patients reported significantly more foods they were “sensitive” to (* 
depicts outliers) 
 
In CD subjects the most commonly reported sensitivities were to peanut (29% of CD 
subjects vs 13% of controls), cashew (25% vs 13%), lentils and broccoli (19% vs 4%), 
hazelnut and brazil nuts (19% vs 13%), and chilli (19% vs 8%). UC subjects also 
commonly reported sensitivity to chilli (44% vs 8%), but otherwise reported 
sensitivities to different foods than CD patients including wheat  (40% vs 8%), milk 
(36% vs 8%), kidney and haricot beans (both 24% vs 0%), coffee and onions (20% vs 
4%) and oranges (20% vs 0%) (Figure 25).  
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Figure 25. Histogram showing the wide range of specific foodstuffs that UC, CD and control patients reported subjective sensitivity 
to 
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IV.6.2 IgG food antibody positivity 
The greatest difference in frequency of IgG positivity in CD patients vs. controls were 
seen for yeast (CD 82.1% positive vs. controls 54.2%, p=0.04), wheat 42.9% vs 12.5%, 
p=0.03), chilli (37.9% vs 8.3%, p=0.02), kiwi (35.7% vs 8.3%, p=0.02), corn (28.6% vs 
0%, p=0.005), millet (28.6% vs 0%. p=0.005) and peanut (28.6% vs 0%, p=0.005) 
There was no correlation between patient reported food sensitivity and IgG antibody 
positivity to foods for CD subjects. 
 
For UC vs control the greatest difference in frequency of IgG positivity was seen for 
corn (24% vs 0%, p=0.02), millet (20% vs 0%, p=0.05) and oat (20% vs 0%, p=0.05). A 
very modest correlation between patient reported food sensitivity and IgG positivity was 
seen for UC and control subjects (Spearman's rank correlation coefficients 0.23 and 
0.26 respectively, p<0.05). No foods showed a significantly greater frequency of 
antibody positivity in controls compared to either IBD group (Figure 26).  
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Figure 26. Histogram showing the range of specific foodstuffs that UC, CD and 
control patients demonstrated IgG positivity to 
 
IV.7 Discussion 
The rates of subjective food sensitivity in our study sample were high in both CD and 
UC compared to controls. This is similar to previous reports (Ballegaard, Bjergstrom et 
al. 1997). 
 
Demonstration of a pathogenic association between such food intolerances and 
conventional markers of allergy has not proven possible. Skin tests and IgE 
measurements are known to be of limited value for the diagnosis of intestinal food 
allergy in general (Crowe and Perdue 1992; Shanahan 1993; Bruijnzeel-Koomen, 
Ortolani et al. 1995). Data regarding the association of food specific IgE antibodies and 
conventional allergy tests with IBD has been contradictory. In studies looking at the 
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presence of IgE antibodies to yeast, corn, celeriac, wheat, egg, milk and soy in CD sera, 
no or very low levels of food-specific IgE were detected (Frieri, Claus et al. 1990; 
Huber, Genser et al. 1998). A study of antibody response to the cow's milk antigen beta-
lactoglobulin in ulcerative colitis and Crohn disease compared to non-atopic controls 
demonstrated no specific IgE response in any group (Paganelli, Pallone et al. 1985). 
However, in another study an increased number of basophils degranulated in the 
presence of cows' milk in UC patients, but normal responses occurred in patients with 
CD (Smart, Danis et al. 1986). Conversely a further study showed a considerable 
increase in positive results to RAST for dietary antigens in IBD (Brignola, Miniero et 
al. 1986).  
 
The major immunoglobulin present in human secretions is a dimeric IgA; pentameric 
IgM is also actively enriched in most exocrine fluids (Brandtzaeg, Bjerke et al. 1987). It 
would seem logical that, in the absence of a convincing association with conventional 
markers of allergy, research should focus on these immunoglobulin isotypes. However, 
data in this area is sparse and inconclusive. One study using 26 monozygotic twin pairs 
with inflammatory bowel disease and 52 healthy controls to examine the presence of 
IgA, IgG and IgM antibodies against ovalbumin, betalactoglobulin, gliadin, whole yeast 
(Saccharomyces cerevisiae) and yeast cell wall mannan showed that individuals with 
ulcerative colitis were indistinguishable from healthy twins and controls, except for 
higher IgA levels to gliadin. Twins with Crohn disease displayed higher antibody titres 
towards yeast cell wall mannan and whole yeast (Saccharomyces cerevisiae) of all 
antibody types (IgA, IgG, and IgM). In all IBD patients the responses to gliadin, 
ovalbumin, and betalactoglobulin were even lower than in the controls (Lindberg, 
Magnusson et al. 1992). 
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While elevation of cow’s milk specific IgG antibodies in IBD has been recognised in 
one study (Knoflach, Park et al. 1987) other studies have not confirmed this finding 
(Jewell and Truelove 1972; Hoier-Madsen, Holm et al. 1989). Elevated levels of IgG 
antibodies to foods in other conditions have been widely considered a phenomenon of 
no pathological significance and IgG antibodies to various food components are 
detectable in healthy individuals although usually at rather low levels. Thus the role of 
this class of antibody in the induction of symptoms remains highly controversial 
(Barnes 1995; Zar, Kumar et al. 2001; Teuber and Porch-Curren 2003). However, 
interest in this Ig isotype has been generated by the finding of apparent clinical utility in 
randomised controlled studies of the use of IgG food antibodies in determining an 
exclusion diet for IBS (Atkinson, Sheldon et al. 2004), and more recently IBD (Bentz, 
Hausmann et al. 2010). We chose to examine IgG food specific antibodies in IBD 
because of the support for an association with GI sensitivity in IBS by the above study 
and because of the lack of data regarding it’s prevalence, except for cow’s milk 
antibodies. 
  
There is no accepted methodology for testing IgG antibody to food antigens. The 
ELISA test used by York Laboratories is commercially available and widely used, but is 
limited by the lack of calibration over the whole response range of the test, thus 
allowing its use only in a qualitative, rather than quantitative manner, requiring the 
selection of an arbitrary cutoff value for positivity. The chosen cutoff of 10 attempts to 
make the test as sensitive as possible. Sensitivity analysis using a higher cutoff of 20 
(which still lies within 0 to 25 AU calibration curve) gives very similar results, in terms 
of the foods that are positive and the relative differences between IBD and control 
patients, but with lower proportions of subjects positive. The comparison of the 
presence of all food specific IgG antibodies to a single reference standard composed of 
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cow’s milk raises the concern that antibodies to other foods might have different 
response characteristics, making the use of a single cutoff for all foods invalid. 
 
Our study is the first report of the prevalence of IgG antibodies to a wide range of food 
antigens in IBD. It shows that patients with IBD do exhibit greater levels of positivity 
for certain IgG food specific antibodies than controls. The weakness of the correlation 
between food antibodies and patient reported sensitivity might be a result of the small 
number of patients in this study. In addition it is recognised that the varying temporal 
and dose-response relationship between foods and GI symptoms means that symptom 
reporting is a poor method for identifying food intolerance, as evidenced by the lack of 
correlation between reported sensitivities and double blind placebo controlled food 
challenge (Pearson, Teahon et al. 1993). 
 
Support for IgG antibody testing as an indicator of GI sensitivity in IBD would require 
both the demonstration of a correlation between disease and IgG levels as well as the 
demonstration of a biologically plausible mechanism for that association. As symptom 
reporting in itself lacks reliability, it might be that correlation of IgG antibody 
production with other tests of GI hypersensitivity could strengthen the association 
between IgG antibody production and hypersensitivity.  
 
As mentioned above it remains possible that IgG antibodies are physiological 
phenomenon not associated with disease. In considering why they might therefore be 
elevated in IBD, if not because of a direct association between the aetiopathogenesis of 
the disease and IgG antibody formation, an obvious conjecture is that changes in 
epithelial permeability, and thus exposure of the GI immune system to the luminal 
environment, might be the common mechanism.  
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For these reasons I decided, in the proceeding study, to investigate whether IgG 
antibodies can predict the foods associated with hypersensitivity using another measure 
of GI sensitivity, the recently described technique of colonic antigen provocation 
(Bischoff, Herrmann et al. 1996; Van Den Bogaerde, Cahill et al. 2002). This approach 
also allowed validation of the observation of elevated IgG antibodies to foods in IBD 
and allowed the theory that IgG antibody positivity relates to intestinal permeability to 
be tested. 
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Chapter V Comparison of gut mucosal 
response to food antigen injection 
with serum IgG food antibodies in 
Crohn disease 
V.1 Introduction 
he association between symptoms of IBD and diet has received much attention 
(see Chapter II). Some studies have claimed that food sensitivities are common 
in CD and have found that when food intolerances are detected, patients on an exclusion 
diet maintain remission significantly longer than those on an unrestricted diet (see 
section II.1.4.8). 
 
However, the tools available for measuring and predicting GI food intolerances remain 
suboptimal. Traditional allergy testing has concentrated on the measurement of IgE 
mediated responses, but this approach has not proven useful in GI food sensitivity 
(Shanahan 1993; Bruijnzeel-Koomen, Ortolani et al. 1995; Crowe 2001). IgG 
antibodies to food components are detectable in healthy individuals, usually at rather 
low levels (Barnes 1995; Zar, Kumar et al. 2001; Teuber and Porch-Curren 2003).  
However, our own observation has been that these levels are significantly increased in 
UC and CD (see Chapter IV).  
 
It has been suggested that the double blind, placebo controlled oral challenge should be 
the gold standard in testing for food hypersensitivity. However, it is a difficult and 
protracted procedure and has not proven practical in the clinical setting (Bischoff, 
Mayer et al. 2000). 
 
T 
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V.1.1 The development of gastrointestinal mucosal 
provocation tests 
Mucosal provocation tests involve localised testing of the mucosa within the organ 
system of interest. This approach has been successful in the bronchial, nasal and 
conjunctival mucosa (Bischoff, Mayer et al. 1997). They involve local application of a 
test substance, in the case of food allergy a food antigen, and measurement of the local 
response either: visually; by the detection of substances secreted in response to the 
provocation; or by the examination of tissue samples taken from the exposed site. 
 
Compared to oral challenges, mucosal provocation tests have theoretical advantages. 
Because the amount of allergen is small, the risk of anaphylactic reaction present with 
oral food challenge is lessened (Sampson 1988). In addition the results can be 
interpreted immediately and directly, reducing the subjectivity inherent in interpreting 
the patient’s symptoms (Bischoff, Herrmann et al. 1996).  
 
Initial attempts to apply these techniques to the GI tract were made with the mucosal 
application of allergen intragastrically (Reimann and Lewin 1988; Bagnato, Di Cesare 
et al. 1995).  In their 1988 study Reimann et al. included 30 patients whose food-
allergic history had been proven through double-blind challenge tests; 20 healthy 
volunteers were also included as controls. They applied allergens endoscopically to the 
gastric mucosa. Two blinded, independent physicians observed the macroscopic 
reaction elicited. Biopsies were taken from the challenged areas for histological and 
histochemical analysis. The 30 patients with document food allergies exhibited 
swelling, erosions, and bleeding at the contact site (Reimann and Lewin 1988).  A 
further study by Bagnato et al. elicited a gastric mucosal reaction to the plant Parietaria, 
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a common cause of  pollen allergy, in those known to exhibit atopy to the plant 
(Bagnato, Di Cesare et al. 1995).  
 
Jejunal perfusion with food allergen and measurement of inflammatory mediator release 
using a double balloon jejunal tube has also been carried out (Bengtsson, Knutson et al. 
1997). Bengtsson et al. examined five patients with milk-related gastrointestinal 
symptoms diagnosed by double-blind placebo-controlled milk challenges, but with 
negative responses to skin prick tests and RASTs with milk. They compared these 
patients with eight healthy control subjects. They performed repeated perfusion studies 
with a two-balloon, six-channel tube by using milk, casein, and whey as antigens. Cow's 
milk induced a pronounced increase in intestinal secretion of histamine and eosinophil 
cationic protein in patients but not control subjects, during the first 20 minutes after 
challenge. This suggested that mast cells and eosinophils are effector cells not only in 
patients with allergic disease but also in patients intolerant to foods and lacking 
circulating antibodies. This strategy has been tested only in dairy allergy to date and is 
limited by the fact that local reactions in the mucosa cannot be observed visually or 
histologically.  
 
Further attempts have centred around allergen injection into the colonic mucosa. 
Bischoff et al. described the development of this technique in their 1997 paper 
(Bischoff, Mayer et al. 1997). They studied 70 adult patients with abdominal symptoms 
suspected to be related to food allergy, and five healthy volunteers. Using their 
technique the caecal mucosa was challenged endoscopically with three food antigen 
extracts, a buffer control, and a positive control (histamine). The mucosal weal and flare 
reaction was registered semiquantitatively 20 minutes after challenge, and tissue biopsy 
specimens were examined for mast cell and eosinophil activation. 
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The provocation test was positive to at least one food antigen in 54 of 70 patients 
(77%), whereas no reaction in response to antigen was found in healthy volunteers. 
Antigen induced weal and flare reactions were correlated with intestinal mast cell and 
eosinophil activation, as well as with patients' history of adverse reactions to food, but 
not with serum concentrations of total or specific IgE or skin test results. 
 
The challenge technique involved the injection of antigen extracts into the mucosa using 
a long plastic tube attached to a fine needle, similar to that used for endoscopic 
sclerotherapy of oesophageal varices. The plastic tube was filled with the test solution 
before introducing it into the working channel of the endoscope, the tube was drawn out 
of the endoscope after each application, and depleted of the test solution by washing 
with 4 ml 0·9% sodium chloride and pressing 8 ml air through the tube before it was 
filled again with the next test solution.  
 
The food allergen extracts used were lyophilised and did not contain additives such as 
glycerine or preservatives. The concentrations used for intestinal challenge were 
assessed by previous dose response experiments. A 1:10 dilution of the stock solutions 
containing 3 mg/ml protein was used in all experiments.  
 
As performed in skin prick tests, the mucosal weal and flare reaction was classified 
semiquantitatively 20 minutes after challenge using a scale of 0 to 4: 0=no reaction, 
1=questionable reaction, 2=moderate reaction (<1 cm diameter), 3=strong reaction (1–2 
cm), and 4=maximal reaction (>2 cm).  
 
The caecum was chosen because its peristaltic movements proved to be less pronounced 
than that of other segments of the large intestine. The same group previously reported 
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studies performed in rectosigmoid colon of five subjects, where they obtained, 
compared with the caecum, similar but weaker mucosal responses (Bischoff, 
Wedemeyer et al. 1996). 
 
In the 1997 paper Bischoff et al. also reported unpublished data where provocation was 
performed during gastroduodenoscopy on six patients(Bischoff, Mayer et al. 1997). The 
mucosal reactions in the stomach were inconsistent, whereas in the duodenum the test 
could be performed with good results. However, gastroduodenoscopy over 20 minutes 
was not well tolerated by the patients. Furthermore, the provocation test was more 
troublesome to carry out in the duodenum for the endoscopist because its peristaltic 
movements interfered with the test procedure.  
 
The technique developed by Bischoff et al. was named the colonoscopic allergen 
provocation (COLAP) test. Detailed data comparing the COLAP test to elimination diet 
and food rechallenge are not available. The above results suggested that it might be a 
useful diagnostic measure in patients with suspected intestinal food allergy and may 
provide a new tool for the study of underlying mechanisms. 
V.1.2 Gastrointestinal provocation tests in IBD 
The COLAP technique was applied in CD by Van Den Bogaerde et al (Van Den 
Bogaerde, Cahill et al. 2002). Their case control study compared 10 patients with CD to 
10 controls using rectal mucosal exposure to six food antigens (cereal, cabbage, citrus, 
milk, yeast and peanut) and control saline.  As well as taking biopsies from exposed 
areas they used laser Doppler blood flowmetry to assess mucosal response to antigen as 
well as measuring in-vitro peripheral blood lymphocyte proliferation in response to the 
same antigens.  
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The Crohn disease group demonstrated higher rectal blood flow than controls in 
response to all food antigens, and this was significantly different for the responses to 
yeast (P = 0.036) and citrus fruits (P = 0.038). Lymphocyte proliferation occurred in 32 
of 60 tests in Crohn disease patients and eight of 60 tests in controls (P < 0.0001). 
 
The authors concluded that the findings support the concept that CD patients 
demonstrate gut specific sensitisation to food antigens and support the use of laser 
Doppler flowmetry as a measure of mucosal reaction to antigen challenge. None of the 
patients in the study had reactions when the antigens were tested by subdermal 
injection. 
 
Why patients with CD might demonstrate higher titres to food specific IgG antigens and 
show greater changes in rectal blood flow in response to food antigen injection has not 
been investigated. CD is known to be associated with increased intestinal permeability 
(see I.1.3.1). Additionally, increased intestinal permeability has been found in patients 
with adverse reactions to foods (Ventura, Polimeno et al. 2006). Whether this increase 
in intestinal permeability, another factor associated with inflammation in the GI tract, or 
an unrelated immune phenomenon, might be the common factor causing raised food 
antibodies and/or provocation reactivity in CD remains to be determined.  
 
The aim of this study was to evaluate a technique of direct colonic mucosal provocation 
in the setting of CD and to correlate this with the presence of serum food-specific IgG 
antibodies, patient perceived food intolerances and intestinal permeability.  
V.2 Collaborators 
The author completed the study design and analysis and performed the majority of the 
patient recruitment and provocation testing. Dr Anton Emmanuel and Stuart Bloom, of 
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University College London, assisted with trial design and analysis. Dr Farooq Rahman 
assisted with patient recruitment. Drs Anton Emmanuel, Farooq Rahman and Nora 
Thoua, of University College London, assisted with antigen provocation testing. Ms 
Audrey Duffy, of Kings College London, completed intestinal permeability testing. 
V.3 Ethical approval 
This study was carried out in accordance with the declaration of Helsinki. It was 
approved by the UCL / UCL Hospitals Joint Research Ethics Committee and written 
informed consent was obtained from all participants. 
V.4 Subjects 
Between August 2007 and February 2008 12 patients were enrolled in the study. 
All patients had Crohn disease as assessed radiologically, colonoscopically and 
histologically. There was no history of previous rectal disease and no macroscopic 
rectal inflammation at the time of the study. Thus all measurements were undertaken in 
macroscopically uninvolved mucosal sites. At the time of the study all patients had 
quiescent disease as determined by the referring physician. No patients were receiving 
steroids, immunomodulatory therapy or biological therapy. Their demographics and 
distribution of disease are summarized in Table 22. 
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Patient Age (years) Disease distribution  Treatment 
1 27 colonic Pentasa 
2 41 colonic Pentasa 
3 54  colonic Nil 
4 32 colonic Pentasa 
5 42 ileal Nil 
6 45 ileocolonic Pentasa 
7 33  ileal Pentasa 
8 37 ileal Pentasa 
9 29 ileocolonic Pentasa 
10 30 colonic Asacol 
11 39 colonic Pentasa 
12 55 ileocolonic Nil 
Table 22. Patient demographics 
 
V.5 Methods 
V.5.1.1 Colonic antigen provocation testing 
Following warm water enema participants underwent flexible endoscopic examination 
of the rectum. During this procedure mucosal injection of the 5 food antigens being 
considered, as well as a control mixture of glycerine and saline, was performed. Antigen 
solutions were used at a 1:10 weight per volume solution. The allergens were pre-
solubilised in 0.5% saline and preserved in 50% glycerine.   
 
The location of injection sites were marked with three small tattoos, using a carbon 
particle based dye (Spot, GI Supply, Camp Hill, Penn.), placed at the points of an 
equilateral triangle, the points being at least 6cm apart. Antigen and control injections 
were then made, two along each side, allowing later differentiation of individual 
injection sites.  
 
The antigen extracts were deposited onto the mucosa using an endoscopic injection 
needle (Variject, Boston Scientific, Tokyo, Japan). The needle was then passed through 
the bleb of antigen solution into the mucosa to a depth of 1 to 2mm. The needle was 
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filled with the test solution by aspirating the solution into the needle before introducing 
the needle into the working channel of the endoscope. The tube was drawn out of the 
endoscope after each application, and depleted of the test solution by washing liberally 
with 0·9% sodium chloride before it was filled again with the next test solution. 
 
The presence of mucosal hyperaemia was measured using laser Doppler flowmetry 
immediately following antigen injection and again at repeat flexible sigmoidoscopy 3.5 
hours following injection.  
V.5.1.2 Laser Doppler flowmetry 
Laser Doppler flowmetry (LDF) is a technique that utilises the frequency shift in light 
reflected from a moving object to estimate blood flow within tissue.  A low intensity 
beam, almost exclusively consisting of monochromatic coherent 780 nm light, is 
generated by a near infrared laser diode source and delivered by a fibre optic probe to 
the tissue of interest. In tissue, red blood cells account for most of the moving 
structures, and the speed of their movement determines the frequency of light which is 
reflected. The light reflected is detected by a photocell and the signal processed to 
determine the frequency shift.  The volume flow measured with this technique 
(expressed as "flux units") approximates to ml of blood per minute per 100 g tissue. The 
approximate area of measurement is 1 mm2 at up to 1 mm depth from the tip of the 
probe.  Movement artefact is eliminated by the built in software which averages 
recorded values over 0.1 second time intervals. 
 
Laser Doppler flowmetry has found clinical application in a variety of conditions such 
as skin grafting, Raynaud's phenomenon, and cerebral hypoperfusion. Validation of this 
technique in the colon was undertaken by Emmanuel and Kamm in 1999 (Emmanuel 
and Kamm 1999). This study, in 26 healthy volunteers, of the use of LDF in the rectal 
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mucosa established the reproducibility of this technique and determined the 
physiological variables which affect mucosal flow. 
 
The study showed excellent coefficients of variation for subjects studied under identical 
conditions on two, three, and four days (0.06, 0.05, and 0.06, respectively).  
While mean mucosal blood flow increased after a standard meal, fasted measurements 
at 0900, 1200, 1600, and 2200 were similar.  
 
However, blood flow was significantly affected by smoking with flow decreasing for 
15 minutes after smoking and returning to baseline at 30 minutes. The menstrual cycle 
also affected flow with follicular phase mucosal flow lower and more reproducible than 
luteal. Ipratropium, metoprolol and sacral nerve stimulation increased flow but inhaled 
salbutamol did not change blood flow.  
 
In our study patients were not permitted to smoke the morning of or during the study, 
patients taking medicines known to affect the mucosal blood flow were excluded and 
women were studied in the follicular phase of the menstrual cycle. At each site of 
injection a measurement was made, taken over at least thirty seconds. An arithmetic 
mean of blood flux (i.e. flow in ml/sec/mm3 of tissue scanned) expressed as flux units, 
was used in analysis. 
V.5.1.3 Intestinal permeability testing 
The research regarding the use of permeability testing in CD was detailed in section 
I.1.3.1. The two methods most employed in IBD have used either sugars, namely 
lactulose, mannitol or rhamnose, or a radioactive moiety, usually Cr51EDTA, as the 
permeability probe. The decision regarding which probe to use in this study was limited 
largely by the difficulties, both practical and regulatory, in handling Cr51, the facilities 
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for which were not available in our unit or with any of our collaborators. Conversely, 
sugar probe permeability testing using lactulose, mannitol and rhamnose was freely 
available and in frequent use at Kings College Hospital in London. For these reasons 
that test was used in this study. 
 
Intestinal permeability was tested in each subject on the day of COLAP testing using a 
previously validated technique (Papadia, Sherwood et al. 2007). Forty-eight hours 
before the test subjects abstained from taking any agents known to affect small bowel 
permeability including nonsteroidal anti-inflammatory drugs, alcohol, and antibiotics. 
After an overnight fast subjects then emptied their bladders, and drank the sugar mix 
test solution, commencing a 5-h study period during which a urine collection was 
maintained. The solution comprised 5 g lactulose, 1 g L-rhamnose, and 500 mg D-
xylose in 100 mL tap water. A light breakfast with a drink was allowed after 2 h. The 
urine collections were preserved by the addition of 1 mL of thymol (5% in propanol) to 
the collecting vessel, the total volume was recorded.  
 
Multiple 5-µL urinary aliquots from the 5-h collection, plus a range of primary sugar 
standards, were applied to a thin layer chromatography (TLC) plate and allowed to dry. 
The TLC plates used were 20 x 20 cm plastic sheets coated with silica gel. A plate 
application chart was used to assign positions on the plates; separate plates were used 
for monosaccharides and for disaccharides. The TLC plates were run using the 
“inverted beaker” technique. The edge of the plate, where the samples were located, was 
dipped into a mobile phase. The solvent mixture for monosaccharide sugars consisted of 
ethyl acetate, pyridine, acetic acid, and water (75 mL, 15 mL, 10 mL, 10 mL). The main 
solvent system for disaccharides was composed of butan-1-ol, ethyl acetate, ethanol, 
acetic acid, and water (35 mL, 10 mL, 45 mL, 7 mL, 7 mL). The sugars were located by 
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the colorigenic chemical reaction (a 4-aminobenzoic acid/sugar complex) after heating 
to 130◦C for 10 min. The method provides quantification of the sugars in the urine 
samples by direct densitometry measurements of the chemically located zones on the 
TLC plate. The absorption of reflected blue light from equal zone areas of primary 
standards was used to provide a standard curve from which the study unknowns could 
be read. The differential five hour urinary excretion ratio of lactulose and L-rhamnose 
(percentage ingested dose) provides an index of small bowel permeability.  
V.5.1.4 Serum food-specific IgG antibody testing 
The technique for collection and testing of serum for food-specific IgG antibodies was 
identical to that described in Chapter IV. Serum IgG antibody levels to a food were 
considered positive when they were above 10 AU. 
V.5.1.5 Questionnaire of patient perceived food sensitivity 
Participants were asked to complete the same questionnaire used in the study described 
in Chapter IV, determining the frequency and severity of GI symptoms and the 
association of perceived food intolerances with these symptoms (see Appendix 3. 
Questionnaire regarding food sensitivities).  
V.5.1.6 Blinding and avoiding bias 
The endoscopist performing mucosal antigen injection and laser Doppler flowmetry was 
blinded as to the antigen and control mixtures being injected. They were also blinded as 
to the patient’s pattern of serum IgG antibody reactivity. Patients remained blinded as to 
their serum IgG antibody reactivity and antigen injection results. 
V.5.1.7 Inclusion criteria 
Patients with small bowel or colonic CD and no history of perianal and rectal CD were 
eligible for inclusion.  
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V.5.1.8 Exclusion criteria 
Patients with active rectal inflammation at the time of endoscopy were excluded. 
Patients taking topical rectal 5-ASA preparations, oral or topical steroid preparations or 
biological agents were excluded, as it is not possible to predict the effect these agents 
will have on local reactivity. Smokers and patients taking Ipratropium or Beta blockers 
were excluded because of the effects of these factors on laser Doppler flowmetry. For 
safety reasons patients with a history of systemic allergic reactions and anaphylaxis 
were excluded. 
V.5.1.9 Statistical analysis 
The main outcome measure for this study was the mean change in mucosal hyperaemia 
(immediately following and 3.5 hours following food antigen injection) between 
patients who had serum IgG positivity for that antigen compared to patients who did 
not. 
 
The secondary outcome measures were correlation of changes in mucosal hyperaemia, 
serum food specific IgG, patient reported food sensitivity, and intestinal permeability as 
measured by lactulose/rhamnose absorption. 
 
The study sample size was based on the primary outcome measure, mean change in 
laser Doppler flow in response to antigen injection in patients with positive IgG for that 
antigen compared to the mean change in patients negative for IgG to that antigen. The 
mean reaction in CD from the previous study (Van Den Bogaerde, Cahill et al. 2002) 
(unpublished data) was 112.5 flux units (sd 24.1) and a clinically significant difference 
would be a 50% higher flux reading in IgG positive vs. negative patients. Using a 
sample size calculation based on a 2-sided T-test with Bonferroni correction for 5 
comparisons this gives a minimum total sample size of 12 patients.  
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T-tests were used to compare the means of normally distributed variables. Correlations 
were examined using Pearson’s correlation coefficient. 
 
V.6 Results 
12 patients were enrolled in the study. Food specific IgG antibody tests were available 
for 11 of 12 subjects. All patients received rectal mucosal injections with the 5 food 
antigens and control solution and had the mucosal blood flow measured by LDF 
immediately after injection and at a mean of 212 minutes following. The absolute 
change in the LDF measurement (in flux units) between time point zero, immediately 
following injection, and three and a half hours later is summarized in Table 23.
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Patient Control Yeast Wheat Milk Egg Kiwi 
1 -15 63 -7 60 50 -22 
2 52 47 -12 54 66 -18 
3 -2 12 19 47 23 139 
4 -32 90 -25 72 71 -26 
5 33 6 26 33 -2 49 
6 2 -11 21 25 17 29 
7 -9 91 52 38 -22 48 
8 -12 14 61 108 -11 -4 
9 -14 35 8 -9 19 16 
10 -4 29 -5 41 4 7 
11 -3 57 -12 19 46 6 
12 -5 50 54 43 24 -13 
Mean change 
in LDF -0.8 40.3 15.0 44.3 23.8 17.6 
p value**  0.001 0.099 0.003 0.018 0.211 
(**statistical significance set at p<0.01, *mucosal blood flow expressed in flux units 
derived by laser Doppler flowmetry) 
Table 23.  Change in mucosal blood flow* at antigen injection sites between time 
zero and three and half hours after injection 
 
There was no change in mean LDF for the control site injection in the study group. 
There was however an increase in LDF for each of the food antigen injection sites at 0 
versus 3.5 hours with statistically significant increases for yeast and milk at a 
significance level of 0.01, using a Bonferonni correction to adjust for multiple 
comparisons across the five antigen injection sites. 
V.6.1 Primary outcome measure 
No difference was seen in mean change in LDF following antigen injection in patients 
with positive IgG for that antigen compared to the mean reaction in patients negative for 
IgG to that antigen (32 vs. 24.5 flux units, p=0.4).  
 
This observation was also made when the absolute value of the IgG test as measured in 
AU was compared to the mucosal reactivity to antigen injection as measured by laser 
Doppler flowmetry (Figure 27). 
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(*mucosal blood flow measured in flux units; **AU=arbitrary units) 
Figure 27. Scatterplot of change in mucosal blood flow vs. food specific IgG 
antibodies 
 
V.6.2 Secondary outcome measures 
No difference was seen in the mean change in LDF in patients who reported sensitivity 
for that food compared to the mean change in patients who did not report sensitivity to 
that food (28.9 vs. 27.6, p=0.9). Nor was there any association between the IgG result 
for each food and patient’s reports of sensitivity to that food (Chi square p=1). 
 
Comparison of intestinal permeability, according to lactulose:rhamnose excretion ratios, 
with IgG values and LDF values following antigen injection showed no correlation 
between permeability and IgG reactivity or mucosal reactivity to any food. 
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V.7 Discussion 
This study confirms the practicality of performing antigen provocation testing in the 
rectum of patients with Crohn disease. It confirms a previous study showing that 
patients with Crohn disease exhibit greater mucosal hyperaemia in response to food 
antigen injection than in response to control injections (Van Den Bogaerde, Cahill et al. 
2002). That study further demonstrated that this difference is greater in Crohn disease 
patients than in controls 
 
Importantly, our study has failed to show an association of this phenomenon with the 
presence of IgG antibodies in the serum or patient’s reports of sensitivity to the foods 
tested. In addition the mucosal response to antigen injection does not seem to be 
correlated with intestinal permeability as measured by lactulose:rhamnose permeability 
testing. This indicates that the mucosal reactivity to antigen injection does not appear to 
be a function of the activity of disease, as indicated by intestinal permeability. All 
subjects in this study were felt clinically to be in disease remission. In addition our 
study demonstrates that patient reported sensitivity to a food does not correlate with the 
presence of serum IgG antibodies to that food. 
 
In determining the presence of subjective sensitivity to a food several methodological 
difficulties arise. No validated technique for the detection of food sensitivities in Crohn 
disease has been reported. Many authors recommend double-blind placebo controlled 
food challenge as the gold standard test for detecting food sensitivity. However, this test 
is cumbersome to administer and is unlikely to be widely applicable in the clinical 
setting. The use of food and symptom diaries has also been examined. However, this 
technique is also difficult to administer and has not been validated in this setting. Our 
technique of direct questioning about a range of sensitivity symptoms to a wide range of 
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foodstuffs may be subject to inaccuracy in the form of recall bias, over-reporting and, 
conversely, its ability to detect food sensitivities to particular foods commonly 
consumed in association with those foods the patient strongly feels to be associated with 
sensitivity. It does, however, provide a practical strategy for the detection of patient 
perceived food sensitivities and does allow direct comparison of patient perceived 
sensitivity with provocation or serological testing using specific food antigens. 
 
The fact that patients with Crohn disease do react to food antigen injection in the rectum 
differently from control substance injection and differently from control patients cannot 
be ignored and the mechanism for this requires further investigation. Whether this 
phenomenon could be used to predict food sensitivities in Crohn disease patients, to 
which they are unaware, could best be tested by comparison with double blind placebo 
controlled food challenge. 
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Chapter VI Conclusions 
VI.1 Dietary factors in the aetiology of IBD 
he aetiology of IBD is a multifactorial process that combines a genetic 
predisposition and luminal environmental factors. The role of diet in this process 
was discussed in the introduction to this thesis. A number of specific dietary nutrients 
have been associated with the development of IBD in epidemiological studies. In IBD 
there is frequent compromise of the epithelial integrity of the gut, which leads to 
increased exposure of the GI immune system to luminal factors. Thus dietary products 
have the opportunity to provide antigenic exposure to the GI immune system.  
 
The signalling mechanism for any such interaction does not appear to be via the 
classical type I allergy mechanism.  However, the effector mechanisms for the type I 
response are altered in IBD, in particular mast cells are strongly implicated in the 
mediation of inflammation in IBD and therapy directed at the mast cell has proven 
effective in IBD. Additionally there is evidence for alteration in the effector 
mechanisms for other immunological processes particularly IgG mediated processes. 
Alterations of the levels of IgG antibodies directed against foods in IBD patients 
compared with controls has been demonstrated and there is evidence for the 
effectiveness of an exclusionary diet informed by the results of serum IgG antibodies to 
foods. 
VI.2 Evidence for dietary manipulation in IBD 
The available evidence regarding manipulation of dietary factors in IBD was discussed 
in chapter II. In UC and CD, disease is produced by an interaction between environment 
and genetically programmed predisposition. The exact mechanisms by which 
T 
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environmental factors influence disease have yet to be fully elucidated but certainly the 
luminal content, as made up by microbiota and dietary products, contains the main part 
of this environmental stimulus.  
 
In both UC and CD the patient perception that dietary components can affect the course 
of their disease is high. The association between the individual foods to which patients 
perceive intolerance and objective tests of hypersensitivity, including double blind 
placebo controlled food challenge, is poor however. In the studies that make up this 
thesis I was unable to demonstrate any association between patient perceived food 
intolerance and two emerging tests of food hypersensitivity, namely food specific IgG 
antibodies and the colonic antigen provocation test. That aside, patients with IBD do 
have increased IgG antibody positivity and increased epithelial reactivity to foods, and 
these changes are not explicable by changes in epithelial permeability, at least when 
measured at the time the hypersensitivity testing is undertaken. 
 
The challenge faced is to resolve the patient perception that diet affects disease with the 
existing evidence and prioritise future work to areas with a probability of clinical 
success that might outweigh the deleterious effects of any dietary changes 
recommended. 
VI.3 Survey of gastroenterologists’ practice 
Chapter III described a survey study conducted in New Zealand and the United 
Kingdom, which showed that dietary management differs greatly between IBS and IBD. 
IBS is a common intestinal condition to which the average gastroenterologist has 
frequent exposure. There is a strong environmental influence on the production and 
maintenance of disease in this condition. However, robust advice regarding how diet 
might best be manipulated to benefit disease is largely lacking. Thus, while the 
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pathophysiology of IBD and IBS are quite separate, some of the therapeutic challenges 
are shared. For this reason I was interested to test the differences in current practice 
between the two conditions.  
 
Patients with IBS are more likely to be given dietary advice by a gastroenterologist and 
are more likely to be given advice about dietary exclusions than IBD patients. The two 
groups are equally likely to be sent for dietetic advice and receive allergy testing, 
although use of both is low. Where dietary exclusion was recommended both groups 
were given advice about fibre, dairy and wheat as well as sugar intake in New Zealand. 
Sensitivity testing, when used, was most commonly “open exclusion and rechallenge” 
and radio-immunosorbent assays.  
 
Those patients with small bowel CD, difficult to control IBD, diarrhoea predominant 
IBS and difficult to control IBS were most likely to receive dietary advice. Respondents 
tended to agree that dietary manipulation was effective in IBS but were not so confident 
of its effect in IBD. 
 
These results suggest that there is a current role for dietary manipulation and exclusion 
in IBD and IBS but that the advice given is generally empiric and that sensitivity testing 
is infrequently used in practice. The fact that practitioners do employ these techniques 
and have some confidence in their benefit, at least in IBS, encourages further research 
in this area. 
VI.4 Food specific IgG antibodies in IBD 
Chapter IV described an observational study of the occurrence of serum IgG antibodies 
to foods in IBD patients compared to controls. In this study CD and UC patients 
reported gastrointestinal intolerances to a greater number of foods than control subjects. 
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There was also a greater frequency of IgG food antibody positivity in UC and CD 
patients compared with controls. However, this was for a different range of foods in 
each disease and there was no correlation between patient reported intolerance and IgG 
food antibody positivity.  
 
A study published following the completion of the investigations that make up this 
thesis generated similar results, albeit with positivity for a different range of foods 
(Bentz, Hausmann et al. 2010). Those authors went on to test the theory that a diet 
guided by the results of IgG food antibodies would be beneficial to gastrointestinal 
symptoms in patients with IBD. An improvement in stool frequency and general well-
being was seen. However, methodological difficulties were observed including a high 
drop out rate, lack of control for concomitant medications and a sham diet that was 
potentially too similar to the specific diet. 
 
Studies such as those above, and those that make up this thesis, challenge the dogma 
that IgG antibodies are a physiological phenomena that is not directly associated with 
the pathophysiology of disease. However, they fail to provide a robust biological 
mechanism for effect. Conversely, an alternative explanation for the presence of 
increased levels of IgG antibodies in IBD has not been forthcoming. In the first study 
that examined IgG food antibodies in IBD and other gastrointestinal disease Davidson 
et al. concluded, “The similar incidence of antibodies in the IBD and coeliac groups 
suggests absorption of dietary antigen secondary to an increased mucosal permeability” 
(Davidson, Lloyd et al. 1979). Other authors have since promoted this conjecture, but 
without any direct evidence to support it and, in fact, one study in the setting of IgG 
antibodies to yeast which demonstrated no association between IgG antibodies and 
changes in permeability (Harrer, Reinisch et al. 2003). The authors of that study 
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concluded, “Elevated serum levels of anti-S. cerevisiae antibodies do not seem to result 
primarily from a defect of the gut barrier”. 
 
Thus, the evidence is that IBD is associated with increased serum IgG antibodies to a 
wide range of foods but that this does not correlate strongly with patient reported food 
intolerance. It is, however, well understood that patient perception of intolerance does 
not correlate well with more robust measures of intolerance such as double blind 
placebo controlled food challenge. The theory that the association between IBD and IgG 
food antibodies might merely reflect the intestinal permeability state had not been well 
tested. In addition the association between the colonic antigen provocation test, patient 
perceived food intolerance, and IgG food antibodies had not been examined. For these 
reasons I went on to compare IgG food antibodies, colonic provocation testing, 
intestinal permeability and patient perceived food intolerance in Chapter V of this 
thesis. 
VI.5 Colonic provocation with food antigens in CD 
The technique of direct mucosal antigen exposure has undergone much iteration. Many 
of the technical difficulties of the technique have been overcome by using the colonic 
mucosa for exposure. These techniques have been tested in CD and the responses found 
to be increased compared with controls. Chapter V described a study correlating colonic 
mucosal response to food antigen with patient reported food intolerances, food specific 
serum IgG antibody responses and intestinal permeability. Quantification of the 
mucosal response to antigen exposure was achieved using laser Doppler flowmetry.  
 
A reaction to colonic mucosal exposure to food antigens was seen with all the foods 
tested, but not with control. Previous studies have shown that these responses are 
greater in CD than controls. The most significant reactions occurred with yeast, milk 
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and egg. However, this response did not correlate with IgG antibody reactivity, patient 
reported food intolerance or intestinal permeability.  
 
Thus, colonic antigen provocation is practically applicable in CD. However, this 
reaction does not correlate with patients’ perception of food intolerance. Nor does it 
appear to be an immediate product of alterations in intestinal permeability. 
 
In conclusion, the studies that make up this thesis have been unable to demonstrate an 
objective relationship between patient perceived food intolerance and hypersensitivity 
testing in the form of serum IgG food antibodies or colonic antigen provocation. What 
has been demonstrated is that gastroenterologists do give dietary advice to at least some 
of their patients with IBD but they are not currently able to provide this information 
unequivocally based on the evidence available. The following future directions are 
therefore suggested. 
VI.6 Future directions 
That patients with IBD experience intolerances to foods is clear. Clinician response to 
this is currently guided by a very limited scientific literature. The result is largely 
generic advice and a lack of confidence in dietary techniques for the management of 
IBD. The research that makes up this thesis suggests that the response of the IBD 
patient to foods in terms of serum IgG antibody production and colonic mucosal 
reactivity is altered, but is unable to elucidate the mechanisms of these changes or 
correlate these changes with the clinical course of the patients’ disease. Future studies 
of these techniques will need to demonstrate whether any association between the tests 
and the symptoms patients experience really exists and whether diets guided by tests 
such as these can be used with effect in the treatment of the symptoms of disease.  
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Finally they will need to clearly define the mechanisms by which such tests predict 
intolerance in patients. 
VI.6.1 Studies comparing IgG food antibodies and COLAP to 
double blind placebo controlled food challenge 
DBPCFC is considered the gold standard for the detection of food hypersensitivity. 
DBPCFC could be compared to a limited range of IgG food antibodies, and to colonic 
provocation, in an observational study. It would be important to ensure that the placebo 
preparation and the active food preparation were indistinguishable, which in practice 
can be very difficult. In addition the dose of active food preparation administered would 
need to be physiologically appropriate. With foods like wheat in a western diet this 
means a large volume of active preparation or, conversely, a large volume of placebo.  
 
Outcome measures would also need to be carefully constructed. In the setting of Crohn 
disease the CDAI could be considered the outcome measure of choice in clinical trials. 
However, it would seem unlikely that the avoidance of a single food type would be 
likely to produce clinically significant changes in this index in the timeframes over 
which such comparisons could be run. Rather, the utilisation of a simple symptom diary 
may be more appropriate. 
 
These considerations aside, a study design such as this would be the design most able to 
affirm or refute the hypothesis that these tests are able to detect food hypersensitivity in 
IBD patients. 
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VI.6.2 Studies comparing an IgG antibody or COLAP 
determined diet to a control diet 
Strategies such as those described above might allow a diagnostic test for 
hypersensitivity to be validated or refuted but are unlikely to allow evaluation of the 
hypothesis that diets guided by such tests can have a clinically significant impact on 
disease status. One study in IBD and 2 studies in IBS have been able to show a clinical 
benefit of dietary manipulation guided by IgG food antibody testing when compared to 
a sham control diet. However, the complexity and diversity of the diets prescribed, and 
the fact that a few key constituent foods formed the main part of the “active” diets, has 
led to the concern that the IgG testing itself does little to inform the diets. 
 
There would certainly be a role for the validation of these results in IBD. Design of the 
sham control presents some difficulties, however. From Chapter IV it seems that the 
rate of positivity to IgG food antibodies is much higher in CD than in controls. This 
makes it very likely that the rates of positivity are also higher in CD than IBS. 
 
Criticisms of the past studies in IBS were that they put too many treatment group 
patients on a wheat, milk and yeast free diet compared to controls and that exclusion of 
those foods is commonly considered beneficial in IBS, hence IgG food antibody testing 
is not needed to design such a diet. This argument does not necessarily hold in CD 
where the range of positive responses to IgG food antibodies is greater. However, based 
on our data, it seems even more likely that patients on the true diet will be required to 
avoid specific foods (such as yeast, milk, wheat, kiwi, chilli and egg, all of which have 
greater than 30% positivity), more so even than in the previous IBS studies. 
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This raises an additional concern, in that it is likely that CD patients on the true diet will 
be instructed to avoid a very wide range of foods based on their IgG food antibody 
result. Hence design of sham diets that balance this significant dietary restriction will be 
particularly difficult. 
 
In the face of this there are four options: 
1. Exclude those six most frequently positive foods in all patients in both groups. This 
will mean a large number of treatment group patients are asked to exclude a diet to 
which they are IgG food antibody negative and vice versa, making any difference 
between the groups very difficult to detect. 
 
2. Repeat the sham approach used in the previous IBS studies. The risk is that this will 
engender the same criticisms as the previous IBS papers and so be difficult to publish 
and unlikely to change clinical practice. However, as above, there is not the same level 
of concern that certain foods are important in generating symptoms for all patients with 
CD and the range of foods implicated is much wider. Nonetheless authors who 
criticised the IBS study are likely to have similar problems with milk and yeast in an 
IBD study. 
 
3. Develop a sham approach that randomises control patients to an "IgG food antibody 
like diet" that is not their own IgG food antibody directed diet. This will mean a 
proportion of controls will be advised to avoid foods they would be predicted to be 
sensitive to by the YT diet. This will increase the apparent placebo effect, but inflation 
of the sample size would decrease the risk of no difference being seen (a type II error) 
and allow subgroup analysis of only those who do not have "crossover" in the diet. I 
have calculated this will affect about two thirds of subjects but will mostly apply only to 
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the foods yeast, wheat and milk and so in the worst case scenario would perform in a 
similar way to the study design of option 1.  
 
4. Do away with a sham diet altogether. Some equivalent form of intervention would 
need to be instituted in order to control for the placebo effect of trial involvement and 
dietary advice. The most appealing would be to apply “standard dietary advice for IBD” 
as the control. Unfortunately no such consensus exists. The British Society of 
Gastroenterology’s latest guidance on IBD has no such consensus on dietary 
intervention in IBD. However the best investigated dietary approach to CD could be 
considered a low fat, low fibre diet (Woolner, Parker et al. 1998). I believe that to place 
both groups on a low fat, low fibre diet, and additionally to give only the treatment 
group dietary advice based on the IgG food antibody result, is the most practical 
approach to design of the study that is most likely to demonstrate any difference in 
outcome. It has the additional benefit of allowing sample size calculation based on the 
effect size of past studies of such low fat, low fibre diets. 
 
Essentially the same principles could be applied in the design of studies aiming to test 
the hypothesis that dietary modifications based on the results of colonic antigen 
provocation can be beneficial in IBD. 
VI.6.3 Studies to elucidate the mechanisms by which IgG food 
antibodies and COLAP might detect food hypersensitivity 
Studies investigating the link between antigen provocation or IgG food antibodies and 
food hypersensitivity in CD, if positive, will require the demonstration of a biological 
mechanism before widespread acceptance is likely. Therefore, any future study of the 
techniques applied in this thesis should attempt to define the mechanisms by which 
these tests might predict food hypersensitivity. The detection of IgG food antibodies in 
 212 
subjects without disease has fuelled the concern that these antibodies might merely be 
physiological. The altered pattern and prevalence of these antibodies in disease states 
such as Crohn disease has been attributed to changes in the permeability of the gut in 
these conditions. However, in Chapter V we showed that alterations in these antibodies 
do not correlate with intestinal permeability at a single point in time. Longitudinal 
studies are necessary to correlate changes in IgG food antibody reactivity with changes 
in intestinal permeability and disease activity over time. 
 
In vitro lymphocyte proliferation studies were utilised by Van den Boegarde et al. (Van 
Den Bogaerde, Cahill et al. 2002). In their study they tested 10 CD patients’ blood 
lymphocytes with 6 different food antigens each. Proliferation was observed in a total of 
32 of the 60 allergen⁄lymphocyte combinations. They compared this to colonic antigen 
provocation and in 15 of these 32, increased rectal reaction was observed in the same 
patient after exposure to the same antigen. This was compared to a total of 24 out of 60 
positive rectal provocation responses. Thus, 15 of 24 (63%) rectal provocation 
responses were associated with a positive lymphocyte proliferation test. Similar 
techniques could be applied in a study of IgG food antibodies or revalidated in future 
studies of antigen provocation. If a correlation existed it might allow in vitro 
investigation to determine the mediators of the reaction including blocking of IgG 
mediated responses to investigate the hypothesis that IgG food antibodies directly 
mediate the immune reaction. 
 
Histological studies should be undertaken in future studies of antigen provocation. Van 
den Boegarde et al. examined biopsy samples from antigen exposure sites using 
haemotoxylin and eosin staining and demonstrated submucosal oedema but no increase 
in lymphocyte numbers (Van Den Bogaerde, Cahill et al. 2002). Degranulation of mast 
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cells could not be accurately assessed using this technique. In the original study of the 
colonic antigen provocation technique in patients with food allergy, examination of 
biopsy specimens from the sites of antigen exposure showed no change in the number 
of eosinophils or mast cells present but did show evidence of mast cell degranulation 
and eosinophil activation in response to antigen provocation (Bischoff, Mayer et al. 
1997). Application of these techniques in any future study of colonic antigen 
provocation in CD would determine whether the mucosal reactions seen in CD were 
mediated in a similar fashion to those in food allergy. 
 
It is evident that patients with CD experience food intolerances. Those patients will 
continue to ask questions of the gastroenterological community regarding the 
mechanism and management of these intolerances. A likely consequence of not seeking 
answers to these questions is that our patients will take advice from other sources, with 
possible negative nutritional consequences. A strategy that allowed the detection of 
clinically significant food intolerances and the design of diets which were associated 
with improved disease outcomes without deleterious nutritional consequences would be 
of great benefit to our patients. This work reinforces the importance of food intolerance 
to patients with IBD and attempts to correlate those intolerances to available tests. 
Future studies should seek to clearly define the association between intolerance tests 
and patient symptoms, investigate the mechanisms by which such tests might predict 
intolerance, and investigate the most promising strategies in carefully designed and 
controlled studies of dietary intervention. 
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Appendices 
Appendix 1.  Correlation coefficients for two rounds of 
survey pilot study 
Question Correlation 
coefficient 
(p or r) 
How would you best describe your practice?   
Gastroenterology time ____% -0.06 Q1. 
General medicine time ____% 0.73 
Are you able to refer to a dietician?  0.71 
Q2. 
Dietician time allocated to your service?  ____________hours 1.00 
Q3. Are you involved in a special IBD clinic 1.00 
Q4. 
Please indicate below how many new and follow-up patients with 
IBD would you see in outpatient clinics in an average month? 
0.71 
Q5. What percentage of the patients with IBD that you see would you give specific dietary advice to? 
NC 
Q6. What percentage of the patients with IBD that you see would you refer for dietetics advice? 
1.00 
Q7. What percentage of the patients with IBD that you see would you ask to exclude specific foods from their diet? 
0.53 
If you do ask patients to exclude foods please indicate the types of foods? 
Fibre containing foods 0.71 
Refined sugars NC 
Dairy products NC 
Wheat 1.00 
Nuts 1.00 
Yeast 1.00 
Q8. 
Eggs 1.00 
Q9. What percentage of the patients with IBD that you see would you perform food allergy or intolerance testing on? 
0.77 
If you do request intolerance testing which tests do you use?  
Skin prick testing 1.00 
Skin patch testing NC 
RAST 1.00 
Open food exclusion and rechallenge 1.00 
Double blind placebo controlled challenge 1.00 
Q10. 
Yorktest IgG test 1.00 
Please indicate which patients with IBD you are most likely to give or send for 
dietary advice? 
Ulcerative colitis 1.00 
Small bowel Crohn’s 1.00 
Large bowel Crohn’s 1.00 
Perianal Crohn’s 1.00 
Q11. 
Very difficult to control IBD NC 
Q12. Do you agree that exclusion diets are effective in the treatment of IBD? 
0.94 
(NC: correlation coefficient not able to be calculated; p: Phi; r: Spearman’s correlation 
coefficient, rho)
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Appendix 1.  Correlation coefficients for two rounds of 
survey pilot study (continued) 
 
 (NC: correlation coefficient not able to be calculated; p: Phi; r: Spearman’s correlation 
coefficient, rho) 
Question Correlation 
coefficient 
(p or r) 
Q13. Please indicate below how many new and follow-up patients with IBS would you see in outpatient clinics in an average month? 
0.63 
Q14. Are you involved in a special IBS clinic 1.00 
Q15. What percentage of the patients with IBS that you see would your give specific dietary advice to? 
0.93 
Q16. What percentage of the patients with IBS that you see would you refer for dietetics advice? 
1.00 
Q17. What percentage of the patients with IBS that you see would you ask to exclude specific foods from their diet? 
0.96 
If you do ask patients to exclude foods please indicate the types of foods? 
Fibre containing foods 0.63 
Refined sugars 1.00 
Dairy products 0.50 
Wheat 1.00 
Nuts 1.00 
Yeast 0.25 
Q18. 
Eggs NC 
Q19. What percentage of the patients with IBS that you see would you perform food allergy or intolerance testing on? 
0.89 
If you do request intolerance testing which tests do you use?  
Skin prick testing 1.00 
Skin patch testing NC 
RAST NC 
Open food exclusion and rechallenge 1.00 
Double blind placebo controlled challenge 1.00 
Q20. 
Yorktest IgG test 1.00 
Please indicate which patients with IBS you are most likely to give or send for dietary 
advice? 
Diarrhoea predominant 0.71 
Constipation predominant 0.25 
Pain predominant NC 
Q21. 
Difficult to control IBS 0.00 
Q22. 
Do you agree that exclusion diets are effective in the treatment of IBS? 0.59 
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Appendix 2.  Covering letter and questionnaire for 
survey 
 
Dear <<mail merge to follow>>, 
 
Please find enclosed a short survey regarding dietary advice in inflammatory bowel 
disease and irritable bowel syndrome. This should take no longer than 3 minutes to fill 
out. This is a national survey that is being sent to all members of the British Society of 
Gastroenterologists. Currently there are no position statements regarding dietary advice 
in either condition. Information about current practice will greatly aid research in this 
area in the future. 
 
Thank you very much for taking the time to fill in this short survey and returning it in 
the stamped, addressed envelope also enclosed. 
 
Kind regards, 
 
 
 
 
 
Anton Emmanuel 
 246 
Can we please start by asking about the type of 
practice you are involved in? 
Q1. How would you best describe your 
practice? (Physicians please indicate the 
percentage of time spent in 
gastroenterology versus medicine) 
Colorectal surgeon ...............  
Other surgeon.......................  
Physician ..............................  
Gastroenterology time ____% 
General medicine time ____% 
Other (PLEASE WRITE 
IN)_____________________ 
 
Q2. Are you able to refer to a dietician? (If 
yes please tell us how much dietetic 
sessional time is allocated to GI patients 
in your service?) 
Yes, a specialist GI dietician  
Yes, a general dietician .......  
No .........................................  
Dietician time allocated to your 
service?  ____________hours 
 
The first part of this questionnaire applies only 
to IBD.  
 
Q3.  Are you involved in a special IBD clinic 
Yes.........................................  
No..........................................  
 
Q4.  Please indicate below how many new 
and follow-up patients with IBD would 
you see in outpatient clinics in an 
average month? 
Less than 20 .........................  
20 to 40 .................................  
40 to 60 .................................  
60 to 80 .................................  
80 to 100...............................  
More than 100......................  
 
Q5.  What percentage of the patients with 
IBD that you see would you give specific 
dietary advice to? 
none ......................................  
less than 25% .......................  
25% to 50%..........................  
50% to 75%..........................  
Over 75%..............................  
 
Q6.  What percentage of the patients with 
IBD that you see would you refer for 
dietetics advice? 
none ......................................  
less than 25% .......................  
25% to 50%..........................  
50% to 75%..........................  
Over 75%..............................  
 
Q7.  What percentage of the patients with 
IBD that you see would you ask to 
exclude specific foods from their diet? 
none ......................................  
less than 25% .......................  
25% to 50%..........................  
50% to 75%..........................  
Over 75%..............................  
 
Q8.  If you do ask patients to exclude foods 
please indicate the types of foods? 
Fibre containing foods ........  
Refined sugars......................  
Dairy products .....................  
Wheat ....................................  
Nuts .......................................  
Yeast......................................  
Eggs ......................................  
Other (PLEASE WRITE 
IN)_______________________ 
__________________________
__________________________
__________________________ 
 
Q9.  What percentage of the patients with 
IBD that you see would you perform 
food allergy or intolerance testing on? 
none ......................................  
less than 25% .......................  
25% to 50%..........................  
50% to 75%..........................  
Over 75%..............................  
 
Q10.  If you do request intolerance testing 
which tests do you use? 
Skin prick testing..................  
Skin patch testing .................  
RAST .....................................  
Open food exclusion and 
rechallenge...........................  
Double blind placebo controlled 
challenge ..............................  
Yorktest IgG test...................  
Other (PLEASE WRITE 
IN)_______________________ 
__________________________
__________________________
__________________________ 
 
Q11.  Please indicate which patients with IBD 
you are most likely to give or send for 
dietary advice? 
Ulcerative colitis..................  
Small bowel Crohn’s ...........  
Large bowel Crohn’s ...........  
Perianal Crohn’s .................  
Very difficult to control  
IBD........................................  
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Q12.  Do you agree that exclusion diets are 
effective in the treatment of IBD? 
Agree strongly ......................  
Agree a little .........................  
Neither Agree nor Disagree   
Disagree a little ...................  
Disagree a lot.......................  
 
The second part of this questionnaire repeats 
the above questions but applies only to IBS.  
 
Q13. Please indicate below how many new 
and follow-up patients with IBS would 
you see in outpatient clinics in an 
average month? 
Less than 20 .........................  
20 to 40 .................................  
40 to 60 .................................  
60 to 80 .................................  
80 to 100...............................  
More than 100 ......................  
 
Q14. Are you involved in a special IBS clinic 
Yes ........................................  
No .........................................  
 
Q15. What percentage of the patients with 
IBS that you see would your give 
specific dietary advice to? 
none ......................................  
less than 25% .......................  
25% to 50%..........................  
50% to 75%..........................  
Over 75%..............................  
 
Q16. What percentage of the patients with 
IBS that you see would you refer for 
dietetics advice? 
none ......................................  
less than 25% .......................  
25% to 50%..........................  
50% to 75%..........................  
Over 75%..............................  
  
Q17. What percentage of the patients with 
IBS that you see would you ask to 
exclude specific foods from their diet? 
none ......................................  
less than 25% .......................  
25% to 50%..........................  
50% to 75%..........................  
Over 75%..............................  
 
Q18. If you do ask patients to exclude foods 
please indicate the types of foods? 
Fibre containing foods.........  
Refined sugars......................  
Dairy products......................  
Wheat....................................  
Nuts.......................................  
Yeast .....................................  
Eggs ......................................  
Other (PLEASE WRITE 
IN)_______________________ 
__________________________
__________________________
__________________________ 
 
Q19. What percentage of the patients with 
IBS that you see would you perform 
food allergy or intolerance testing on? 
none ......................................  
less than 25% .......................  
25% to 50%..........................  
50% to 75%..........................  
Over 75%..............................  
 
Q20. If you do request intolerance testing 
which tests do you use? 
Skin prick testing .................  
Skin patch testing.................  
RAST....................................  
Open food exclusion and 
rechallenge ...........................  
Double blind placebo controlled 
challenge...............................  
Yorktest IgG test ..................  
Other (PLEASE WRITE 
IN)_______________________ 
__________________________
__________________________
__________________________ 
 
Q21. Please indicate which patients with IBS 
you are most likely to give or send for 
dietary advice? 
Diarrhoea predominant........  
Constipation predominant ...  
Pain predominant .................  
Difficult to control IBS........  
 
Q22. Do you agree that exclusion diets are 
effective in the treatment of IBS? 
Agree strongly......................  
Agree a little .........................  
Neither Agree nor Disagree   
Disagree a little ....................  
Disagree a lot ....................... 
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Appendix 3. Questionnaire regarding food sensitivities  
 
Dear Participant, 
 
Thank you for agreeing to take part in this study. Please take the time to complete the 
questions below. The questionnaire usually takes 20 to 30 minutes to complete. 
 
Q1. Over the last month how many times per day on average have you opened your 
bowels?  _________ times per day. 
 
Q2.  Over the last month what has the consistency of your bowel motions mostly been? 
□Hard pellets □Formed stool □Loose stool □Watery stool  
□Alternating between soft and loose stool 
 
Q4. Do you have problems with persistent nausea or vomiting? □Yes □No 
 
Q3.  Are you allergic or sensitive to any food? □Yes □No 
 
Q4. For each of the foods below please tick the box(es) that best describe the type of 
allergy/sensitivity you experience to that food, or write in the type of allergy/sensitivity 
you experience.  If you do not experience allergy/sensitivity to the food please leave 
blank. 
 
 
 
Rash or 
swelling 
of the 
lips and 
throat 
Eczema
/derm-
atitis 
Asthma Diarr-
hoea 
Constip
-ation 
Abdom-
inal 
Pain 
Bloat-
ing 
Heart-
burn 
Other (please 
describe) 
Barley □ □ □ □ □ □ □ □  
Buckwheat □ □ □ □ □ □ □ □  
Corn 
(maize) 
□ □ □ □ □ □ □ □  
Millet □ □ □ □ □ □ □ □  
Oat □ □ □ □ □ □ □ □  
Rice □ □ □ □ □ □ □ □  
Rye □ □ □ □ □ □ □ □  
Wheat □ □ □ □ □ □ □ □  
Cows milk □ □ □ □ □ □ □ □  
Egg - white □ □ □ □ □ □ □ □  
Egg - yolk □ □ □ □ □ □ □ □  
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Rash or 
swelling 
of the 
lips and 
throat 
Eczema
/derm-
atitis 
Asthma Diarr-
hoea 
Constip
-ation 
Abdom-
inal 
Pain 
Bloat-
ing 
Heart-
burn 
Other (please 
describe) 
Beef □ □ □ □ □ □ □ □  
Chicken □ □ □ □ □ □ □ □  
Duck □ □ □ □ □ □ □ □  
Lamb □ □ □ □ □ □ □ □  
Pork □ □ □ □ □ □ □ □  
Turkey □ □ □ □ □ □ □ □  
Crab, 
Lobster, 
Prawn / 
Shrimp 
□ □ □ □ □ □ □ □  
Mussell, 
Oyster, 
Scallop 
□ □ □ □ □ □ □ □  
Herring, 
Mackerel 
□ □ □ □ □ □ □ □  
Plaice / 
Sole 
□ □ □ □ □ □ □ □  
Salmon / 
Trout 
□ □ □ □ □ □ □ □  
Tuna □ □ □ □ □ □ □ □  
Cod, 
Haddock 
□ □ □ □ □ □ □ □  
Almond □ □ □ □ □ □ □ □  
Brazil □ □ □ □ □ □ □ □  
Cashew □ □ □ □ □ □ □ □  
Coconut □ □ □ □ □ □ □ □  
Hazelnut □ □ □ □ □ □ □ □  
Peanut □ □ □ □ □ □ □ □  
Walnut □ □ □ □ □ □ □ □  
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Rash or 
swelling 
of the 
lips and 
throat 
Eczema
/derm-
atitis 
Asthma Diarr-
hoea 
Constip
-ation 
Abdom-
inal 
Pain 
Bloat-
ing 
Heart-
burn 
Other (please 
describe) 
Asparagus □ □ □ □ □ □ □ □  
Aubergine □ □ □ □ □ □ □ □  
Avocado □ □ □ □ □ □ □ □  
Carrot □ □ □ □ □ □ □ □  
Celery □ □ □ □ □ □ □ □  
Cucumber □ □ □ □ □ □ □ □  
Haricot 
bean 
□ □ □ □ □ □ □ □  
Kidney 
bean 
□ □ □ □ □ □ □ □  
Spinach □ □ □ □ □ □ □ □  
Lentils □ □ □ □ □ □ □ □  
Lettuce □ □ □ □ □ □ □ □  
Mushroom □ □ □ □ □ □ □ □  
Broccoli, 
Brussell 
Sprouts, 
Cabbage, 
Cauliflower 
□ □ □ □ □ □ □ □  
Onion □ □ □ □ □ □ □ □  
Pea □ □ □ □ □ □ □ □  
Peppers 
(Capsicum) 
/ Paprika 
□ □ □ □ □ □ □ □  
Potato □ □ □ □ □ □ □ □  
Soya bean □ □ □ □ □ □ □ □  
String bean □ □ □ □ □ □ □ □  
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Rash or 
swelling 
of the 
lips and 
throat 
Eczema
/derm-
atitis 
Asthma Diarr-
hoea 
Constip
-ation 
Abdom-
inal 
Pain 
Bloat-
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Apricot □ □ □ □ □ □ □ □  
Banana □ □ □ □ □ □ □ □  
Blackberry □ □ □ □ □ □ □ □  
Black-
currant 
□ □ □ □ □ □ □ □  
Cherry □ □ □ □ □ □ □ □  
Cranberry □ □ □ □ □ □ □ □  
Grape □ □ □ □ □ □ □ □  
Grapefruit □ □ □ □ □ □ □ □  
Kiwi □ □ □ □ □ □ □ □  
Lemon □ □ □ □ □ □ □ □  
Lime □ □ □ □ □ □ □ □  
Cantaloup, 
Honeydew, 
Water-
melon 
□ □ □ □ □ □ □ □  
Olive □ □ □ □ □ □ □ □  
Orange □ □ □ □ □ □ □ □  
Peach □ □ □ □ □ □ □ □  
Pear □ □ □ □ □ □ □ □  
Pineapple □ □ □ □ □ □ □ □  
Plum □ □ □ □ □ □ □ □  
Raspberry □ □ □ □ □ □ □ □  
Strawberry □ □ □ □ □ □ □ □  
Tomato □ □ □ □ □ □ □ □  
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Chilli 
pepper 
□ □ □ □ □ □ □ □  
Cinnamon / 
Clove 
□ □ □ □ □ □ □ □  
Coriander / 
Cumin / 
Dill 
□ □ □ □ □ □ □ □  
Garlic □ □ □ □ □ □ □ □  
Ginger □ □ □ □ □ □ □ □  
Basil, Mint, 
Sage, 
Thyme 
□ □ □ □ □ □ □ □  
Mustard 
seed 
□ □ □ □ □ □ □ □  
Nutmeg / 
Peppercorn 
□ □ □ □ □ □ □ □  
Parsley □ □ □ □ □ □ □ □  
Sesame 
seed 
□ □ □ □ □ □ □ □  
Vanilla □ □ □ □ □ □ □ □  
Carob □ □ □ □ □ □ □ □  
Cocoa bean □ □ □ □ □ □ □ □  
Coffee □ □ □ □ □ □ □ □  
Cola nut □ □ □ □ □ □ □ □  
Hops □ □ □ □ □ □ □ □  
Sunflower 
seed 
□ □ □ □ □ □ □ □  
Tea □ □ □ □ □ □ □ □  
Yeast 
(brewers 
and bakers) 
□ □ □ □ □ □ □ □  
If there are other foods, not listed above, that cause you significant symptoms, please list them using the blank table 
below 
Name of 
Food 
Rash or 
swelling 
of the 
lips and 
throat 
Eczema
/derm-
atitis 
Asthma Diarr-
hoea 
Constip
-ation 
Abdom
-inal 
Pain 
Bloat-
ing 
Heart-
burn 
Other (please 
describe) 
 □ □ □ □ □ □ □ □  
 □ □ □ □ □ □ □ □  
 □ □ □ □ □ □ □ □  
 □ □ □ □ □ □ □ □  
 □ □ □ □ □ □ □ □  
 □ □ □ □ □ □ □ □  
